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Abstract
The theory of metastatic cascade suggests that vasculature plays a central role
in the metastatic processes by being the major route of spreading. Two main
circulatory systems in the body are responsible for cancer cell dissemination;
the blood vascular system and the lymphatic system. However, comparing
between these circulatory systems, much less is known about lymphatic
vessels, with few studies being conducted about the initial steps of metastasis.
In the first part of this project, a series of 202 formalin fixed paraffin embedded
(FFPE) cutaneous melanoma sections were stained with D2-40, CD34 and
CD68 to identify lymphatics, blood vessels and macrophages respectively, to
examine vessel distribution and the involvement of inflammatory infiltrate in
mediating vascular invasion (VI). Sections were also stained by conventional
haematoxylin and eosin (H&E), to assess VI, and results compared against
those obtained by immunohistochemistry (IHC) that allow discrimination of
lymphatic and blood vessel invasion. It was found that lymphatics are mainly
located at the peritumoural area of the tumour but intratumoural lymphatics are
present and appeared to be functional based on the presence of tumour emboli
in the vessels. In addition, vascular invasion in melanoma is mainly lymphatic
vessel invasion with H&E assessment underestimating its incidence. Lymphatic
vessel invasion were significantly associated with markers of aggressive
disease which suggest their importance in melanoma. Lymphatic vessel
invasion was also associated with a high macrophage count, suggesting a role
for macrophage in mediating the process of metastatic via lymphatic vessels.
In the second part of this project, the adhesion pattern of melanoma and breast
cancer cell lines to blood and lymphatic endothelial cell models; large vessel
versus microvessel and primary versus immortalised cells were compared. In
DGGLWLRQWKHHIIHFWRIPDFURSKDJHVHFUHWHGF\WRNLQHV71)ĮDQG,/ȕWXPRXU
conditioned media and macrophage conditioned media on the adhesive process
were also studied. Both melanoma and breast cancer cells exhibited a higher
OHYHO RI DGKHVLRQ WR EORRG FRPSDUHG WR WKH O\PSKDWLF HQGRWKHOLDO FHOOV ,/ȕ
stimulation of endothelial cells, tumour cells or both together showed a
III
significant increased in the percentage of adhered tumour cells to the
endothelial cell models with a higher increased to the lymphatic endothelial
cells. A significant increased tumour cell adhesion was also observed with
macrophage conditioned media and this effect seemed to be associated with
WKH DPRXQW RI ,/ȕ SUHVHQW ,QWHUHVWLQJO\ WKH LQFUHDVHG DGKHVLRQ HIIHFW
observed with this supernatant was removed with the use of interleukin-1
converting enzyme (ICE) inhibitor.
Expression of adhesion molecules; CLEVER-1, ICAM-1 and VCAM-1 were
examined to study which adhesion molecules might regulate the process of
WXPRXUHQGRWKHOLDOLQWHUDFWLRQV6WLPXODWLRQRIHQGRWKHOLDOFHOOPRGHOVZLWK,/ȕ
did not show any significant altered CLEVER-1 expression suggesting that
although CLEVER-1 is an important lymphatic specific adhesion molecule, it
may not be the principle regulator of tumour-endothelial interactions. This
process may be regulated by ICAM-1 and VCAM-1 in which the expression
LQFUHDVHGVLJQLILFDQWO\XSRQVWLPXODWLRQZLWK,/ȕ
,Q WKH WKLUG SDUW RI WKLV VWXG\ WKH HIIHFW RI 71)Į ,/ȕ WXPRXU FRQGLWLRQHG
media and macrophage conditioned media stimulation on melanoma and breast
cancer cell migration were investigated using wound healing assays. Following
H[SRVXUHWR71)ĮDQG,/ȕDVLJQLILFDQWLQFUHDVHLQWKHSHUFHQWDJHRIZRXQG
FORVXUH ZDV REVHUYHG DQG WKH LQFUHDVH ZDV KLJKHU LQ ,/ȕ VWLPXODWHG FHOOV
Similarly, when tumour cells were exposed to macrophage conditioned media,
there was an increase in the percentage of wound closure compared to control
FHOOV7KHHIIHFWRI,/ȕDQGPDFURSKDJHFRQGLWLRQHGPHGLDRQEUHDVWFDQFHU
cell migration across blood and lymphatic endothelial cells were also studied
using Boyden chamber transmigration assay. Significant increased in tumour
FHOOV WUDQVPLJUDWLRQ ZDV REVHUYHG ZLWK ,/ȕ VWLPXODWLRQ ZLWK VLPLODU DIILQLW\
across both endothelial cell types. However, when cells were stimulated with
macrophage supernatant from lipopolysaccharide (LPS) stimulated
macrophages, an increase transmigratory effect was notably observed to the
lymphatic endothelial cells. Interestingly, the increased adhesion effect was
removed with the used of ICE inhibitors.
IV
7KHODVWSDUWRIWKLVVWXG\GHDOWZLWK,/ȕH[SUHVVLRQLQEUHDVWWLVVXHVDPSOHV
1511 early stage breast cancer tissue microarray samples were stained with
FRPPHUFLDOO\DYDLODEOH,/ȕDQWLERG\WRH[DPLQHWKHDVVRFLDWLRQZLWKO\PSKDWLF
YHVVHO LQYDVLRQ FOLQLFRSDWKRORJLFDO YDULDEOHV DQG FOLQLFDO RXWFRPH +LJK ,/ȕ
expression in tumour cells was significantly associated with the absence of both
intra-tumoural and peri-tumoural lymphatic vessel invasion. A significant
DVVRFLDWLRQ ZDV DOVR REVHUYHG EHWZHHQ ORZ ,/ȕ H[SUHVVLRQ LQ WXPRXU FHOOV
with breast cancer specific survival and disease free interval.
In conclusion, lymphatic vessels have been found to play a significant role in
breast cancer and melanoma cells progression by being the major route for
YDVFXODUGLVVHPLQDWLRQ,QWKHLQYLWURVHWWLQJVWKLVVWXG\KDVVKRZQWKDW,/ȕ
with macrophages as the main producer, could regulate tumour cell invasion
especially to the lymphatic circulation. This project has yielded some important
results towards understanding of the lymphatic vasculature and modulation of
lymphatic vessel invasion. However, more studies are needed to enable
translation of research into clinical management of cancer.
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TDL tumour derived lysate
Thy-1 thymus cell antigen 1
TIL tumour infiltrating lymphocytes
TMA tissue microarray
71)Į WXPRXUQHFURVLVIDFWRUDOSKD
TNM tumour nodes metastasis
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1CHAPTER 1: GENERAL INTRODUCTION
21.1 Cancer
Cancer is a class of complex diseases involving dynamic changes in the human
genome (Hanahan and Weinberg, 2000). There are more than 100 distinct
types of cancer that are characterised by uncontrolled cell growth and spread of
abnormal cells in the body.
Cancers are classified by the types of tissue in which they develop (histological
type) and by their primary location. From a histological standpoint, this disease
is grouped into five major categories that are summarised in Table 1-1.
Table 1-1: Classification of cancer based on histological types. Adapted from (Weinberg,
2007)
Histological
types
Definition
Tumours arising from epithelial tissue
Carcinoma - malignant neoplasm of epithelial origin
- 80 to 90% of all cancer cases (breast, colon, lung)
- divided into 2 major subtypes;
(a) adenocarcinoma –develops in an organ or glands
(b) squamous cell carcinoma –originates in the squamous epithelium
Tumours arising from non-epithelial tissue
Sarcoma -cancers originating in supportive or connective tissue such as bones,
cartilage, tendons, muscle and fat.
-named based on the tissue types from which they arise for example;
(a) osteosarcoma –arises from bone
(b) chondrosarcoma – arises from cartilage
(c) liposarcoma –arises from smooth muscle
Haematopoietic
malignancies
-cancers arise from various cell types that constitute the blood forming
tissue including the cells of immune system. These includes;
(a) myeloma - cancer originates from plasma cells of bone marrow which
interfere with the production of normal blood cells.
(b) leukemia - cancer of the blood or bone marrow associated with
overproduction of immature white blood cells.
(c) lymphoma - solid tumour of lymphoid cells in the lymphatic system
Neuroectodermal
tumours
-cancers arise from cells that form various components of the central and
peripheral nervous system
-include are gliomas, glioblastomas, neuroblastomas, schwannomas and
meduloblastomas.
Others -cancers that do not fit into the major classifications for example;
(a) melanomas – melanocytes, while having embryonic origin close to
neuroectodermal cells, settled in the skin and eyes during development
and acquire no direct connections with the nervous system.
(b) small cell lung carcinoma – contains cells of unclear origins.
3Cancers are usually named based on the tissue of origin with histological types
of cancer as suffix. For example, hepatocarcinoma is cancer arising from liver
parenchyma or liposarcoma is cancer arising from fat cells.
Of all cancers, melanoma and breast cancer are the focus of this study and will
be covered in depth in the subsequent chapters.
1.2 Metastatic dissemination of cancer
The process of tumourigenesis involves multistep genetic alterations that
transform normal human cells into highly malignant cells. In order for a cell to
become malignant, it must successfully overcome many barriers and normal
regulatory circuits that govern the human body. According to Hanahan and
Weinberg (2000), there exist six essential alterations in cell physiology that
collectively dictate malignant growth, which are; (1) sustained growth signalling,
(2) non-sensitivity to growth suppressor signalling, (3) the ability to evade
apoptosis, (4) limitless replicative potential, (5) the ability to induce
angiogenesis and (6) tissue invasion and metastasis. The authors suggested
that most if not all cancer cells have acquired these six capabilities during their
transformation from normal cells through various mechanistic strategies.
Recently, with the advancement in cancer research, Hanahan and Weinberg
(2011) have suggested two emerging hallmarks to these six core hallmarks,
which are reprogramming of energy metabolism to fuel cell growth and division
and evading immune destruction.
Metastasis, an extension of local invasion process involved the spread of
tumour cells from primary tumour site in which cancer develops to other site of
the body. Metastasis remains a therapeutic challenge in the field of cancer
research in which 90% of cancer patients succumb to multiple secondary
tumour growths (Sporn, 1997).
There are two theories that explain the occurrence of metastasis. Late stage or
clonal selection theory hypothesises that only a small fraction of cancer cells in
the primary tumour will have selective advantage to cause distant metastasis
through various accumulations of genetic alterations that take place as the
4cancer progresses (Talmadge, 2007). Contrary to the late stage theory, the
recent advances in microarray based approaches have shown that the ability of
tumour cells to metastasise may not be acquired over time but is a pre-
programmed event giving them an inherited general predisposition for
metastasis (Weigelt et al., 2005).
Different types of tumours have different preferential sites of metastasis. Breast
cancer commonly spreads to the bones, lungs and liver whilest melanoma
frequently spread to the lungs and bones (Chen et al., 2009). There have been
a number of different hypotheses regarding the involvement of certain organs in
the metastatic dissemination of cancer. The ‘seed and soil’ theory, proposed by
Stephen Paget in 1889 (Paget, 1889), stated that metastatic process did not
occur by chance but occurred in an organ-specific manner in which certain
organs provided a well suited environment (soil) for the tumour cells (seeds) to
grow. The tendency for certain tumours to preferentially grow in particular
organs suggests that local growth factors, specific endothelial cell surface
receptors (Kuwashima, 1997; Paschos et al., 2009) and specific chemotactic
agents (Mochizuki et al., 2004) differentially expressed by different organs might
be responsible for the distribution pattern of metastasis. Contrary to the ‘seed
and soil’ theory, James Ewing in 1928 proposed that the anatomical structure of
the vascular system is solely accountable for the distribution pattern of
metastasis (Ribatti et al., 2006). He hypothesised that when tumour emboli,
following detachment from the primary tumour site and following intravasation
into the circulation got mechanically trapped in the vessel of the first organ
encountered, metastasis are likely to occur in that particular organ.
Regardless of hypotheses, a malignant cell must go through a series of
sequential steps, collectively known as the metastatic cascade for a successful
metastasis. A tumour cell must be able to (a) detach from the primary tumour
mass, (b) invade and migrate through the extracellular matrix, (c) penetrate into
the local vasculature (blood and/or lymphatic vessels), (d) survive the host
immune response within the circulation, (e) extravasate into the new
tissue/organ, and (f) adapt and divide to form a new tumour. For these to occur,
5a tumour cell must undergo various genetic and epigenetic changes to
overcome protective mechanisms within the host body and immune system
(Yokota, 2000). The latter steps of this metastatic cascade i.e movement of
cells in the circulation, extravasation and colonisation into secondary site have
been well documented. It is known that cancer cells express endothelial
adhesion receptors similar to leukocytes, therefore mimicking leukocyte
transmigration from the blood circulation into the tissue following inflammation.
Basically, circulating leukocytes extravasate from the circulation through the
open inter-endothelial junctions in a multi-step processes which involves (a)
leukocyte rolling on endothelial cells, (b) activation of integrins via G-protein
coupled receptors, (c) tight adhesion to the endothelial cells and (d) leukocyte
diapedesis
On the contrary, there is a lack of knowledge about the initial steps of
metastasis that leads to, and includes, intravasation of cancer cells into the
circulation, especially in carcinomas. The initial steps of metastasis, collectively
termed invasion is believed to include multiple events such as alteration in
cellular adhesion and cellular motility that eventually leads to intravasation of
cancer cells into the circulation. These initial steps of metastasis are the focus
of this thesis and will be discuss in greater details in Chapters 2, 3, 4 and 5.
The theory of metastatic cascade suggests that the tumour vasculature plays a
central role in the metastatic processes by being the major route of spreading.
Tumour cells could spread via two main circulatory systems in the body (1) the
blood vascular system and/or (2) the lymphatic system. The spread of cancer
cells via the blood vessels is termed haematogenous spread while the spread of
cancer cells via the lymphatics is known as lymphogenous spread. Currently,
vascular invasion is identified as the presence of tumour cells within thin walled
vessels in haematoxylin and eosin (H&E) stained tissue samples but it is difficult
to distinguish between lymphatic vessel invasion and blood vessel invasion.
Therefore, are there any other methods that could improve the accuracy of
detection? And if so, could these methods be routinely used in clinical settings?
6Detection of vascular invasion in patients’ specimens will be discussed further in
Chapter 2.
For a tumour cell to enter the circulation, they must first adhere to blood or
lymphatic endothelial cells before penetration and migration into the vessels.
What are the pathways and mechanisms used by the tumour cells in these
processes? These metastatic processes i.e adhesion, migration as well as
transmigration across the endothelium differ dependent upon the vessel types,
the role of cell adhesion molecules, the action of chemokines or cytokines and
the presence of inflammatory infiltrates in the tumour environment and will be
discussed further in Chapters 3, 4 and 5.
1.3 The lymphatic system
The lymphatic system is composed of a vascular network of lymph vessels and
lymphoid tissues and was initially described by Hippocrates (460-360 B.C.) as
‘white blood’ in an axillary node. However, Aselli, an Italian anatomist was
credited with the discovery of lymphatic system when he observed milky liquid
in vein-like vessels in the mesentry (Hong et al., 2004b). Since then, many new
techniques have been developed to study the gross anatomical details of the
lymphatic system such as mercury injection and Evan blue dye injection into the
lymphatic vessels and also indirect injection methods (Johnson and Jackson,
2008)
The lymphatic system has many properties in common with the blood vascular
system; however, they also have very distinct structural features. This system
consists of (1) lymphatic capillaries, (2) collecting afferent and efferent
lymphatics, (3) lymph nodes, (4) lymphatic trunks and (5) lymphatic ducts with
diameters ranging between 10µm to 2mm. Lymphatic capillaries possess a
more irregular and wider lumen than blood capillaries. They lack supporting
structure such as pericytes and have incomplete basement membrane. Under
normal physiological conditions, the lymphatic capillaries remain in a partially or
fully collapsed stage. In blood vessels, tight and adherens junctions maintain
firm cell to cell adhesion while focal point adhesion are the main intracellular
7junction in lymphatic vessels. Lymph vessels attached to extracellular matrix by
anchoring filaments which are elastic fibres opposed to collagen and laminin
which attached blood vessels to extracellular matrix (Nathanson, 2003; Stacker
et al., 2002). Figure 1-1 shows the structural and functional differences between
blood and lymphatic vasculatures.
The lymphatic system plays an important role in the maintenance of tissue
homeostasis. The blind-ending vessels of lymphatics collect intercellular fluid
from the interstitial compartment and eventually drain it back into the blood
circulation via a combination of osmotic and hydrostatic pressure, thus
maintaining normal fluid balance within the body (Karpanen et al., 2006). When
interstitial pressure within the tissue compartment rises, the overlapping
intracellular junctions will be forced to open, permitting the entry of fluid into the
lymph vessels. Once inside the lumen, the interstitial fluid is known as the
lymph. The lymph fluid is moved along the lymphatic circulation, through the
lymph nodes and ultimately into the right lymphatic duct and the thoracic duct
where they are returned to the blood circulation via the right and left subclavian
Figure 1-1: Structure of blood and lymphatic capillaries. The lymphatic capillaries
differ in that they are wider and possess a more irregular and wider lumen which lack
continuous basal lamina and pericytes which are supporting cells that cover the blood
endothelial cell in blood capillaries. Adapted from (Pepper and Skobe, 2003)
8veins (Oliver, 2004). In addition to this, the lymphatic system is also involved in
the body’s immune defence by directing antigen presenting cells from tissue to
the lymph nodes. This system is also responsible for the transportation of fatty
acids and fats in the form of milky fluid called chyle (Podgrabinska et al., 2002).
Impaired function of lymphatic, congenital or acquired, can result in the
formation of lymphedema, a condition of localised fluid retention and tissue
swelling which is often caused by inflammatory or neoplastic obstruction
(Pepper, 2001). Lymphatic vessels are also involved in metastatic
dissemination of cancer cells. Evidence has shown that the extent of
lymphangiogenesis i.e. the formation of lymphatic vessels from pre-existing
lymphatics create a favourable environment for tumour cells dissemination.
Increased lymphatic vessels density in and around the tumour is associated
with lymphatic metastasis and reduced patient survival (Straume and Akslen,
2004; Zhang et al., 2009) –this topic would be discussed further in Chapter 2.
Although it was long suggested that the metastatic spread of tumour cells via
the lymphatics follows the routes of natural lymph drainage, the exact
mechanisms of how tumour cells enter the lymphatic capillaries is still uncertain.
The entry of tumour cells into the lymphatic vessels was thought to be a passive
process facilitated by a complex interaction between interstitial pressure and the
structure of the lymphatics which would not offer a significant barrier for the
entry of tumour cells (Gershenwald and Fidler, 2002; Mandriota et al., 2001).
However, recent works have suggested that lymphatic endothelium may play a
more active role in the recruitment of tumour cells. They secreted chemokines,
which are small molecular size protein that attracted tumour cells towards
lymphatic capillaries (Achen and Stacker, 2008; Nathanson, 2003). Chemokines
receptor-ligand relationships are important to regulate leukocytes trafficking and
this relationship was hypothesised to be exploited by cancer cells to modulate
entry into the lymphatic circulation (Pepper, 2001). The role of lymphatic
specific adhesion molecules is also of particular important because in order for
tumour cells to migrate and transmigrate into the lymphatic vessels, they first
required an adhesive interaction with lymphatic endothelial cells. To date, many
9adhesion molecules preferentially expressed on lymphatic endothelial cells
have been discovered and will be discussed further in Section 1.5.
In comparison with vascular circulation, lymphatic research has progressed
slowly, mainly because of the lack of histological and immunohistochemical
markers that could reliably distinguish between blood and lymphatic endothelial
cells. However, in recent years, the identification of lymphatic vessels has been
made possible by the discovery of specific lymphatic markers such as (1) D2-
40/podoplanin (Breiteneder-Geleff et al., 1999; Kahn and Alexander, 2002), (2)
LYVE-1 (Banerji et al., 1999b), (3) Prox-1 (Wigle et al., 2002), and (4) VEGFR-3
(Joukov et al., 1996). Since then, research related to the lymphatics has greatly
expanded.
1.4 Molecular markers of lymphatic vessels
1.4.1 D2-40/podoplanin
D2-40 is a monoclonal antibody first developed against an oncofetal antigen
(M2A) associated with germ cell neoplasias (Marks et al., 1999). This antibody
binds to an O-linked sialoglycoprotein (molecular weight -40kDa) found on
lymphatic endothelial cells but not on the endothelium of arteries and veins.
Since D2-40 staining is immunonegative in blood endothelium, this antibody has
been used as a reliable marker to evaluate lymphatic invasion in many cancer
types. However, this antibody is not specific to endothelial cells as it can, in
certain settings, stain mesothelial cells, myoepithelial cells, basal and follicular
dendritic cells (Kaiserling, 2004).
The commercially available D2-40 antibody binds to a fixation resistant epitope
on podoplanin molecules (Schacht et al., 2005b), an integral transmembrane
glycoprotein selectively expressed on the apical surface of alveolar type I cells
in rat lung. Podoplanin was first reported by Wetterwald et al. (1996) as E11
DQWLJHQ ,W LV KRPRORJRXV WR 7Į ZKLFK ZDV GHWHFWHG LQ FKRURLG SOH[XV
intestine, kidney, thyroid and esophagus of foetal rat (Wetterwald et al., 1996).
On endothelial cells, podoplanin is expressed on the lymphatic endothelial cells
but not on blood endothelial cells. Its expression has been observed on the
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small lymphatic capillaries but not on larger lymphatic trunks or high endothelial
venules of the lymph nodes (Breiteneder-Geleff et al., 1999). Ultrastructural
analysis revealed its predominant localisation to the luminal surface of
lymphatic vessels. Podoplanin is also implicated in the development of
lymphatic vessels. Podoplain-/- mice have defects in lymphatic vessels but not
blood vessels resulting in the formation of dilated, disorganised lymphatic
capillaries (Ramirez et al., 2003; Schacht et al., 2003).
1.4.2 LYVE-1
Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) is a homolog to
CD44, a cell surface glycoprotein involved in cell-cell interactions, cell adhesion
and migration. LYVE-1 is expressed on luminal and abluminal surfaces of
lymphatic endothelial cells of both normal and neoplastic tissue. LYVE-1 is also
expressed on tissue especially where high level of hyaluronan absorption and
degradation occurs such as activated tissue macrophage and sinusoidal
epithelium of the liver and spleen (Banerji et al., 1999a; Banerji et al., 1999b;
Hong et al., 2004b; Schledzewski et al., 2006). Although a reliable marker to
study lymphatics in normal tissue, LYVE-1 expression is altered in inflammatory
conditions. Studies are currently underway to determine how pro-inflammatory
cytokines could influence LYVE-1 function and expression (Carreira et al., 2001;
Jackson, 2004).
1.4.3 Prox-1
Prospero-related homeobox-1 (Prox-1) is a member of the homeobox gene
family and was originally cloned by homology to the Drosophila gene prospero,
a gene required for normal differentiation of neuronal lineage (Hong et al.,
2004a). In early embryonic development, Prox-1 expression in the cardinal vein
promotes and maintains the budding of venous endothelial cells that will
differentiate into lymphatic endothelium. It was shown that the endothelial cells
in Prox-1 deficient mice remain as blood vascular endothelium as they failed to
acquire the lymphatic phenotype. In humans, Prox-1 is detected in the nuclei of
lymphatic endothelial cells in all stages of development; early embryonic, foetal
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and adult tissue but not detected in the blood endothelial cells (Wilting et al.,
2002).
1.4.4 VEGFR-3
Vascular endothelial growth factor receptor 3 (VEGFR3) also known as FLT4 is
a tyrosine kinase receptor expressed specifically on lymphatic endothelial cells
in normal adult tissues. However, it is also expressed on blood endothelium
during wound healing and on some tumour blood endothelium as well as the
myoepithelial cells. VEGFR-3 binds to vascular endothelial growth factor-C and
–D and is associated with lymphangiogenic processes and tumour
angiogenesis (Laakkonen et al., 2008). Activated VEGFR-3 stimulates
lymphatic endothelial cell proliferation, increasing the ability of cancer cells to
metastasise to the lymphatic vessels (Podgrabinska et al., 2002).
1.4.5 Thy-1
Thymus cell antigen-1 (Thy-1) or CD90 has been used as murine T-cell marker
for over three decades (Saalbach et al., 2005). However, its expression on
lymphatic endothelial cells has only recently been discovered. Thy-1 is strongly
expressed by tumour associated lymphatic vessels at much higher levels than
blood endothelial cells. Importantly, Thy-1 was up-regulated in lymphatic
endothelial cells but not on blood endothelial cells when samples were treated
with tumour necrosis factor (TNF) (Jurisic et al., 2010)
In addition to the more commonly used markers discussed above, there are
other lymphatic specific markers available. CC chemokine ligand 21 (CCL21) is
expressed on lymphatic endothelial cells and high endothelial venules as well
as T cell areas of the spleen, lymph node and Peyer’s patches (Gunn et al.,
1998). Neurophilin-2 and Angiopoietin-2 are non-tyrosine and tyrosine kinase
receptor respectively and have been implicated in lymphangiogenic signalling
pathways (Baldwin et al., 2002; Maisonpierre et al., 1997).
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On top of these commonly used and commercially available lymphatic specific
markers, a number of additional lymphatic specific adhesion molecules are
discussed below.
1.5 Adhesion molecules of lymphatic endothelium
1.5.1 Junctional Adhesion Molecules
Junctional adhesion molecules (JAMs) are members of the immunoglobulin
superfamily characterised by immunoglobulin folds at their extracellular domain.
These 20-30 kDa proteins can be found localised at the tight junctions of
endothelial and epithelial cells as well as on the leukocytes and platelets
(Ghislin et al., 2011). JAMs are molecules with dual main functions; regulating
cell and membrane polarity, in doing so organising the tight junction’s formation
and also involved in cell-cell and cell-leukocyte interactions.
There are three different homologous molecules in the JAM family, JAM-A,
JAM-B and JAM-C (Cera et al., 2004); each has shown differential human
tissue expression profiles. JAM-A/JAM-1 has a wider distribution compared to
the others. This molecule is present on both epithelial and endothelial cells and
mainly localises at the tight junctions of these cells. It is also expressed on
circulating leukocytes (neutrophils, monocytes, lymphocytes) and platelets.
Knockdown of JAM-A protein expression in MCF7 cells was shown to
significantly reduced the breast cancer cell adhesion and migration (McSherry
et al., 2011).
Human JAM-B/JAM-2 on the other hand is localised at the tight junctions of
both vascular and lymphatic endothelial cells with a more prominent expression
on the high endothelial venules (HEVs). As with JAM-A, JAM-C expression can
be observed on various human leukocytes subsets, dendritic cells, natural killer
cells and platelets. In addition to HEVs, vascular expression of JAM-C can also
be found on blood vessels and lymphatic vessels. Regarding their involvement
in cancer cell dissemination, JAM-C has been shown as a novel player in
melanoma metastasis to the lung which promotes the transendothelial migration
of melanoma cells. Endothelial specific JAM-C deficient mice displayed
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significantly decreased B16 melanoma cell metastasis to the lung and soluble
JAM-C treatment in mice was shown to prevent melanoma lung metastasis
(Langer et al., 2011).
1.5.2 Sphingosine-1-phosphate receptor
Sphingosine-1-phosphate receptor (S1P) was thought as an end product of
sphingolipids, a class of lipid molecules present on plasma membranes of all
eukaryotic cells. For the last fifteen years, research has been focusing on this
protein molecule due to findings that S1P can regulate both cell growth and
apoptosis. To date, S1P has been shown to be involved in various cellular
processes such as angiogenesis, wound healing and tumourigenesis as well as
autoimmune diseases such as multiple sclerosis (Kim et al., 2009). However,
the role of S1P receptors in controlling lymphocytes trafficking in and out of the
lymph nodes is relatively novel with studies reporting that both lymphocytes and
lymphatic endothelium strongly express S1P receptors (Matloubian et al.,
2004). Furthermore, it was shown that the level of sphingosine kinase 1
(SphK1), which phosphorylates sphingosine to S1P, is overexpressed in various
cancer types (van Brocklyn, 2011; Young and van Brocklyn, 2007) and
inhibition of SphK1 with either a SphK1 inhibitor or siRNA reduced human liver
cancer cell migration and invasion (Bao et al., 2012).
1.5.3 Mannose Receptor
Mannose receptor (MR) is a calcium dependent carbohydrate binding protein.
This 180-kDa protein is expressed on macrophages; hence is also known as
macrophage mannose receptor, plays a role in cell-cell recognition, serum
glycoprotein turnover and in the phagocytosis/endocytosis of pathogens through
its recognition of complex carbohydrate structures on the surface of cells
(Linehan, 2005).
Besides macrophages, MR is also expressed on the afferent and efferent
lymphatics of lymph nodes with no expression observed on HEVs (Irjala et al.,
2003), suggesting that the vascular expression of MR is strictly on lymphatic
endothelial cells. Functionally, MR has been shown to be involved with
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lymphocyte binding to lymphatic endothelium via L-selectin dependent
mechanisms. L-selectin is a cell adhesion molecule found on leukocytes that act
as receptors for leukocytes to enter lymphoid tissues. Hypothetically, tumour
cells that express L-selectin may spread from lymph vessels using the same L-
selectin mediated binding to the MR as in the case of lymphocytes. In fact, Irjala
et al. (2003) has shown that the binding of head and neck carcinoma cells to the
lymphatic endothelium is MR dependent. In their in vitro adhesion assay, a
statistically significant reduction (>50%) in the adhesion of squamous cell
carcinoma cells was obtained using anti-MR antibody. Another study using MR-
deficient mice has shown that the lack of MR in these mice not only leads to
faster growth of primary tumours but tumours possessed a smaller metastatic
lesion in the draining lymph nodes (Marttila-Ichihara et al., 2008). Their results
suggested that, in the absence of MR, tumour cells cannot metastasise
efficiently to the lymph nodes.
1.5.4 CLEVER-1
Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1)
is a large glycoprotein molecule ranging from 270- to 300-kDa in size. The
structure of CLEVER-1 consists of 7 fasciclin domains, 22 epidermal growth
factor (EGF)-like repeats and 2 laminin-type EGF-like domains (Shetty et al.,
2011). This protein has independently been characterized as FEEL-1, MS-1,
Stabilin-1/STAB-1 depending on the detection antibodies used.
The use of these antibodies on fresh frozen tissues revealed some
disagreement in the staining pattern as different antibodies recognise different
epitopes on the same molecule. FEEL-1 was found to be highly expressed in
the spleen and lymph nodes as well as in CD14+ mononuclear cells (Adachi
and Tsujimoto, 2002). MS-1 antigen is expressed in macrophages and in the
non-continuous sinusoidal endothelial cells in human spleen, liver, lymph nodes
and adrenal cortex but no expression was detected in nonsinusoidal continuous
endothelium of the same organ (Goerdt et al., 1991). CLEVER-1 on the other
hand is expressed on lymphatic vessels and inflamed blood vessels and also on
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macrophages and has been used as a marker for regulatory/suppressive
macrophages besides a pan-macrophage marker, CD68 (Algars et al., 2011).
In a study comparing the expression of CLEVER-1 between lymphatic and
vascular endothelial cells, it was shown that the expression of CLEVER-1 was
mainly in lymphatic but not in the normal vascular endothelial cells (Salmi et al.,
2004). However, vascular expression of CLEVER-1 can be observed in
inflamed vascular vessels surrounded by inflammatory infiltrates and this
observation was in accordance with the other studies (Ammar et al., 2011; Irjala
et al., 2003; Kzhyshkowska et al., 2006) all of which, using different antibodies,
demonstrated vascular expression of CLEVER-1 during wound healing, tumour
vascularisation and chronic inflammatory condition of the skin. In addition, using
formalin fixed paraffin embedded (FFPE) breast cancer samples, CLEVER-1
expression in vascular vessels was shown to correlate significantly with the
density of inflammatory infiltrate, primarily macrophages (Ammar et al., 2011).
Regarding the expression of CLEVER-1 in lymphatic vessels, Ammar et al.
(2011) observed that although both hTERT-LEC and HUVEC expressed
CLEVER-1, surface expression was only detected on lymphatic endothelial
cells. This finding is of special importance in relation to the role of CLEVER-1 as
a lymphatic adhesion molecule. An in vitro study utilising flow chamber
adhesion assay demonstrated that CLEVER-1 facilitates peripheral blood
mononuclear cell (PBMC) transmigration through lymphatic endothelium (Salmi
et al., 2004). CLEVER-1 was shown to facilitate lymphocyte binding not only to
the lymphatic vessels but also to the HEVs (Irjala et al., 2003). A significant
decrease in lymphocyte binding to lymphatic endothelium was observed when
an inhibition assay was carried out with anti-CLEVER-1 antibody. CLEVER-
1/Stabilin-1 was also shown to support regulatory T cells (Tregs)
transendothelial migration across human hepatic sinusoidal endothelial cells
under flow conditions (Shetty et al., 2011) .
In a study focusing on the adhesion of tumour cells to the lymphatic
endothelium, by utilising Stamper-Woodruff in vitro adhesion assay, Irjala et al.
(2003) demonstrated the adhesion of both head and neck squamous cell
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carcinoma (HNSCC) and lymphoma cells to lymphatic endothelium and HEVs.
Although both tumours differ in their binding affinity to the endothelium, the
incorporation of anti-CLEVER-1 antibody significantly reduced the lymphatic
adhesion of these cancer cell lines suggesting the role of CLEVER-1 in tumour
cells trafficking within the lymphatics. An immunohistochemistry (IHC) study
with fresh frozen tumour materials demonstrated heterogeneous lymphatic
expression of CLEVER-1 and that this expression was variable between
tumours (Irjala et al., 2003). However, this study utilised just a small number of
HNSCC samples (n=17) with limited follow-up information. Moreover, CLEVER-
1 expression on lymphatic vessels was associated with lymph nodes metastasis
and macrophage infiltrates suggesting that CLEVER-1 may be an important
mediator of tumour cell metastasis to the lymph nodes which is regulated by
inflammatory conditions, most likely by macrophage-associated cytokines
(Ammar et al., 2011). Studies to date have shown very promising results
regarding the potential of CLEVER-1 as a potential target in anticancer based
therapy. However, the ligands of CLEVER-1 in adhesion and transmigration
remains unidentified and how CLEVER-1 mediates these events is as yet
unclear (Johnson and Jackson, 2008) The role of CLEVER-1 in tumour-
endothelial adhesion will be discussed further in Chapter 3.
1.5.5 ICAM-1 and VCAM-1
Apart from lymphatic specific adhesion molecules described above, there are
also a number of adhesion molecules which are typically expressed on
endothelial cells such as ICAM-1 and VCAM-1. Intracellular adhesion molecule
1 (ICAM-1) or cluster of differentiation 54 (CD54) is a transmembrane
glycoprotein in the immunoglobulin superfamily of adhesion molecules. ICAM-1
is expressed at low levels in fibroblasts, endothelial cells and some leukocytes.
ICAM-1 has been intensively analysed as an important adhesive receptors on
endothelial cells for the firm adhesion of leukocytes. This receptor binds to
OHXNRF\WHVȕ2 integrin /LFA-1 in the leukocytes extravasation processes (Senger
et al., 2002). ICAM-1 is also present on the surface of many cancer types and in
cancer patients, a soluble form of ICAM-1 is present at an elevated level. ICAM-
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1 plays an important role in the immune response and most importantly in the
metastatic progression of various types of cancer. ICAM-1 expression in human
lung cancer and melanoma was associated with advance stages of this cancer
which has metastasised (Lin et al., 2006). In addition, ICAM-1 mediates
leukocyte-endothelial cell adhesion and may play a role in the development of
artherosclerosis and rheumatoid arthritis (Chen et al., 2011).
Vascular cell adhesion molecule 1 (VCAM-1) or cluster of differentiation 106 is a
cell surface sialoglycoprotein, a type I membrane protein that is a member of
the immunoglobulin superfamily. It is expressed at low concentrations in the
membrane of leukocytes, vascular endothelial cells, macrophages and
O\PSKRF\WHV9&$0LVDPDMRUOLJDQGIRUȕ1 integrin /very late antigen (VLA)-4
(Senger et al., 2002) and is mainly involved in the inflammation-related
leukocyte extravasation. In addition, various inhibition studies have shown that
the adhesion of cancer cells to endothelial cells is due to the interaction
EHWZHHQ WKH HQGRWKHOLDO 9&$0 DQG WKH Į4ȕ1 integrins on the cancer cells
(Saalbach et al., 2005; Zhu et al., 2002).
It was shown that the expression levels of ICAM-1 and VCAM-1 increases
during inflammatory conditions (Hayes and Seigel, 2009) and their expression
PLJKW EH HQKDQFHG XSRQ F\WRNLQH VWLPXODWLRQ VXFK DV ,/ DQG 71)Į 7KH
expression level of ICAM-1 and VCAM-1 in normal and cytokines stimulated
endothelial cells with a focus on lymphatic endothelial cells would be discussed
further in Chapter 3.
1.6 Cancer and inflammation
The accumulation of inflammatory cells, i.e inflammatory infiltrate, in tumour
microenvironment suggests a link between inflammation and cancer.
Epidemiological studies have revealed an association between chronic
inflammation and cancer development; for example, inflammatory bowel
disease can lead to cancer in the large intestine, and gastric ulceration caused
by Helicobacter pylori increases the risk of gastric cancer. Non-steroidal anti-
inflammatory agents used as prevention and protection from various tumours
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reflect the fact that inflammation is a risk factor for certain cancers. Tumour
inflammatory microenvironment consists of (1) innate immune cells such as
macrophages, neutrophils, dendritic cells, mast cells and natural killer cells and
(2) adaptive immune cells which are the T and B lymphocytes. These cells
together with the cancer cells and the surrounding stroma communicate with
each other by direct contact or produce cytokine/chemokines to influence
tumour growth and survival.
1.6.1 Macrophage
Macrophages are, besides the T cell lymphocytes, a major component of
leukocyte infiltrate in the tumour microenvironment. These specialised
phagocytic cells differentiate from monocytes and are recruited through the
local expression of various chemo-attractants such as colony stimulating factor
1 (CSF-1), macrophage chemo-attractant protein 1 (MCP-1/CCL2), CCL5 and
CXCL1 or through the action of other growth factors such as VEGF-A. In human
tissue, macrophages are identified by the expression of specific proteins such
as CD14, CD11b, EMR1 and CD68 (Mantovani et al., 2008).
There are two pathways of macrophage activation based on triggering signals;
the classical M1 macrophage activation or the alternatively activated M2
macrophage also known as tumour associated macrophage (TAM). M1
macrophages are usually associated with an active defense mechanism against
PLFURRUJDQLVPV DQG WXPRXU FHOOV UHVSRQVH WR LQWHUIHURQȖ DQG PLFURELDO
products such as lipopolysaccharide (LPS) and produce high IL-12 (interleukin)
and IL-23 production. By contrast, M2 forms which are activated by IL-4, IL-13,
glucocorticoids, IL-10 and immunoglobulin complexes/TLR ligands can
suppress immunity, are involved in matrix remodelling (Kzhyshkowska et al.,
2008) and can promote both angiogenesis (Hussein, 2006; Joimel et al., 2010)
and lymphangiogenesis (Coffelt et al., 2009; Jeon et al., 2008). In terms of
lymphatic vessel formation, macrophages express lymphangiogenic growth
factors, VEGF-C and VEGF-D which are able to stimulate the lymphatic vessel
receptor, VEGFR-3 (Attout et al., 2009). Evidence also shows that
macrophages promote metastasis via the production of various cytokines such
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DV71)Į+DKQHHWDODQG,/ȕ9RURQRYHWDO7KHVHDXWKRUV
VXJJHVW WKDW ERWK 71)Į DQG ,/ȕ HQKDQFH WKH H[SUHVVLRQ RI DGKHVLRQ
molecules on endothelial and malignant cells thus facilitating the invasion of
malignant cells into the circulation and their dissemination to remote tissues -
this topic will be discussed further in Chapters 3, 4 and 5.
 ,/ȕ
,QWHUOHXNLQ  EHWD ,/ȕ LV D SURLQIODPPDWRU\ F\WRNLQH ZKLFK EHORQJV WR WKH
LQWHUOHXNLQ  JHQH IDPLO\ EHVLGHV LQWHUOHXNLQ  DOSKD ,/Į DQG LQWHUOHXNLQ 
receptor antagonist (IL-1Ra) (Song et al., 2003). This cytokine, which could
evoke a wide variety of biological effects, is actively secreted by activated
KXPDQPRQRF\WHVDQGPDFURSKDJHV,/ȕLVILUVWV\QWKHVLVHGLQWKHF\WRSODVP
DV ELRORJLFDOO\ LQDFWLYH N'D SUHFXUVRU SURLQIODPPDWRU\ ,/ȕ SUR,/ȕ
which would remained cytosolic until it is cleaved by interleukin 1 converting
enzyme (ICE)/caspase 1 to the active 17kDa form. Once released from the cells
LQWRWKHH[WUDFHOOXODUVSDFHRUFLUFXODWLRQ,/ȕFDQWULJJHULQWHUOHXNLQUHFHSWRU
1 (IL-1R1) on both near and distant cells from the production site. This mature
,/ȕ UHOHDVHG IURP WKH FHOOV PXVW FRPSHWH ZLWK LQWHUOHXNLQ  UHFHSWRU
antagonist (IL-1Ra) which binds to IL-1R1 without triggering any signals. The
FOHDYDJHRISUR,/ȕLQWRLWVPDWXUHIRUPE\,&(LVDSK\VLRORJLFDOO\FRQWUROOHG
event; however, other enzymes such as trypsin, elastase and various other
SURWHDVHV FDQ FOHDYH DQG DFWLYDWH ,/ȕ XQGHU FRQGLWLRQV RI FHOO QHFURVLV RU
mechanical injury (Dinarello, 1996; Voronov et al., 2003).
,/ȕLVLQYROYHGLQWKHUHJXODWLRQRILPPXQHUHVSRQVHDQGKDVEHHQVKRZQWR
promote inflammation, angiogenesis, tissue remodelling and metastatic spread
in human cancer (Watanabe et al., 2012). This cytokine could upregulate major
genes involved in inflammation such as nitric oxide synthase (iNOS),
F\FORR[\JHQDV DQG SKRVSKROLSDVH$ ,/ȕ DOVR H[HUWV LWVHIIHFW WKURXJK WKH
regulation of other proliferative cytokines, growth factors, chemokines and
adhesion molecules. A number of studies have reported the association
EHWZHHQLQFUHDVHG,/ȕH[SUHVVLRQVLQWXPRXUPLFURHQYLURQPHQWZLWKDPRUH
YLUXOHQWWXPRXUSKHQRW\SH/HZLV6DLMRHWDOE,/ȕZDVVKRZQ
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to be linked with increased tumour invasiveness, angiogenesis and immune
VXSSUHVVLRQ RI FDQFHU FHOOV 7KH LQYROYHPHQW RI ,/ȕ LQ WKH LQLWLDO VWHSV RI
metastasis will be discussed further in Chapters 3, 4 and 5.
 71)Į
7XPRXUQHFURVLVIDFWRUDOSKD71)ĮLVDPXOWLIXQFWLRQDOF\WRNLQHZKLFKSOD\V
diverse important roles in cell survival, proliferation, differentiation and cell
GHDWK +DKQH HW DO  :DQJ DQG /LQ  71)Į LV V\QWKHVLVHG DV D
PHPEUDQHERXQG SURWHLQ SUR71)Į ZKLFK ZRXOG WKHQ EH FOHDYHG E\ 71)
FRQYHUWLQJHQ]\PH7$&(71)ĮKDVEHHQUHSRUWHGWRSOD\DUROH LQYDULRXV
pathological responses such as rheumatoid arthritis, septic shock and
transplant rejection (Wang and Lin, 2008).
,Q FDQFHU ELRORJ\ 71)Į ZDV UHSRUWHG WR SOD\ D GXDO UROH ZLWK ERWK WXPRXU
SURPRWLRQ DQG WXPRXU UHJUHVVLRQ HIIHFWV 71)Į H[SUHVVLRQ ZDV KLJKHU LQ
various pre-neoplastic and tumour tissues which was associated with the
SURJUHVVLRQ RI PDOLJQDQW GLVHDVHV /LQ DQG .DULQ  71)Į VHFUHWLRQ E\
cancer cells could regulate expression of various cytokines, growth factors and
adhesion molecules including expression of angiogenic factors such as vascular
endothelial growth factor (VEGF) that could promote angiogenesis and cancer
FHOO PHWDVWDVLV 71)Į LQFUHDVHG WXPRXU FHOOV LQYDVLYHQHVV WKURXJK
upregulation of matrix metalloproteases and integrins (Sun et al., 2010; van
*UHYHQVWHLQ HW DO  $QWLFDQFHU HIIHFWV RI 71)Į PD\ LQYROYH WKH
activation of the immune cells such as cytotoxic T-lymphocytes or tumour
infiltrating dendritic cells that could trigger a potent adaptive immune response
leading to tumour recognition and preventing tumour promotion (Wang and Lin,
 7KH LQYROYHPHQW RI 71)Į LQ WKH LQLWLDO VWHSV RI PHWDVWDVLV ZLOO EH
discussed further in Chapters 3, 4 and 5.
The aims and objectives of the present study were to;
1. Build upon previous work in breast cancer by examining the
characteristics of lymphatic vessels (lymphatic vessel density and lymphatic
vessel invasion), in cutaneous melanoma, in comparison to blood vessel
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characteristics (microvessel density and blood vessel invasion) and to examine
such results in light of the level of inflammatory infiltrate (macrophage) and their
relationship to tumour clinicopathological characteristics and patient prognosis.
2. Conduct in-vitro investigations of tumour cell adhesion, migration and
transmigration using lymphatic and vascular endothelial cell models to
understand the regulation of lymphovascular invasion in the tumour and the
influence of macrophage and/or macrophage associated factors in these
processes.
These aims will form the basis of subsequent chapters.
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CHAPTER 2: DISTRIBUTION AND CHARACTERISTICS
OF LYMPHATIC AND BLOOD VESSELS, AND OF
LYMPHOVASCULAR INVASION IN MELANOMA
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2.1 Abstract
Background: Vascular invasion (both to blood and lymphatic) is an important
step in the metastatic cascade. Unlike blood vessels, less is known about the
role of lymphatic vessels in cancer progression. Progress of lymphatic research
has been slow primarily due to the lack of tools which were able to specifically
distinguish lymphatic from blood endothelial cells. This chapter aims to
investigate the incidence of lymphatic vessel invasion and lymphatic vessel
density in comparison with blood vessel invasion and blood vessel density as
prognostic biomarkers in cutaneous melanoma patients. In addition, the
topography and characteristics of lymphatic and blood vessels in cutaneous
melanoma and the association of these characteristics with clinicopathologic
variables and clinical outcome were studied. The role of tumour associated
macrophages in these processes was also investigated.
Methods: A series of 202 primary invasive cutaneous melanoma samples with
a mean follow up time of 38 months were used in this study. Three
commercially available immunohistochemical (IHC) markers were used to stain
the 202 sections; D2-40, CD34 and CD68 to stain lymphatic vessels, blood
vessels and macrophages respectively. To access lymphatic vessel density,
each tumour section was divided into two zones; intra-tumoural and peri-
tumoural. Positive vessels were counted in each zone which was normalised to
the tumour surface area. The sum of lymphatic vessel density in the two zones
gave total lymphatic density. Microvessel density and the number of
macrophages in each tissue section were counted using the Chalkley method in
three hotspot areas with the average value used for analysis. Lymphatic vessel
invasion was determined as the presence of tumour cells within D2-40 stained
vessels while blood vessel invasion was determined as the presence of tumour
cells within CD34 positive vessels but D2-40 negative. All characteristics of
lymphatic and blood vessels were tested for association with clinicopathological
variables and clinical outcome. The frequency of vascular invasion assessed by
IHC was also compared with haematoxylin and eosin (H&E) staining.
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Results: Using IHC, vascular invasion was detected in 29.9% of cases (55/184)
compared to 8.0% of vascular invasion (16/199) detected by H&E. Of the
vascular invasion detected by IHC, 85.5% (47/55) was via the lymphatic vessels
opposed to 9.1% (5/55) having blood vessel invasion alone. 5.4% of tumours
(3/55) had both lymphatic and blood vessel invasion. Lymphatic vessel invasion
was significantly associated with tumour stage, Breslow thickness, Clarks level,
ulceration and mitotic rate (p<0.001). No associations were observed between
relapse-free survival or overall survival with any characteristics of lymphatic and
blood vessels assessed. High macrophage counts were significantly associated
with Breslow thickness, ulceration and mitotic rate (p<0.001, p<0.001 and
p=0.005 respectively). High macrophage counts were also significantly
associated with high microvessel density (p=0.003) and lymphatic vessel
invasion (p=0.002).
Conclusions: Vascular invasion in melanoma is essentially invasion of
lymphatic vessels with conventional assessment of vascular invasion, by H&E,
underestimating its incidence. Detection is significantly improved by the use of
IHC. The association of lymphatic vessel invasion with markers of aggressive
disease suggests importance in melanoma. A high macrophage count
associated with lymphatic vessel invasion suggesting a role for macrophage
and/or their associated factors in mediating the process of metastatic spread via
lymphatic vessels.
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2.2 Introduction and aims
2.2.1 Melanoma
2.2.1.1 Epidemiology and risk factors
Melanoma, a malignant tumour of melanocytes, is the most lethal and most
aggressive form of human skin cancer. This disease is mainly localised in the
skin (cutaneous melanoma) but can also occur in other body parts such as the
bowel and the eyes (uveal melanoma). Although the incidence of melanoma
accounts for 5 to 7% of all skin cancers, the mortality data indicated that
melanoma causes nearly 80% of all skin cancer related deaths (Gahl et al.,
2009). In the USA, 60,000 new cases of melanoma were recorded annually with
a mortality rate of 8,000 people and these figures are expected to rise over the
next decade at a faster rate compared to other cancers (Lazovich et al., 2010).
One reason for this is may be because of the depletion in stratospheric ozone
layer leading to increases in solar UV-B radiation at the surface of the earth
(Norval et al., 2011)
The risk factors of developing melanoma, as in most cancers, are both intrinsic
and environmental with interaction between the two. The incidence of
melanoma increases with age with a median age at diagnosis of 57 years
(Rajer et al., 2005). Epidemiological studies have established the role of
sunlight exposure as the most relevant causative factor of melanoma (Pfeifer
and Besaratinia, 2011; Rass and Reichrath, 2008). The risk of melanoma
increases with intermittent sun exposure and there is a strong association
between early life exposure to UV-A and UV-B with the risk of melanoma in
adulthood (Norval et al., 2011). Individuals with three or more atypical
(dysplastic) naevi and multiple melanocytic naevi are also considered a
significant risk factor for melanoma (Mackie et al., 2009).
5% of all cutaneous melanoma occurs in familial settings involving germline
mutations in cell cycle regulatory genes; CDKN2A (cyclin dependent kinase
inhibitor 2A) and CDK4 (cyclin dependent kinase 4) genes (Liang et al., 2011).
Another melanoma susceptibility gene is the MC1R (melanocortin 1 receptor)
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gene which encodes a protein located on the surface of melanocytes.
Melanocytes produce melanin, a pigment that gives colour to skin, hair and
eyes. Eumelanin and pheomelanin are two forms of melanin produced by
melanocyes. Individuals with typical melanoma susceptible phenotypes such as
pale Caucasian skin, red or blonde hair and blue eyes possess a higher
proportion of MC1R variants which reduce the ability of MC1R to stimulate
eumelanin production causing melanocytes to make more pheomelanin.
Pheomelanin does not protect individuals from UV radiation; they are more
prone to sunburn reactions and other UV-induced skin damaged making these
individuals prone to a higher risk of melanoma (Fargnoli et al., 2010; Thody et
al., 1991). Table 2-1 summarises the established and postulated risk factors for
cutaneous melanoma.
Table 2-1: Established and postulated risk factors for cutaneous melanoma. Adapted
from (Mackie et al., 2009)
Risk factors for cutaneous melanoma
Personal history of melanoma Invasive cutaneous melanoma in one/more first
degree relatives
Multiple melanocytic naevi (>100) Multiple clinically atypical (dysplastic) naevi (>3)
High/intermittent sun exposure Higher socioeconomic status
Race/pale Caucasian skin Use of sunbeds
Red/blonde hair Occupation
Age
Key genetic changes in melanoma involve the mitogen-activated protein kinase
(MAPK) pathway which regulates crucial cellular activities such as gene
expression, apoptosis, proliferation and differentiation of cells. Extensive
mutation analysis has identified that BRAF and NRAS mutations occurr in two
thirds and one third of melanomas respectively (Curtin et al., 2006). Both
mutations cause increased expression of cyclin D1, a regulatory subunit
involved in controlling a cell progression through G1 to S phase of the cell cycle.
Phosphatidylinositol 3’ kinase pathway (PI3K) is also mutated in melanoma.
Loss of heterozygosity has been demonstrated in the PTEN (phosphatase and
tensin homolog) locus which acts as a tumour suppressor and negative growth
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regulator of PI3K activity. Subsequently, this activates the AKT pathway which
phosphorylates a number of targets involved in the regulation of cell growth and
survival. Figure 2-1 illustrates the MAPK and PI3K pathway in cutaneous
melanoma. Besides these, the p53 and retinoblastoma pathway which are
frequently inactivated in a number of human cancers are also inactivated in
melanoma. Mutational analysis have estimated the incidence of p53 mutation to
be 15 to 25% of melanomas (Bardeesy et al., 2001) while mutation of
retinoblastoma pathway occurs in 10 to 40% of total melanoma incidence
(Fecher et al., 2007a).
Figure 2-1: The MAPK and PIK3 pathway in melanoma. Receptor tyrosine kinases (RTK)
are the key regulators for many cellular processes in human. Defect in any genes
involved in this pathway may play critical role in the development of melanoma and its
progression. MAPK signalling cascade will be activated upon signals from the RTK
which eventually promote cell proliferation. Similarly, these signals will also promote cell
survival via the PI3K pathway.
The primary treatment of melanoma is surgical excision with safety excision
margins around the tumour site. Narrow excision margins of tumour site (1 to 2
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cm) are appropriate compared to wide excision (>3cm) as studies have
consistently found equivalent rate of local recurrence and disease free and
overall survival between both tumour margins (Balch et al., 2001a; Lens et al.,
2002). Interferon alpha-2b (Intron A) is usually used for adjuvant treatment of
melanoma which was shown to increase relapse free and overall survival in the
group that received high dose of this biologic therapy compared to control group
(Kirkwood et al., 1996). However, the use of high dose interferon treatment is
still controversial and inconclusive because this treatment was shown to have
no effect in overall survival especially in patients with sentinel node
micrometastasis (Wheatley et al., 2003).
2.2.2 Histological classification of melanoma
The histological classification of melanoma is based on the microscopic
appearance of the tumour. For malignant melanoma, histological criteria of each
subtype are related to the location and organisational pattern of melanocytes,
cytological features and location of the malignant melanoma (Duncan, 2009).
Four major subtypes of malignant melanomas are (1) superficial spreading
malignant melanoma (SSMM), (2) nodular malignant melanoma (NMM), (3)
acral lentiginous malignant melanoma (ALMM) and (4) lentigo maligna
melanoma (LMM).
SSMM is the most frequent form of cutaneous melanoma characterised by the
presence of a radial growth phase of epithelioid melanocytes in a pagetoid
fashion along the epidermis. Pagetoid is a term used to describe upward
spreading of melanocytes into the epidermis. It is common in sun exposed skin
especially on the trunk of males and on the lower extremities of females. 25% of
SSMM evolved from pre-existing congenital or dysplastic nevi (Forman et al.,
2008).
NMM is the second most common types of malignant melanoma. This disease
is characterised by the presence of a vertical growth phase and the absence of
a radial growth phase. NMM is the most aggressive of all histological types as it
grows rapidly in thickness. It can occur anywhere in the body, usually found on
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the sun exposed areas of the skin without the need of a pre-existing mole (Gahl
et al., 2009).
ALMM is the most frequent histological type of melanoma occurring in Asian
and Black populations (Phan et al., 2007). It is observed on the palms, soles
and nailbeds (subungual skin) and is characterised by lentiginous proliferation
of melanocytes along the basal layer of the epidermis in the radial growth phase
(Kuchelmeister et al., 2000).
LMM develop from lentigo maligna, a non invasive skin growth also known as
melanoma in-situ or Hutchinson’s melanotic freckle. This disease typically found
on sun-exposed areas such as the face and neck of elderly people and
histologically characterised by the presence of atypical melanocytes along the
dermal-epidermal junction (McKenna et al., 2006).
Besides the four major subtypes, other unusual or rare variants of melanoma
include desmosplastic melanoma, nevoid melanoma, small cell melanoma,
mucosal melanoma and soft tissue melanoma. Histological subtypes of
malignant melanoma and its incidence are summarised in Table 2-2.
Table 2-2: Histological subtypes of malignant melanoma and their incidence. Adapted
from (Forman et al., 2008; McKenna et al., 2006).
Subtypes Incidence (%) Subtypes Incidence (%)
Major subtypes Rare variants
Superficial spreading 50 – 75 Desmoplastic melanoma 2 – 4
Nodular 15 – 35 Nevoid melanoma <1
Lentigo maligna 5 – 15 Small cell melanoma <1
Acral lentiginous 5 – 10 Mucosal melanoma
Soft tissue melanoma
<1
<1
2.2.3 Staging of melanoma
The TNM (Tumour Nodes Metastasis) system by the American Joint Committee
on Cancer (AJCC) is the most commonly used system to describe the stages of
melanoma. This system classifies melanoma based on their (1) tumour size (T),
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(2) lymph node involvement (N) which includes in-transit metastasis and (3)
distant metastasis (M) which includes plasma level of lactate dehydrogenase
enzyme (reviewed in section 2.2.4.8). A summary of AJCC TNM staging system
in melanoma is shown in Appendix A-Table A1. The stage groupings and the 5-
year overall survival rates are shown in Appendix A-Table A2 (Balch et al.,
2009).
2.2.4 Prognosis
2.2.4.1 Breslow depth
At present, the most important feature that influences the prognosis of
melanoma patients is Breslow’s depth; the thickness of tumour invasion in
millimeters. Breslow’s depth is measured vertically from the top of granular layer
of the epidermis to the deepest point of tumour penetration. Table 2-3 shows
the depth of melanoma invasion and approximate 10-year survival rates of
patients (Marghoob et al., 2000).
Table 2-3: Breslow thickness (mm) and the approximate 10-year survival rates of patients
with melanoma Adapted from (Marghoob et al., 2000).
Breslow thickness (mm) Approximate 10-year survival rates (%)
<1.00 > 92
1.01 – 2.00 80
2.01 – 4.00 63
> 4.00 50
2.2.4.2 Mitotic rate
Mitotic rate, expressed as the number of cells exhibiting mitosis per square
milimeter, is an indicator of tumour proliferative rate. According to a recent
review by AJCC (Balch et al., 2009), it is identified as the second most powerful
and independent predictive factor of survival after Breslow thickness in the T
category of the TNM staging system. Many studies have also demonstrated a
highly significant correlation between increasing mitotic rates and declining
survival rates (Azzola et al., 2003; Murali et al., 2010). Based on the AJCC
review, the most significant correlation with survival was identified at a threshold
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of at least 1 mitotic rate per mm2 determined histologically in H&E stained tissue
(Balch et al., 2009).
IHC determination using a cell proliferation marker, Ki67, has been shown to
correlate with worse prognosis in melanoma (Gimotty et al., 2005) but results
have not been consistent (Ohsie et al., 2008). Although Ki-67 is associated with
cell proliferation, only a subset of the cells expressing this marker will actually
undergo mitosis (Scholzen and Gerdes, 2000).
2.2.4.3 Clark’s level of invasion
Clark’s level of invasion describes the level of melanoma invasion based on
anatomical structure of the skin. This measurement provides a system to relate
the degree of melanoma penetration into the skin to the 5-year survival rates
after surgical removal of melanoma. Five anatomical skin levels are classified in
this system with increase prognostic significant at higher level as follows;
1. Level I: in-situ melanoma which is confined to the epidermis.
2. Level II: invasion into papillary dermis
3. Level III: invasion into the junction of papillary dermis and reticular
dermis but no extension to the reticular dermis.
4. Level IV: invasion into reticular dermis
5. Level V: invasion into deep subcutaneous tissue.
With the revised 6th edition of melanoma staging system in 2001, Clark’s level
was only used to predict prognosis in patients with thin tumours (<1.0mm) as it
was shown to be less predictive of outcome and less reproducible in patients
with thicker tumour (>1.0mm). However, mitotic rate has replaced Clark’s level
as the primary criteria in defining T1 patients in the 7th edition of melanoma
staging system (Balch et al., 2009; Balch et al., 2001b).
2.2.4.4 Distant metastasis
Lung, central nervous system, liver and bone are the most frequently involved
distant sites of metastasis. Metastasis is the term which refers to the spread of
tumour cells from primary tumour site in which cancer develops to other site of
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the body and this has been discussed in greater details in Section 1.2-Chapter
1. The site of metastatic dissemination can influence prognosis. Of note,
superficial distant metastases, for example to the skin, subcutaneous tissue or
lymph nodes has better prognostic value that visceral distant metastases such
as to the lung, liver or bone (Chen et al., 2009). Table 2-4 shows site of distant
metastases in melanoma and the one-year survival rates.
Table 2-4: Site of distant metastasis and 1 year survival rates in melanoma. Adapted from
(Balch et al., 2001b).
Site of distant metastasis 1-year survival rates (%)
Superficial distant metastasis (distant skin,
subcutaneous sites, distant lymph nodes) (M1a)
59
Metastases to the lung (M1b) 57
Any visceral sites 41
* M1a = melanoma patients with distant metastasis in the skin, subcutaneous tissue or
distant lymph nodes and a normal LDH level.
*M1b = melanoma patients with metastasis to the lung (or with a combination of lung and
skin or subcutaneous metastases) and a normal LDH level.
2.2.4.5 Ulceration
Histologically, ulceration is defined by the absence of an intact epidermis layer
over any part of the tumour, which commonly occurs in 20 to 60% of melanoma
patients. It can act as independent predictive factor of disease recurrence and
worse overall survival (McCready et al., 2000).Survival rates of patients with
ulcerated melanoma are lower compared to patients with a non-ulcerated
melanoma of the same stage. For example, in stage IIB melanoma (i.e. tumour
thickness of >2mm with no nodal involvement and no distant metastasis),
patients with ulceration have a 5 year survival rates of 68% compared to 71% in
patient without the presence of ulceration (Balch et al., 2009). Furthermore,
although ulceration can occur in melanoma of any thickness, its presence is
significantly linked to thicker tumours (Walters et al., 2007).
2.2.4.6 Histological type
From the four major histological types of melanoma (reviewed in section 2.2.2)
lentigo maligna melanoma is associated with the worse prognosis, followed by
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superficial spreading malignant melanoma, acral lentiginous malignant
melanoma and nodular malignant melanoma. However, histological type is not
a significant independent variable when other prognostic factors are included in
multivariate analysis (Morales et al., 1992; Phan et al., 2007).
2.2.4.7 Age
Patient’s age is an independent prognostic factor with respect to overall
survival. There was a significant decline in the survival rate of patients with
melanoma with increasing age at diagnosis (Rutkowski et al., 2010). Each 10
years increase in age was associated with a steady decrease in both 5 and 10
year survival rates as shown in table 2-5.
Table 2-5: 5- and 10-year survival rates by age group. Adapted and reproduced from
(Balch et al., 2001b). Copyright© 2001 by American Society of Clinical Oncology with
permission conveyed through Copyright Clearance Center Inc.
Age group (years) 5 year survival rates
(% ± SE)
10 year survival rates
(% ± SE)
10 – 19 87 ± 2.6 81 ± 3.5
20 – 29 87 ± 1.1 77 ± 1.6
30 – 39 86 ± 0.8 77 ± 1.2
40 – 49 85 ± 0.8 75 ± 1.2
50 – 59 82 ± 0.9 69 ± 1.3
60 – 69 78 ± 1.0 63 ± 1.6
70 – 79 71 ± 1.7 56 ± 2.7
> 80 60 ± 5.0 43 ± 7.0
2.2.4.8 Prognostic biomarkers
The use of prognostic biomarkers in cancer is very important as this help to
measure disease progression and the effect of treatments on individual
patients. Due to the aggressive nature of cutaneous melanoma, there is a
critical need to identify the subset of patients with localised lesions that would
benefit from adjuvant treatment after surgery.
Lactate dehydrogenase (LDH), an enzyme involved in the conversion of
pyruvate and lactate is routinely measured to check for tissue damage
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especially to the heart, skeletal muscle, brain and lungs. In patients with cancer,
elevated LDH level in the blood is used as an indicator of metastatic cancer.
Although LDH is not specific for melanoma, its measurement is useful at time of
diagnosis and for post surgery monitoring. The updated AJCC melanoma
staging system demonstrates elevated serum LDH levels as an independent
and significant predictor of survival especially in stage IV patients. LDH is the
only serum biomarker that has been included in the current melanoma staging
system (Balch et al., 2009).
S-100B is another serum biomarker that shows promising results in melanoma
as an indicator of relapse. This protein is a member of S100 protein family that
modulates a large number of biological activities via calcium binding. S100B
protein is involved in the regulation of cell morphology, cell differentiation, cell
motility, transcription and cell cycle progression. Overexpression of
intratumoural S100B has been detected in malignant melanoma with the
strength of expression was found to correlate with the degree of malignancy
(Harpio and Einarsson, 2004). Comprehensive analysis in high-risk melanoma
patients revealed that increased S-100B serum concentration could be used as
an indicator of early distant metastasis which is highly specific and relatively
sensitive compared to using LDH (Domingo-Domenech et al., 2007; Egberts et
al., 2009).
IHC is a widely used technique to investigate protein expression in tumour
tissue. High throughput analysis of proteins across large cohort of patients can
be studied using tissue microarray where hundreds of samples can be spotted
on a single glass slide. Many IHC based studies have been able to identify
proteins which could be useful as prognostic biomarkers in melanoma. For
example, increased expression of adhesion molecules such as MCAM/MUC18,
L1-CAM and CAECAM-1 are significantly associated with worse disease free
survival (Li et al., 2002; Xie et al., 1997). Ki-67, PCNA and metallothionine;
proteins which contributed to replicative potential are also associated with
disease free and overall survival (Fecher et al., 2007b).
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Many other markers of malignant melanoma have been identified. Although
some of them have been shown to be of diagnostic and prognostic value, the
results need to be validated in adequately powered prospective studies for them
to be used clinically.
2.2.4.9 Lymph node involvement
The extent of regional lymph node involvement is one of the most reliable
prognostic factors available and has long been used as a criterion of tumour
aggressiveness. Prognosis is less favourable with increasing numbers of
involved lymph nodes (Koskivuo et al., 2007).
Sentinel lymph node (SLN) biopsy is a technique developed to surgically assess
subclinical nodal metastasis without the invasiveness and morbidity associated
with standard lymphadenectomy; surgical removal of one or more groups of
lymph nodes (Nowecki et al., 2008). To determine the sentinel lymph node (first
lymph node the tumour is draining into), a low activity radioactive substance and
a blue dye is injected near the tumour. The path of the radioactive material
towards the draining lymph nodes is recorded and the blue dye assists the
surgeon visually in finding the SLN, which is then removed and checked for the
presence of cancer cells by a pathologist (Essner, 2006). SLN biopsy is usually
carried out in patients with a Breslow thickness of >1mm (Niakosari et al.,
2005b). However, in some cases, patients with a tumour thickness less than
1mm are sometimes positive for SLN biopsy because of the aggressive nature
of some thinner tumours. Therefore, in addition to these criteria, younger age,
sex, mitotic rate, location of primary tumour, the presence and absence of
ulceration and lymphovascular invasion are additional clinicopathological criteria
suggested as important predictive factor of SLN biopsy in melanoma (Chao et
al., 2004; Cuellar et al., 2004; Kesmodel et al., 2004; Sondak et al., 2004).
However, although SLN biopsy is used routinely in melanoma patients, the false
negative rate reported with this procedure is rather alarming. From the
literature, the rate of false negative SLN was reported between 0.4 to 14%
(Morton et al., 1999; Phan et al., 2009; Topar et al., 2006). In addition, it was
reported that tumour related deaths were not significantly higher in positive SLN
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patients compared to patients with negative SLN (Topar et al., 2006),
suggesting the need of additional prognostic criteria in melanoma progression.
Lymphovascular invasion encompassing both lymphatic vessel invasion and
blood vessel invasion is a commonly reported histological finding in primary
tumour assessment. The detection of vascular invasion in primary tumour
indicates tumours metastatic potential. In melanoma, it has been reported as a
predictor of shorter overall survival and disease free survival (Kashani-Sabet et
al., 2001). Currently, lymphovascular invasion is identified using conventional
H&E staining as the presence of tumour emboli within vascular spaces lined by
a single layer of endothelial cells. Unfortunately this technique cannot discern
between blood vessel and lymphatic vessel invasion, and in addition it cannot
distinguish tumour emboli that completely obliterate the lumen of vessels or
distinguish retraction artefacts from true tumour emboli which eventually will
contribute to the false negative and false positive interpretation of those
samples.
With advances in immunohistochemical techniques and the discovery of
selective markers, blood vessels can now be reliably differentiated from
lymphatics. The use of lymphatic specific markers (reviewed in Section 1.4) has
enabled lymphatic characteristic in neoplasms to be studied in a robust fashion
and by using these markers, lymphatic vessel invasion has been shown to be
an important characteristic in various settings and an independent prognostic
factor in certain cancers such as breast carcinoma (Mohammed et al., 2008).
Lymphatic vessel invasion was reported to not only correlate significantly with
SLN positivity but also has strong correlations with distant metastasis, overall
survival and disease free interval (Doeden et al., 2009b; Petersson et al., 2009).
Questions exist as to whether the detection of tumour cells within lymphatic
vessels using lymphatic specific markers should be routinely assessed clinically
and whether lymphatic vessel invasion positivity should be use as a predictive
factor of SLN biopsy in melanoma and if so, which of these markers give
reliable and robust results.
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With the discovery of these lymphatic specific markers, a number of studies
have investigated lymphatics in solid tumours, however many questions remain
unanswered. There is still debate concerning the topography and characteristics
of lymphatic vessels in tumour specimens. Lymphangiogenesis, the formation of
lymphatic vessels, is thought to play a role in the metastatic dissemination of
cancer via lymph vessels. VEGF-C and VEGF-D are novel members of the
VEGF family, which can regulate lymphatic vessel formation via VEGFR-3, a
receptor predominantly expressed by the lymphatic vessel during development
(Plate, 2001; Skobe et al., 2001; Stacker et al., 2001). Activated VEGFR-3
stimulates lymphatic endothelial cell proliferation, increasing the ability of cancer
cells to metastasise to lymph vessels in addition to lymph nodes. However,
whether actual lymphangiogenesis occurs inside the tumour is still debatable as
various publications show variability over the presence of intratumoural
lymphatics verses peritumoural lymphatics (Gao et al., 2008; Ji et al., 2007;
Longatto-Filho et al., 2007; Williams et al., 2003). Studies using colorectal
carcinoma (Omachi et al., 2007) and gastric carcinoma (Gao et al., 2008) have
concluded that peritumoural lymphatic vessels, rather that intratumoural are
responsible for metastatic spread via the lymphatics. They showed that
increased peritumoural lymphatic vessel density (LVD) correlates with
increased nodal metastasis and decreased overall survival. Opposing results
have been reported which demonstrated that lymphatic proliferation does occur
in the intratumoural area and based on the existence of tumour emboli within
vessels in this area, it was concluded that these vessels do function as one of
the pathways for metastatic spread (Ji, 2006; Mohammed et al., 2008).
Other than using lymphatic specific markers to identify lymphatic vessel density
and lymphatic vessel invasion, the assessment of microvessel density and
blood vessel invasion is also important in the study of tumour blood vascularity.
Angiogenesis, the formation of new blood vessels has long been appreciated to
play an important role in tumour progression by being the route for tumour cell
dissemination as well as providing nutrients for the growing tumour mass. Both
angiogenesis and lymphangiogenesis share similar regulatory mechanisms at
the cellular level, occurring through sequential steps that involve the expression
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of vascular endothelial growth factors (VEGF’s) and matrix metalloproteinases
(MMP’s) followed by endothelial cell migration, proliferation and organisation
into functional vessels. However, although both angiogenic and
lymphangiogenic pathways share some common regulatory mechanisms, there
are also a distinct regulatory pathways that are related to their specific
physiological functions.
CD34 is a widely used endothelial marker to detect the presence of blood
vessels. CD34 detects a 110-kDa transmembrane glycoprotein selectively
expressed on majority of haematopoietic stem/progenitor cells, bone marrow
stromal cells, endothelial cells, embryonic fibroblasts and some nervous tissue.
In addition, it is also expressed on dermal dendritic cells, perifolicullar cells of
normal skin and stromal spindle-shaped cells in Kaposi’s sarcoma (Nickoloff,
1991).
CD31, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1)
has also been used as a panvascular marker to demonstrate the presence of
endothelial cells in histological tissue sections. This 130-kDa transmembrane
glycoprotein is found in large quantities on the surface of endothelial cells and is
also expressed on most cells of hematopoietic lineage including monocytes,
platelets, neutrophils and some T-cell subsets. The encoded CD31 protein is
involved in leukocyte transendothelial migration as well as angiogenesis
(Privratsky et al., 2010).
Factor VIII related antigen or von Willebrand factor (vWf) has been used to
study angiogenesis in various human tumours. This factor is synthesised in
endothelial cells and megakaryocytes and under pathological condition, it
mediates the adhesion of platelets to the walls of injured vessels (Muller et al.,
2002).
During invasion, tumour cells interact with their microenvironment and are
influenced by signals from endothelial, stromal, immune cells and inflammatory
cells present in tumour microenvironment. Inflammatory infiltrates such as
neutrophils, monocytes, lymphocytes, natural killer cells and macrophages often
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exist in this environment and are believed to help promote tumour growth and
invasion into the circulation. Of these, macrophages (reviewed in Section 1.6.1-
Chapter 1) represent a major inflammatory component of many tumours (Qian
and Pollard, 2010) and have been associated with tumour progression due to
their involvement in inducing angio- and lymphangiogenesis. Patients with high
macrophage densities seem to have worse prognosis in many types of cancers.
Therefore, it is of interest in the current study to examine the correlation of
macrophage infiltrates in tumour specimens with characteristics of blood and
lymphatic vessels as assessed by immunohistochemical markers.
CD68 is a heavily glycosylated transmembrane protein with a molecular weight
of 110-kDa which is highly expressed by human monocytes and tissue
macrophage. CD68, a homologue of mouse macrosialin, is closely related to
the lysosomal associated, mucin-like, membrane protein family. A small fraction
of CD68 is found on the cell surface however it is predominantly located in
lysosomal membranes. CD68 is widely used as pan-macrophage marker in IHC
and this antibody detects both subtypes of macrophages; protumoural M2
macrophages and classical immunostimulating macrophages. as well as
various cells of macrophage lineage including monocytes, histiocytes, giant
cells, Kupffer cells and osteoclasts (Holness and Simmons, 1993).
The aims and objectives of the current chapter were to;
1. Study the topography and characteristics of lymphatic vessels in cutaneous
melanoma and to examine their associations with clinicopathological criteria.
2. Distinguish between lymphatic vessel invasion and blood vessel invasion in
cutaneous melanoma by comparing the differential expression of blood vascular
marker, CD34 and lymphatic marker, D2-40 in FFPE samples using IHC.
3. Compare between conventional assessment of vascular invasion using H&E
with that determined using IHC.
4. Investigate the role of lymphatic and blood vessel invasion, and lymphatic
and microvessel density as prognostic biomarkers in cutaneous melanoma
patients.
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5. Investigate the role of tumour associated macrophage in influencing
lymphatic vessel invasion and lymphatic vessel density as well as blood vessel
invasion and microvessel density in cutaneous melanoma patients by
investigating the associations between macrophage counts and characteristics
of the vessels.
The results of this chapter have been published in the journal of Modern
Pathology.
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2.3 Materials and Methods
2.3.1 Patients and specimens
This study was conducted on 202 consecutive FFPE archival specimens of
cutaneous melanoma obtained from the Royal Surrey County Hospital. Ethical
approval for this study was granted by Leeds (East) REC (06/Q1206/149).
Clinical characteristics of the patients and tumours are summarised in Table 2-
6.
Table 2-6: Clinicopathological characteristics of patients
Clinical feature Number
(%)
Clinical feature Number
(%)
Gender
Female
Male
99 (49.0)
103 (51.0)
Sentinal node biopsy
Negative
Positive
70 (34.7)
132 (65.3)
Breslow thickness (mm)
<1.4
>1.4 <2.1
>2.1 <3.4
>3.4
57 (28.2)
50 (24.8)
46 (22.8)
49 (24.3)
Histological subtype
Superficial spreading
Nodular
Other
Not determined
141 (74.2)
37 (19.5)
12 (6.3)
12
Melanoma site
Trunk
Leg
Arm
Head/Neck
73 (36.1)
67 (33.2)
45 (22.3)
17 (8.4)
Diameter (mm)
<9
9-12
>12
Not determined
65 (33.9)
65 (33.9)
62 (32.3)
10
Ulceration
No
Yes
Not determined
145 (74.4)
50 (25.6)
7
Number of positive nodes
0
1 or 2
>3
70 (34.7)
123 (60.9)
9 (4.5)
Clarks level
II/III
IV
V
Not determined
44 (22.0)
141 (70.5)
15 (7.5)
2
Mitotic rate (per mm2)
<3
3-7
>7
Not determined
68 (33.8)
62 (30.8)
71 (35.3)
1
Perineural infiltration
No
Yes
Not determined
186 (98.4)
3 (1.6)
13
Regression
No
Yes
Not determined
171 (85.5)
29 (14.5)
2
Tumour infiltrating lymphocytes (TILs)
Absent 52 (26.4)
Non-brisk 126 (64.0)
Brisk 19 (9.6)
Not determined 5
Microsatellites
No
Yes
Not determined
163 (86.7)
25 (13.3)
14
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The median age of patients at time of diagnosis was 53 years (range: 14 to 88
years). 65.3% (n=132) patients were positive for SLN biopsy with 28.2% (n=57)
having Breslow thickness of <1.4mm. 61.6% (n=62) patients relapsed and 45
patients died from the disease. Mean follow up period for the cohort was 38
months. Relapse-free survival was calculated from the date of initial surgery to
the first relapse or from the date of the initial surgery to the last date known to
have not relapsed for those censored. Overall survival time was calculated from
the date of initial surgery to death or from the date of initial surgery to the last
date known to be alive for those censored.
2.3.2 Immunohistochemistry
Three consecutive FFPE melanoma sections from each patient were stained
with commercially available markers; CD34, D2-40 and CD68 to stain blood
vessels, lymphatic vessels and macrophages respectively. Staining optimisation
was conducted on tonsil tissue and breast composite whole sections before
using them in the main melanoma cohort. 4µm thick whole sections from each
specimen were deparaffinised in two histolene baths for 5 minutes each then
rehydrated in a series of descending ethanol concentrations (100%, 90%, 70%,
50% and 30% in water for 1 minute at each concentration). For CD34 and
CD68, antigen retrieval was carried out in 0.01molL-1 sodium citrate buffer
(pH6) in a microwave for 20 minutes; 10 minutes at full power (750W) followed
by 10 minutes at low power (450W). For D2-40, antigen retrieval was not
required (Mohammed et al., 2007). Endogenous hydrogen peroxidase activity
was then blocked in 0.3% hydrogen peroxide in methanol for 10 minutes. Non-
specific staining was blocked using normal swine serum (DAKO) (1:5 dilution in
Tris buffered saline, TBS).
Following blocking, sections were incubated with the primary antibody diluted in
blocking solution (CD34 1:500, D2-40 1:100, CD68 1:100) for 1 hour at room
temperature. Details of antibodies used are summarised in Table 2-7. Unbound
primary antibody was washed with TBS prior to the addition of biotinylated
secondary antibody (1:100 dilution in blocking buffer) for 30 minutes followed by
the addition of avidin-biotinylated horseradish peroxidase (1:100 dilution in
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blocking buffer) for another hour at room temperature (StreptABComplex/HRP
Duet, Mouse/Rabbit kit, DAKO, K0492). For CD34 and D2-40,
LPPXQRKLVWRFKHPLFDO UHDFWLRQV ZHUH GHYHORSHG XVLQJ  ғ GLDPLQREHQ]LGLQH
(Liquid DAB+ Substrate Chromogen System, DAKO, K3468) for 7 minutes.
Sections were then counterstained with Gills formula Haematoxylin (Vector
Laboratories) for 3 minutes and rinsed off under running tap water. Sections
were dehydrated in a series of ascending ethanol concentrations (30%,
50%,70%, 90% and 100% in water for 1 minute at each concentration), fixed in
histolene and mounted with DPX. For CD68, immunoreactions were visualised
using permanent red solution (AEC+ Substrate Chromogen, DAKO) to
distinguish macrophages from melanocytes, added for 20 mins prior to
counterstaining with Gills formula Haematoxylin. Slides were mounted straight
away, omitting the dehydration steps, using aqueous-based Glycergel mounting
medium (Dako, 0365). Sections were left to dry overnight before viewing under
the microscope.
Tonsil sections were used as both positive and negative controls each time
staining was conducted. The procedure as above was applied for the positive
controls. For the negative control, primary antibody was omitted. In addition,
H&E staining was conducted on a consecutively cut sections and used to
assess vascular invasion alongside CD34 and D2-40 staining.
Table 2-7: Antibodies used in IHC
Antibody Source Type Antigen
Retrieval
Concentration
CD34 AbD Serotec
MCA5479
(Oxford, UK)
Rabbit
polyclonal
Microwave 1:500
D2-40 Covance
SIGNET
3730-1000
(Cambridge, UK)
Mouse
monoclonal
Not
required
1:100
CD68 Abcam
AB955-500
(Cambridge, UK)
Mouse
monoclonal
Microwave 1:100
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2.3.3 Microscopic analysis
2.3.3.1 Assessment of microvessel density (MVD) and macrophage count
Sections stained with CD34 and CD68 were used for the evaluation of
microvessel density and macrophages count respectively using the Chalkley
25-point counting method which has been reliably used to assess angiogenesis
in malignant tumours (Fox et al., 1994; Fox et al., 1995). With this method, a
‘hotspot,’ i.e. the area with highest vessels/macrophages staining, was identified
in each of the stained slides at 100x magnification. The Chalkley eyepiece
graticule was adjusted so that there was a maximum overlap between graticule
points and the positively stained vessels/macrophages (Figure 2-2). These
points of overlap were counted at 200x magnification. The mean value from
three hotspot areas for an individual tumour was used for analysis. 20% of
slides were examined by two independent pathologists blinded to
clinicopathologic data and scores. Rabab A. A. Mohammed assessed MVD and
blood vessel invasion and Bernard Ho examined the macrophages count.
2.3.3.2 Assessment of location/distribution of lymphatic vessels and
lymphatic vessel density
Sections stained with D2-40 were used for the evaluation of lymphatic vessel
density across the whole section. Two characteristics of lymphatic vessels were
examined i.e. (1) the distribution of lymphatic within (intra-tumoural) and around
(peri-tumoural) the tumour and (2) the lymphatic vessel density across the
Figure 2-2: Representation of a hotspot
of CD34 positive vessels superimposed
with Chalkley graticule. The grid is
adjusted so that there was a maximum
overlap between positively stained
vessels with the black dots of the
graticule. Average value from 3 counts is
the MVD for an individual tumour which
was used for analysis (200x
magnification).
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whole section. With this method, each tumour section was examined by low
power magnification (40x) and divided into two areas, intra-tumoural being the
area of the tumour, and peritumoural area being the surrounding normal area
within one high power microscopic field under the microscope (100x
magnification) as shown in Figure 2-3. Positively stained vessels were counted
across the total tumour area by counting fields of view using 100x magnification
representing a surface area of 153.86mm2. Lymphatic vessel density in each
area was obtained by dividing the sum of lymphatic vessel density in all fields in
that area, presented as vessels/mm2. Total lymphatic vessel density for each
specimen is the sum of both intra-tumoural lymphatic vessel density with peri-
tumoural lymphatic vessel density. 30% of slides were examined by three
independent assessors blinded to clinicopathological data and scores. Mark J
Vasco assessed lymphatic vessel density and lymphatic vessel invasion and
Martin Cook and Ian O. Ellis assessed lymphatic vessel invasion.
Figure 2-3 Representation of how tumour sections were divided into two areas to assess
the distribution of lymphatic vessels. Left panel: schematic diagram of a tumour section
divided into intratumoural-IT and peritumoural-PT area. Right panel: division of IT and PT
area in an actual tumour section (200x magnification).
Most studies have used the hotspot methodology to assess lymphatic vessel
density in tissue samples (Doeden et al., 2009b; Giorgadze et al., 2004).
Although the method of examining lymphatic vessel density across the whole
tumour section as adopted in this study is time consuming, it allows all
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lymphatic vessels across the whole tumour section to be assessed enabling
information of lymphatic distribution to be obtained (Mohammed et al., 2007).
2.3.3.3 Assessment of vascular invasion
Sections stained with D2-40 and CD34 were used for the evaluation of vascular
invasion. Lymphatic vessel invasion was identified as the presence of tumour
cells within a D2-40 stained vessel. As CD34 can also stain a subset of
lymphatic vessels, blood vessel invasion was defined when tumour cells were
detected in CD34 positive but D2-40 negative vessels. Sections with lymphatic
vessel invasion or blood vessel invasion were categorised as vascular invasion
positive. All probable lymphatic vessel invasions were reviewed by consultant
pathologist (Prof Ian Ellis and/or Martin Cook). Vascular invasion was reported
as negative, probable or positive. In term of analysis, probable vascular
invasions were group with the positive cases. Vascular invasion in H&E stained
sections were also examined by consultant pathologist (Mark Vasco and/or
Martin Cook) and were reported as negative, probable or positive. The
frequency of vascular invasion detected by H&E staining was compared with
that detected by IHC. False positive cases were recorded when H&E sections
were positive for vascular invasion but negative in IHC. False negatives were
recorded when vascular invasion was negative in the H&E sections but positive
in IHC. The location of lymphatic vessel invasion was also assessed in a similar
way as was used in the lymphatic vessel density assessment, i.e. within the
total tumoural area, intra-tumoural or within the area surrounding the tumour,
peri-tumoural. Some tumours were not scored due to missing tissue during the
staining and preparation techniques or due to a lack of peri-tumoural area.
2.3.4 Statistical analysis
Microvessel density, lymphatic vessel density and macrophage count were
plotted in distribution histograms and classified into two groups according to the
median value (high>median, low<median). Statistical analysis was performed
using these groups with grouped clinicopathological parameters. Vessel
invasion was divided into negative, probable or positive groups and used as a
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basis to determine association between all parameters (microvessel density,
lymphatic vessel density, blood vessel invasion, lymphatic vessel invasion and
PDFURSKDJH FRXQW 8VLQJ 3HDUVRQ &KL 6TXDUH WHVW RI DVVRFLDWLRQ Ȥ2) (or
Fisher’s Exact test if a cell count was <5), the relationship between vascular
invasion, vessel density and clinicopathological data were assessed. Overall
survival and relapse free survival analyses were performed using the Kaplan-
Meier method and the statistical significance between groups assessed by the
long rank test. Multivariate survival analysis was performed using Cox
regression analysis. An arbitrary significance level of 1% was used.
Concordance between results from individual observers was evaluated using
intraclass correlation coefficient (ICC). Statistical analysis was carried out by
Sabreena Safuan, Sarah Storr as well as collaborators from Leeds University;
Angana Mitra and Julia Newton-Bishop using SPSS version 17.0 and STATA
version 10 (StataCorp 2007, Stata statistical software: Release 10, College
Station, TX: Stata CorpLP).
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2.4 Results
2.4.1 Distribution of lymphatic and blood vessels in cutaneous melanoma
Figure 2-4 summarises the distribution of lymphatic vessels within the intra-
tumoural and peri-tumoural area as well as the total lymphatic vessel density
count in 202 cutaneous melanoma samples used in this study. The majority of
lymphatic vessels were located in the peri-tumoural area and were observed in
all cases where this area was assessable (181/181). Intra-tumoural lymphatic
vessels were detected in 86.4% of tumours (165/191). Peri-tumoural lymphatic
vessel density ranged from 0.009 to 0.198/mm2 and intra-tumoural lymphatic
vessel density ranged from 0.000 to 0.130/mm2. Total lymphatic vessel density
ranged from 0.004 to 0.266/mm2. The medians of intra-tumoural, peri-tumoural
and total lymphatic vessel density were 0.010/mm2, 0.060/mm2 and 0.077/mm2
respectively.
Figure 2-4 Histogram showing (A)
intratumoural, (B) peritumoural and
(C) total lymphatic vessel density in
202 cutaneous melanoma samples.
X axis represents number of
lymphatic vessel per unit area
(mm2)
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Figure 2-5 shows the distribution of microvessel density in the total cohort of
202 cutaneous melanoma patients. Microvessel density ranged from 0.667 to
9.000 with a median of 4.883 vessels. Lymphatic vessel density and
microvessel density were not directly compared due to the difference in their
assessment methods; which were required due to the high frequency of blood
vessels observed in all samples in comparison to the relatively low level of
lymphatic vessel density in the same samples. However, it was observed that
the density of blood vessels were much higher than that of lymphatic vessels
under the same field view (Figure 2-6).
Figure 2-6 Morphology and distribution of (A) lymphatic vessels and (B) blood vessels in
melanoma. It was observed that the density of blood vessels was much higher compared
to lymphatic vessels under the same microscopic field view. 200x magnification.
Figure 2-5 Histogram showing
microvessel density in 202 cutaneous
melanoma samples. X axis represents
number of microvessel per hotspot
count.
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2.4.2 Relationship between lymphatic and microvessel density with
clinicopathological variables
Table 2-8 and 2-9 show the association between lymphatic vessel density and
microvessel density respectively with clinicopathologic variables in melanoma.
No significant association was observed between intra-tumoural lymphatic
vessel density and clinicopathologic variables however, it was marginally
DVVRFLDWHGZLWK UHODSVHVWDWXV Ȥ2=4.91, d.f.=1, p=0.03) and tumour infiltrating
O\PSKRF\WHV 7,/V Ȥ2=6.08, d.f.=2 p=0.05). Peri-tumoural lymphatic vessel
density and total lymphatic vessel density was significantly associated with
Clarks level of invasion (Fisher’s Exact test, p=0.01 and p=0.01 respectively).
Total lymphatic vessel density was also significantly associated with the
DEVHQFH RI WXPRXU LQILOWUDWLQJ O\PSKRF\WHV Ȥ2=11.21, d.f.=2, p=0.004). High
PLFURYHVVHOGHQVLW\ZDVDVVRFLDWHGZLWK WKHSUHVHQFHRIXOFHUDWLRQȤ2=17.79,
d.f.=1, p<0.001) and high mitotic rate (p=0.002). It was positively associated
ZLWK VWDJH Ȥ2=12.91, d.f.=2, p<0.001) and was marginally associated with
SRVLWLYHVHQWLQHOO\PSKQRGHVELRSV\Ȥ2=4.01, d.f.=1, p=0.05).
2.4.3 Distribution and frequency of blood and lymphatic vessel invasion
in melanoma detected by IHC and H&E staining
Vascular invasion; both lymphatic and blood vessel invasion was assessed in
consecutive melanoma sections. Intratumoural, peritumoural or any lymphatic
vessel invasion (total invasion from combination of intratumoural and
peritumoural invasion) was detected in 17.3% (33/191), 14.9% (27/181), 26.9%
(50/186) of cases respectively. Blood vessel invasion occurred in 4.2% (8/190)
cases, 3 of which also had lymphatic vessel invasion.
The presence of vascular invasion determined by IHC and H&E was also
directly compared. Invasion of both blood and lymphatic; categorised as any
vascular invasion was detected in 29.9% of cases (55/184) by IHC opposed to
8.0% of cases (16/199) detected by H&E. Of the vascular invasion detected by
IHC 85.5% (47/55) were purely invasion of lymphatics, 9.1% (5/55) were solely
via the blood vessels while 5.4% had both lymphatic and blood vessel invasion
(3/55).
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Table 2-8: Association between lymphatic vessel density and clinicopathological characteristics
Categories Lymphatic Density n(%)
Intra-tumoural Peri-tumoural Total
Low High p value Low High p value Low High p value
Gender Female 48 (50.5) 44 (45.8) 0.52 45 (50.6) 44 (47.8) 0.71 50 (52.1) 42 (44.2) 0.28
Male 47 (49.5) 52 (54.2) 44 (49.4) 48 (52.2) 46 (47.9) 53 (55.8)
Sentinal node
biopsy (SNB)
Negative 38 (40.0) 28 (29.2) 0.12 35 (39.3) 31 (33.7) 0.90 36 (37.5) 30 (31.6) 0.39
Positive 57 (60.0) 68 (70.8) 26 (29.9) 28 (30.8) 60 (62.5) 65 (68.4)
Relapse Status No 57 (61.3) 71 (76.3) 0.03 61 (70.1) 63 (69.2) 0.90 61 (65.6) 67 (72.0) 0.34
Yes 36 (38.7) 22 (23.7) 26 (29.9) 91 (30.8) 32 (34.4) 26 (28.0)
Staging IA/IB 23 (25.6) 17 (18.1) 0.69 23 (26.7) 17 (19.3) 0.58 22 (24.2) 18 (19.4) 0.78
IIA 6 (6.7) 5 (5.3) 6 (7.0) 5 (5.7) 6 (6.6) 5 (5.4)
IIB/IIC 6 (6.7) 5 (5.3) 5 (5.8) 6 (6.8) 5 (5.5) 6 (6.5)
IIIA 38 (42.2) 45 (47.9) 33 (38.4) 44 (50.0) 37 (40.7) 46 (49.5)
IIIB 17 (18.9) 22 (23.4) 19 (22.1) 16 (18.2) 21 (23.1) 18 (19.4)
Number of
positive nodes
0 38 (40.0) 28 (29.2) 0.31 35 (39.3) 31 (33.7) 0.35 36 (37.5) 30 (31.6) 0.37
1 or 2 53 (55.8) 63 (65.6) 48 (53.9) 58 (63.0) 54 (56.3) 62 (65.3)
      
Melanoma site Trunk 40 (42.1) 32 (33.3) 0.27 35 (39.3) 32 (34.8) 0.44 35 (36.5) 37 (38.9) 0.12
Leg 25 (26.3) 38 (39.6) 30 (33.7) 29 (31.5) 35 (36.5) 28 (29.5)
Arm 23 (24.2) 19 (19.8) 20 (22.5) 21 (22.8) 23 (24.0) 19 (20.0)
Head/neck 7 (7.4) 7 (7.3) 4 (4.5) 10 (10.9) 3 (3.1) 11 (11.6)
Histological
subtype
Superficial spreading 65 (74.7) 70 (75.3) 0.21 68 (79.1) 64 (74.4) 0.72 67 (75.3) 68 (74.7) 0.55
Nodular 14 (16.1) 20 (21.5) 13 (15.1) 17 (19.8) 15 (16.9) 19 (20.9)
Other 8 (9.2) 3 (3.2) 5 (5.8) 5 (5.8) 7 (7.9) 4 (4.4)
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Table 2-8: Cont..
Categories Lymphatic Density
Intra-tumoural Peri-tumoural Total
Low High p value Low High p value Low High p value
Diameter (mm) <9 29 (32.2) 32 (34.8) 0.90 32 (37.6) 28 (31.8) 0.70 29 (32.2) 32 (34.8) 0.28
9-12 31 (34.4) 29 (31.5) 26 (30.6) 31 (35.2) 26 (28.9) 34 (37.0)
>12 30 (33.3) 31 (33.7) 27 (31.8) 29 (33.0) 35 (38.9) 26 (28.3)
Breslow
thickness (mm)
<1.4 31 (32.6) 23 (24.0) 0.40 27 (30.3) 27 (29.3) 1.00 29 (30.2) 25 (26.3) 0.47
      
      
      
Ulceration No 69 (76.7) 67 (71.3) 0.41 66 (75.9) 64 (73.6) 0.73 69 (75.0) 67 (72.8) 0.74
Yes 21 (23.3) 27 (28.7) 21 (24.1) 23 (26.4) 23 (25.0) 25 (27.2)
Clarks level II/III 20 (21.5) 22 (22.9) 0.37 20 (22.7) 22 (23.9) 0.01 20 (21.3) 22 (23.2) 0.01
IV 63 (67.7) 69 (71.9) 56 (63.6) 68 (73.9) 61 (64.9) 71 (74.7)
V 10 (10.8) 5 (5.2) 12 (13.6) 2 (2.2) 13 (13.8) 2 (2.1)
Mitotic rate (per
mm2)
<3 38 (40.4) 26 (27.1) 0.15 36 (40.9) 26 (28.3) 0.20 39 (41.1) 25 (26.3) 0.08
3-7 26 (27.7) 32 (33.3) 24 (27.3) 31 (33.7) 24 (25.3) 34 (35.8)
>7 30 (31.9) 38 (39.6) 28 (31.8) 35 (38.0) 32 (33.7) 36 (37.9)
Perineural
infiltration
No 85 (96.6) 90 (100) 0.12 81 (96.4) 85
(100.0)
0.12 86 (96.6) 89
(100.0)
0.25
Yes 3 (3.4) 0 (0.0) 3 (3.9) 0 (0.0) 3 (3.4) 0 (0.0)
Regression No 78 (83.9) 82 (85.4) 0.77 75 (86.2) 75 (81.5) 0.40 81 (86.2) 79 (83.2) 0.57
Yes 15 (16.1) 14 (14.6) 12 (13.8) 17 (18.5) 13 (13.8) 16 (16.8)
Microsatellites No 76 (86.4) 79 (88.8) 0.63 69 (83.1) 78 (91.8) 0.09 74 (84.1) 81 (91.0) 0.16
Yes 12 (13.6) 10 (11.2) 14 (16.9) 7 (8.2) 14 (15.9) 8 (9.0)
Tumour
infiltrating
lymphocytes
(TILs)
Absent 32 (34.4) 18 (19.1) 0.05 28 (32.2) 19 (20.7) 0.21 35 (37.6) 15 (16.0) 0.004
Non-brisk 54 (58.1) 64 (68.1) 51 (58.6) 62 (67.4) 50 (53.8) 68 (72.3)
Brisk 7 (7.5) 12 (12.8) 8 (9.2) 11 (12.0) 8 (8.6) 11 (11.7)
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Table 2-9: Association between microvessel density, macrophage count and blood vessel invasion with clinicopathological characteristics
Category Microvessel density Macrophage count Blood vessel invasion Vascular invasion
H&E
Low High p
value
Low High p
value
Absent Present p
value
Absent Present p
value
Gender Female 44 (46.3) 45 (47.4) 0.88 51 (53.7) 44 (44.0) 0.18 86 (47.3) 3 (37.5) 0.73 90 (49.2) 6 (37.5) 0.37
Male 51 (51.3) 50 (52.6) 44 (46.3) 56 (56.0) 96 (52.7) 5 (62.5) 93(50.8) 10 (62.5)
Sentinal node
biopsy (SNB)
Negative 38 (40.0) 25 (26.3) 0.05 32 (33.7) 36 (36.0) 0.73 61 (33.5) 2 (25.0) 1.00 68(37.2) 2(12.5) 0.06
Positive 57 (60.0) 70 (73.7) 63 (66.3) 64 (64.0) 121 (66.5) 6 (75.0) 115(62.8) 14(87.5)
Relapse Status No 62 (68.1) 63 (67.0) 0.87 66 (72.5) 65 (65.7) 0.31 121 (68.4) 4 (50.0) 0.23 126(70.8) 8(50) 0.09
Yes 29 (31.9) 31 (33.0) 25 (27.5) 34 (34.3) 56 (31.6) 4 (50.0) 52(29.2) 5(50)
Staging IA/IB 29 (31.2) 10 (11.1) <0.001 22 (23.9) 19 (19.6) 0.05* 39 (22.2) 0 (0.0) 0.47 42(23.7) 1(6.7) 0.21
IIA 6 (6.5) 3 (3.3) 5 (5.4) 6 (6.2) 9 (5.1) 0 (0.0) 10(5.6) 1(6.7)
IIB/IIC 2 (2.2) 9 (10.0) 2 (2.2) 10 (10.3) 10 (5.7) 1 (14.3) 12(6.8) 0(0.0)
IIIA 44 (47.3) 40 (44.4) 48 (52.2) 37 (38.1) 80 (45.5) 4 (57.1) 75(42.4) 11(73.3)
IIIB 12 (12.9) 28 (31.1) 15 (16.3) 25 (25.8) 38 (21.6) 2 (28.6) 38(21.5) 2(13.3)
Number of
positive nodes
0 38 (40.0) 25 (26.3) 0.06* 32 (33.7) 36 (36.0) 0.91 61 (33.5) 2 (25.0) 0.41 68 (37.2) 2(12.5) 0.09
1 or 2 51 (53.7) 67 (70.5) 59 (62.1) 59 (59.0) 113 (62.1) 5 (62.5) 107(58.5) 13(81.3)
        
Melanoma site Trunk 34 (35.8) 37 (39.0) 0.82 32 (33.7) 39 (39.0) 0.19 67 (36.8) 4 (50.0) 0.38 65(35.5) 7(43.8) 0.62
Leg 34 (35.8) 28 (29.5) 39 (41.1) 27 (27.0) 59 (32.4) 3 (37.5) 61(33.3) 5(31.3)
Arm 20 (21.1) 23 (24.2) 19 (20.0) 25 (25.0) 43 (23.6) 0 (0.0) 43(23.5) 2(12.5)
Head/neck 7 (7.4) 7 (7.4) 5 (5.3) 9 (9.0) 13 (7.1) 1 (12.5) 14(7.7) 2(12.5)
Histological
subtype
Superficial
spreading
70 (77.8) 64 (71.9) 0.36 73 (81.1) 63 (67.0) 0.03 130 (75.1) 4 (66.7) 0.37 127 (73.8) 12 (80.0) 0.80
Nodular 14 (15.6) 21 (23.6) 11 (12.2) 26 (27.7) 34 (19.7) 1 (16.7) 35(20.3) 2(13.3)
Other 6 (6.7) 4 (4.5) 6 (6.7) 5 (5.3) 9 (5.2) 1 (16.7) 10(5.8) 1(6.7)
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Table 2-9: Cont…
Microvessel density Macrophage count Blood vessel invasion Vascular invasion (H&E)
Low High p
value
Low High p
value
Absent Present p
value
Absent Present p
value
Diameter (mm) <9 36 (38.7) 22 (25.0) 0.14 36 (40.0) 27 (28.1) 0.23 55 (31.4) 3 (50.0) 0.45 63(36.0) 2(13.3) 0.02
9-12 28 (30.1) 34 (38.6) 27 (30.0) 26 (37.5) 61 (34.9) 1 (16.7) 54(30.9) 10(66.7)
>12 29 (31.2) 32 (36.4) 27 (30.0) 33 (34.4) 59 (33.7) 2 (33.3) 58(33.1) 3(20.0)
Breslow
thickness (mm)
<1.4 35 (36.8) 18 (18.9) 0.02 34 (35.8) 20 (20.0) <0.001 53 (29.1) 0 (0.0) 0.24 55 (30.1) 1 (6.3) 0.14
         
         
         
Ulceration No 80 (87.0) 54 (59.3) <0.001 79 (85.0) 60 (62.5) <0.001 130 (73.9) 4 (57.1) 0.39 129 (72.9) 13 (86.7) 0.36
Yes 12 (13.0) 37 (40.7) 14 (15.0) 36 (37.5) 46 (26.1) 3 (42.9) 48 (27.1) 2 (13.3)
Clarks level II/III 23 (24.2) 19 (20.4) 0.62 20 (21.3) 22 (22.2) 0.75 42 (23.2) 0 (0.0) 0.33 43 (23.6) 0 (0.0) 0.04
IV 66 (69.5) 65 (69.9) 68 (72.3) 68 (68.7) 124 (68.5) 7 (100.0) 126 (69.2) 13 (86.7)
V 6 (6.3) 9 (9.7) 6 (6.4) 9 (9.1) 15 (8.3) 0 (0.0) 13 (7.1) 2 (13.3)
Mitotic rate
(per mm2)
<3 41 (43.2) 21 (22.3) 0.002 36 (38.3) 27 (27.0) 0.005 61 (33.7) 1 (12.5) 0.29 64 (35.2) 3 (18.8) 0.03
3-7 30 (31.6) 28 (29.8) 35 (37.2) 26 (26.0) 56 (30.9) 2 (25.0) 51 (28.0) 10 (62.5)
>7 24 (25.3) 25 (47.9) 23 (24.5) 47 (47.0) 64 (35.4) 5 (62.5) 67 (36.8) 3 (18.8)
Perineural
infiltration
No 87 (96.7) 87 (100.0) 0.25 86 (96.6) 94 (100.0) 0.11* 168 (98.2) 6 (100.0) 1.00 170 (99.4) 13 (86.7) 0.02
Yes 3 (3.3) 0 (0.0) 3 (3.4) 0 (0.0) 3 (1.8) 0 (0.0) 1 (0.6) 2 (13.3)
Regression No 84 (88.4) 75 (80.7) 0.14 83 (88.3) 81 (81.8) 0.21 151 (83.9) 8 (100.0) 0.61 155 (85.2) 13(86.7) 1.00
Yes 11 (11.6) 18 (19.3) 11 (11.7) 18 (18.2) 29 (16.1) 0 (0.0) 27 (14.8) 2(13.3)
Microsatellites No 79 (87.8) 74 (86.0) 0.73 78 (87.6) 80 (86.0) 0.75 149 (87.6) 4 (66.7) 0.18 149 (87.6) 11(73.3) 0.13
Yes 11 (12.2) 12 (13.0) 11 (12.4) 13 (14.0) 21 (12.4) 2 (33.3) 21(12.4) 4(26.7)
Tumour
infiltrating
lymphocytes
(TILs)
Absent 28 (30.4) 21 (22.3) 0.45 35 (37.2) 16 (16.5) 0.005 44 (24.7) 5 (62.5) 0.07 48(26.7) 4(26.7) 0.59
Non-brisk 56(60.9) 63(67.0) 51 (54.3) 71 (73.2) 116 (65.2) 3 (37.5) 113(62.8) 11(73.3)
Brisk 8(8.7) 10 (10.6) 8 (8.5) 10 (10.3) 18 (10.1) 0 (0.0) 19(10.6) 0(0.0)
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184 samples had both H&E and IHC results available and vessel invasion in
these cases were compared. In this group of cases, 14 patients had vascular
invasion evident in sections stained by H&E, 9 of which were shown to be false
positives by IHC (64.33%). Of the 170 cases negative for vascular invasion
determined by H&E, 50 were false negative (29.4%). Examples of H&E and IHC
staining are shown in Figure 2-7, 2-8 and 2-9.
Figure 2-7 Example of false negative determinant in H&E stained tissue. In this tumour,
vascular invasion in H&E stained tissue (A) was scored as negative. However, using IHC,
vascular invasion was scored as positive. This specimen will be scored as lymphatic
vessel invasion positive because tumour emboli were detected within D2-40 vessels (B)
but CD34 negative (C). 200x magnification
Figure 2-8 Example of true positive lymphatic vessel invasion determination in H&E
stained tissue. In this tumour, vascular invasion in H&E stained tissue (A) was scored as
positive. The presence of vascular invasion is clearly observed in D2-40 stained tissue
(B) and was scored as lymphatic vessel invasion positive. Consecutive sections stained
with blood marker, CD34 (C) was also shown. 200x magnification
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Figure 2-9 Examples of positive lymphatic vessel invasion and macrophage infiltrates. In
this tumour, the presence of vascular invasion is clearly observed in D2-40 stained tissue
(A) and was scored as lymphatic vessel invasion positive. Consecutive section showed
macrophage infiltrates surrounding the lymphatic vessels (B).
2.4.4 Relationship between vascular invasion and macrophage count
with clinicopathological characteristics
Intra-tumoural lymphatic vessel invasion was significantly associated with
increased stage (Fisher’s Exact test, p=0.004), increased Breslow thickness
)LVKHU¶V ([DFW WHVW S WKH SUHVHQFH RI XOFHUDWLRQ Ȥ2=14.69, d.f.=1,
p<0.001), increased Clark’s level (Fisher’s Exact test, p<0.001), high mitotic
UDWH )LVKHU¶V ([DFW WHVW S WKH SUHVHQFH RI PLFURVDWHOOLWHV Ȥ2=6.18,
GI  S  DQG QRGXODU KLVWRORJLFDO VXEW\SH Ȥ2=18.94, d.f.=2, p<0.001)
(Table 2-10). Significant association of peri-tumoural lymphatic vessel invasion
was observed with increased stage (Fisher’s Exact test, p<0.001), increased
Breslow thickness (Fisher’s Exact test, p=0.002) the presence of ulceration
Ȥ2=16.99, d.f.=1, p<0.001), and nodular histological subtype (Fisher’s Exact
test, p<0.001) (Table 2-10). However, peri-tumoural lymphatic vessel invasion
was not associated with Clark’s level, mitotic rate or the presence of
microsatellites. Any lymphatic vessel invasion was significantly associated with
increased stage (Fisher’s Exact test p<0.001), increased Breslow thickness
Ȥ2  GI  S WKH SUHVHQFH RI XOFHUDWLRQ Ȥ2=22.59, d.f.=1,
S LQFUHDVHG&ODUN¶V OHYHO Ȥ2=16.83, d.f.=2, p<0.001), high mitotic rate
Ȥ2  GI  S WKH SUHVHQFH RI PLFURVDWHOOLWHV Ȥ2=6.64, d.f.=1,
S  DQG QRGXODU KLVWRORJLFDO VXEW\SH Ȥ2=28.47, d.f.=2, p<0.001). Blood
vessel invasion was not significantly associated with any clinicopathological
variable. Table 2-10 summarises the association of these parameters with
clinicopathological criteria of cutaneous melanoma.
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Table 2-10: Association between lymphatic vessel invasion with clinicopathological characteristics
Category Lymphovascular invasion Any vessel invasion
Intra-tumoural Peri-tumoural Any lymphovascular invasion
Absent Present p
value
Absent Present p
value
Absent Present p
value
Absent Present p value
Gender Female 78 (49.4) 14 (42.4) 0.47 76 (49.4) 13 (48.1) 0.91 68 (50.0) 23 (46.0) 0.63 64 (49.6) 25 (45.5) 0.61
Male 80 (50.6) 19 (57.6) 78 (50.6) 14 (51.9) 68 (50.0) 27 (54.0) 65 (50.4) 30 (54.5)
Sentinal node
biopsy (SNB)
Negative 58 (36.7) 8 (24.2) 0.17 58 (37.7) 8 (29.6) 0.42 53 (39.0) 13 (26.0) 0.10 49 (38.0) 14 (25.5) 0.10
Positive 100 (63.3) 25 (75.8) 96 (62.3) 19 (70.4) 83 (61.0) 37 (74.0) 80 (62.0) 41 (74.5)
Relapse Status No 110 (71.0) 18 (58.1) 0.16 109 (72.2) 15 (55.6) 0.08 98 (73.1) 29 (60.4) 0.10 93 (73.2) 31 (58.5) 0.05
Yes 45 (29.0) 13 (41.9) 42 (27.8) 12 (44.4) 36 (26.9) 19 (39.6) 34 (26.8) 22 (41.5)
Staging IA/IB 38 (25.0) 2 (6.3) 0.004 39 (26.4) 1 (3.8) <0.001 37 (28.2) 3 (6.3) <0.001 35 (28.0) 3 (5.8) <0.001
IIA 10 (6.6) 1 (3.1) 10 (6.8) 1 (3.8) 9 (6.9) 2 (4.2) 8 (6.4) 2 (3.8)
IIB/IIC 7 (4.6) 4 (12.5) 6 (4.1) 5 (19.2) 5 (3.8) 6 (12.5) 5 (4.0) 6 (11.5)
IIIA 71 (46.7) 13 (37.5) 69 (46.6) 8 (30.8) 62 (47.3) 17 (35.4) 59 (47.2) 20 (38.5)
IIIB 26 (17.1) 13 (40.6) 24 (16.2) 11 (42.3) 18 (13.7) 20 (41.7) 18 (14.4) 21 (40.4)
Number of
positive nodes
0 58 (36.7) 8 (24.2) 0.34 58 (37.7) 8 (29.6) 0.05 53 (39.0) 13 (26.0) 0.16 49 (38.0) 14 (25.5) 0.09
1 or 2 93 (58.9) 23 (69.7) 91 (59.1) 15 (55.6) 78 (57.4) 33 (66.0) 76 (58.9) 36 (65.5)
        
Melanoma site Trunk 63 (39.9) 9 (27.3) 0.43 59 (38.3) 8 (29.6) 0.77 56 (41.2) 13 (26.0) 0.26 53 (41.1) 16 (29.1) 0.46
Leg 52 (32.9) 11 (33.3) 48 (31.2) 11 (40.7) 42 (30.9) 19 (38.0) 39 (30.2) 21 (38.2)
Arm 32 (20.3) 10 (30.3) 35 (22.7) 6 (22.2) 28 (20.6) 14 (28.0) 28 (21.7) 14 (25.5)
Head/neck 11 (7.0) 3 (9.1) 12 (7.8) 2 (7.4) 10 (7.4) 4 (8.0) 9 (7.0) 4(7.3)
Histological
subtype
Superficial
spreading
120 (81.6) 15 (45.5) <0.001 121 (81.8) 11 (45.8) <0.001 111
(85.4)
22 (46.8) <0.001 106
(85.5)
24 (48.0) <0.001
Nodular 20 (13.6) 14 (42.4) 19 (12.8) 11 (45.8) 13 (10) 20 (42.6) 13 (10.5) 20 (40.0)
Other 7 (4.8) 4 (12.1) 8 (5.4) 2 (8.3) 6 (4.6) 5 (10.6) 5 (4.0) 6 (12.0)
58
Table 2-10 Lymphovascular invasion Any vessel invasion
Category Intra-tumoural Peri-tumoural Any lymphovascular invasion
Absent Present p
value
Absent Present p
value
Absent Present p
value
Absent Present p
value
Diameter (mm) <9 53 (34.9) 8 (26.7) 0.09 49 (33.6) 11 (40.7) 0.66 46 (35.1) 14 (29.8) 0.52 42 (33.6) 15 (30.0) 0.60
9-12 45 (29.6) 15 (50.0) 50 (34.2) 7 (25.9) 41 (31.3) 19 (40.4) 40 (32.0) 20 (40.0)
>12 54 (35.5) 7 (23.3) 47 (32.2) 9 (33.3) 44 (33.6) 14 (29.8) 43 (34.4) 15 (30.0)
Breslow
thickness
(mm)
<1.4 51 (32.3) 3 (9.1) <0.001 52 (33.8) 2 (7.4) 0.002 49 (36.0) 5 (10.0) <0.001 47 (36.4) 5 (9.1) <0.001
        
        
        
Ulceration No 121 (79.6) 15(46.9) <0.001 119 (80.4) 11 (42.3) <0.001 109 (83.2) 23 (47.9) <0.001 103 (82.4) 26 (50.0) <0.001
Yes 31 (20.4) 17 (53.1) 29 (19.6) 15 (57.7) 22 (16.8) 25 (52.1) 22 (17.6) 26 (50.0)
Clarks level II/III 39 (25.0) 3 (9.1) <0.001 40 (26.1) 2 (7.4) 0.04 37 (27.4) 5 (10.0) <0.001 36 (28.1) 5 (9.3) <0.001
IV 111 (71.2) 21 (63.6) 103 (67.3) 21 (77.8) 93 (68.9) 35 (70.0) 87 (68.0) 39 (72.2)
V 6 (3.8) 9 (27.3) 10 (6.5) 4 (14.8) 5 (3.7) 10 (20.0) 5 (3.9) 10 (18.5)
Mitotic rate
(per mm2)
<3 62 (39.5) 2 (6.1) <0.001 57 (37.3) 5 (18.5) 0.09 55 (40.7) 7 (14.0) <0.001 52 (40.6) 8 (14.5) <0.001
3-7 52 (33.1) 6 (18.2) 47 (30.7) 8 (29.6) 43 (31.9) 13 (26.0) 41 (32.0) 14 (25.5)
>7 43 (37.4) 25 (75.8) 49 (32.0) 14 (51.9) 37 (27.4) 30 (60.0) 35 (27.3) 33 (60.0)
Perineural
infiltration
No 143 (97.9) 32 (100.0) 1.00 141 (98.6) 25 (96.2) 0.40 124 (98.4) 47 (97.9) 1.00 118 (98.3) 50 (98.0) 1.00
Yes 3 (2.1) 0 (0.0) 2 (1.4) 1 (3.8) 2 (1.6) 1 (2.1) 2 (1.7) 1 (2.0)
Regression No 128 (82.1) 32 (97.0) 0.03 131 (86.2) 19 (70.4) 0.04 114 (85.1) 41 (82.0) 0.61 107 (89.3) 46 (83.6) 0.917
Yes 28 (17.9) 1 (3.0) 21 (13.8) 8 (29.6) 20 (14.9) 9(18.0) 20 (15.7) 9 (16.4)
Microsatellites No 132 (90.4) 23 (74.2) 0.01 126 (88.7) 21 (80.8) 0.26 115 (91.3) 36 (76.6) 0.01 110 (91.7) 38 (76.0) 0.006
Yes 14 (9.6) 8 (25.8) 16 (11.3) 5 (19.2) 11 (8.7) 11 (23.4) 10 (8.3) 12 (24.0)
Tumour
infiltrating
lymphocytes
(TILs)
Absent 41 (26.5) 9 (28.1) 0.41 42 (27.6) 5 (18.5) 0.23 36 (26.9) 12 (24.5) 0.19 32 (25.2) 16 (29.6) 0.19
Non-brisk 96 (61.9) 22 (68.8) 92 (60.5) 21 (77.8) 81 (60.4) 35 (71.4) 79 (62.2) 36 (66.7)
Brisk 18 (11.6) 1 (3.1) 18 (11.8) 1 (3.7) 17 (12.7) 2 (4.1) 16 (12.6) 2 (3.7)
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Vascular invasion determined by IHC (intra-, peri-tumoural lymphatic vessel or
blood vessel invasion), was positively associated with increased stage (Fisher’s
([DFW WHVWS LQFUHDVHG%UHVORZWKLFNQHVVȤ2=29.00, d.f.=3, p<0.001),
WKHSUHVHQFHRIXOFHUDWLRQ Ȥ2=19.51, d.f.=1, p<0.001), increased Clark’s level
Ȥ2 GI SDQGWKHSUHVHQFHRIPLFURVDWHOOLWHVȤ2=7.69, d.f.=1,
p=0.006). In addition, vascular invasion was also significantly associated with
QRGXODU KLVWRORJLFDO VXEW\SH Ȥ2=26.65, d.f.=2, p<0.001) and these data are
summarised in table 2-9.
High macrophage count was associated with the presence of ulceration
Ȥ2  GI  S %UHVORZ WKLFNQHVV Ȥ2=24.49, d.f.=3, p<0.001),
PLWRWLF UDWH Ȥ2=10.67, d.f.=2, p=0.005) and the presence of non brisk or brisk
7,/V Ȥ2=10.53, d.f.=2, p=0.005). Table 2-9 summarises the association
between macrophage count and the clinicopathological data.
2.4.5 Relationship between vessel density, vessel invasion and
macrophage count
Intra-tumoural lymphatic density was significantly associated with intra-tumoural
O\PSKDWLF YHVVHO LQYDVLRQ Ȥ2=8.05, d.f.=1, p=0.005) but no significant
association was observed with peri-tumoural invasion. Blood microvessel
density was associated with intra-tumoural, peri-tumoural and any lymphatic
LQYDVLRQ Ȥ2  GI  S  Ȥ2  GI  S  Ȥ2=14.77, d.f.=,1
p<0.001 respectively).
High macrophage count was significantly associated with the presence of any
O\PSKDWLFYHVVHOLQYDVLRQȤ2=9.15, d.f.=1, p=0.002), blood microvessel density
Ȥ2  GI  S  DQG ,+& GHWHUPLQHG YDVFXODU LQYDVLRQ Ȥ2=8.66,
d.f.=1, p=0.003), indicating the likely importance of macrophage in the process
of tumour vascularisation and lymphatic dissemination. Table 2-11 shows the
associations between these variables.
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Table 2-11: Association between variables used in the study (LVD, LVI, MVD, BVI and macrophage count)
lymphatic density Lymphatic invasion Blood
vessel
density
Blood
vessel
invasion
Macrophage Any
vessel
invasionIT PT Total IT PT Total
lymphatic
density
Intra-tumoural 0.004 <0.001 0.005 0.67 0.016 0.093 0.280 0.070 0.016
Peri-tumoural 0.004 <0.001 0.752 0.028 0.156 0.060 0.120 0.603 0.117
Total <0.001 <0.001 0.079 0.074 0.071 0.125 0.721 0.048 0.138
Lymphatic
invasion
Intra-tumoural 0.005 0.752 0.079 0.001 <0.001 0.010 0.150 0.012 <0.001
Peri-tumoural 0.670 0.028 0.074 0.001 <0.001 0.004 0.066 0.015 <0.001
Total 0.016 0.156 0.071 <0.001 <0.001 <0.001 0.389 0.002 <0.001
blood vessel density 0.093 0.060 0.125 0.01 0.004 <0.001 0.279 0.003 <0.001
Blood vessel invasion 0.280 0.120 0.721 0.150* 0.066 0.389 0.279 0.726 <0.001
Macrophage 0.070 0.603 0.048 0.012 0.015 0.002 0.003 0.726 0.003
Any vessel invasion 0.016 0.117 0.138 <0.001 <0.001 <0.001 <0.001 <0.001 0.003
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2.4.6 Clinical outcome and vessel density, invasion and macrophage
involvement
In univariate analysis, none of the variables assessed in this study were
statistically associated with relapse-free or overall survival and were therefore
not assessed in multivariate analysis (Figure 2-10 and 2-11).
Figure 2-10 Kaplan-Meier analysis of vessels invasion (assessed by IHC) with relapsed
free (A) and overall survival (B). No association were observed between IHC determinant
vessels invasion with either relapsed free or overall survival in the 202 cohorts of
melanoma samples used in this study.
Figure 2-11 Kaplan-Meier analysis of vessels invasion (assessed by H&E) with relapsed
free (A) and overall survival (B). No association were observed between H&E determinant
vessels invasion with either relapsed free or overall survival in the 202 cohorts of
melanoma samples used in this study.
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2.5 Discussion
The aims of the current chapter were to study the topography and
characteristics of lymphatic vessels in cutaneous melanoma and to examine
their associations with clinicopathological criteria. In addition we aimed to
distinguish between lymphatic vessel invasion and blood vessel invasion in
cutaneous melanoma by comparing the differential expression of blood vascular
marker, CD34 and lymphatic marker, D2-40 in FFPE samples using IHC.
Furthermore, comparison between conventional assessments of vascular
invasion using H&E with that determined using IHC marker was made. Finally,
we aimed to investigate the role of lymphatic and blood vessel invasion, and
lymphatic and blood vessel density as prognostic biomarkers in cutaneous
melanoma patients. We sought to access the role of tumour associated
macrophage in influencing lymphatic vessel invasion and lymphatic vessel
density as well as blood vessel invasion and blood vessel density in cutaneous
melanoma patients by investigating the associations between macrophage
counts and characteristics of the vessels.
Questions exist regarding the distribution of lymphatic vessels in solid tumours.
Initial studies in colorectal carcinomas had reported the absence of intra-
tumoural lymphatics and concluded that peri-tumoural lymphatics are
responsible for metastatic dissemination of cancer (Omachi et al., 2007).
Functional intra-tumoural lymphatics were not detected in mouse tumours
expressing elevated levels of VEGF-C (Weidner et al., 1991). Such findings
suggest that functional lymphatics in the tumour margin alone are sufficient for
lymphatic metastasis. The existence of intra-tumoural lymphatic vessels has
been in doubt as it was thought that lymphatics could not penetrate into
expanding primary tumours because of the high physical pressure existed
inside the tumour mass (Stacker et al., 2002). However, with the discovery of
new molecular markers that are lymphatic specific and with the emergence of
better imaging techniques, intra-tumoural lymphatics have been observed
(Mochizuki et al., 2004; Ribatti et al., 2006). In fact, the presence of intra-
tumoural lymphatics in melanoma has been demonstrated by others (Cueni and
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Detmar, 2009; Maddaluno et al., 2009). One study showed that intra-tumoural
lymphatic vessel density is significantly higher in malignant melanomas
compared to both common acquired nevi and dysplastic nevi (Baluk et al.,
2007). However, this study did not report any associations with
clinicopathological criteria. Whether increased intra-tumoural lymphatics in their
study have any significant relationship to poor prognosis cannot be determined.
In the present study which is the largest and most comprehensive of its type,
intra-tumoural lymphatic vessels were detected in 86.4% of tumours and their
significant association with a number of clinicopathological variables linked with
a more aggressive disease may suggest their biological importance and vessel
functionality. Previous studies using limited sample size, have also
demonstrated the association between intra-tumoural lymphatic vessel density
and positive SNB which was not observed in this study (Doeden et al., 2009b;
Niakosari et al., 2008). Association of intra-tumoural lymphatic vessel density
with distant metastasis was also reported suggesting an important role of these
lymphatics in melanoma dissemination (Petersson et al., 2009).
In this cohort of melanoma patients, total lymphatic vessel density was
associated with Clark’s level and tumour infiltrating lymphocytes. Studies that
have previously investigated lymphatic vessel density in melanoma have
reported various associations with clinicopathological criteria. Lymphatic vessel
density has been associated with age (Massi et al., 2006; Straume et al., 2003),
the presence of inflammatory infiltrate (Dadras et al., 2003a; Massi et al., 2006),
positive sentinel lymph node (Massi et al., 2006), tumour stage (Valencak et al.,
2004) and tumour thickness (Straume et al., 2003). In the present study, no
associations were observed between lymphatic vessel density with clinical
outcome (relapse free or overall survival).
Microvessel density was associated with the presence of ulceration, high mitotic
rate and stage. Associations between microvessel density with Clark’s level and
tumour stage have also been previously reported (Valencak et al., 2004). We
also tested for correlations between blood and lymphatic vessel density.
However, no correlations were observed between microvessel density and
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lymphatic vessel density in melanoma and this observation was in accordance
with other studies (Bono et al., 2004; Schoppmann et al., 2006). Current results,
as with those found in breast cancer, suggest that although both angiogenic and
lymphangiogenic pathways share some common regulatory mechanisms, there
may also be distinct regulatory pathways (Mohammed et al., 2007).
The presence of vascular invasion is an important prognostic factor in most
cancer types. In breast cancer, vascular invasion is associated with local
recurrence and metastasis (Gonzalez-Vela et al., 2001; Parveen and Shahid,
1997; Rakha et al., 2011). However, the role of vascular invasion in melanoma
is not as established. The assessment of vascular invasion in the primary
tumour using conventional staining is problematic due to difficulties in identifying
vessel endothelium surrounding tumour emboli, coupled with the inability to
differentiate between capillaries and artefactual spaces caused by shrinking in
routine histological sections (Fallowfield and Cook, 1989; Kashani-Sabet et al.,
2001). Conventional staining is also unable to distinguish between lymphatic
vessel invasion and blood vessel invasion.
In this study the detection rate of vascular invasion increases from 8% to 29.9%
when using H&E compared to when IHC markers were used. As reported from
different cohort of patients, the detection rate of vascular invasion using either
H&E or IHC markers varies. The detection rates of vascular invasion
determined in H&E stained tissues in comparison to lymphatic vessel invasion
determined by IHC in previously published studies have ranged from 0% to
16%; n=44 (Niakosari et al., 2005a), 0% to 17%; n=36 (Sahni et al., 2005), 0%
to 23%; n=74 (Petersson et al., 2009), 3.1% to 21.9%; n=64 (Fohn et al., 2011)
and 4% to 37%; n=27 (Petitt et al., 2009). Clearly, the use of IHC markers in
this study and other studies showed that this technique is able to overcome the
limitations of using conventional H&E staining. D2-40, which is a selective
lymphatic marker, was commonly used in studies examining the biological role
of lymphatic in tumours while CD34 is used as selective blood vascular marker
in angiogenesis studies. As reported in other study, CD34 is sometimes co-
expressed with D2-40 on lymphatic vessels (Fidler, 1997).
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Interestingly, this large series of patients shows that vascular invasion in
melanoma is essentially invasion of lymphatic vessels (26.9% vs 4.2%).
Reported detection rates for lymphatic vessel invasion are 16% (Doeden et al.,
2009a; Doeden et al., 2009b; Niakosari et al., 2005a), 17% (Sahni et al., 2005),
21.9% (Fohn et al., 2011), 23% (Petersson et al., 2009), 33% (Niakosari et al.,
2008; Xu et al., 2008), 37% (Petitt et al., 2009), 47% (Shields et al., 2004), and
63% (Emmett et al., 2010) in melanoma. A preference of lymphatic over blood
vessel invasion has been reported previously with varying frequencies of blood
vessel to lymphatic vessel invasion of 3% to 16% (Doeden et al., 2009a), 4.7%
to 33% (Xu et al., 2008) and 43% to 47% (Shields et al., 2004) respectively. In
fact, Shields and colleagues have developed a prognostic index based on their
cohort of metastatic melanoma samples which combined the information on
thickness, lymphatic density and lymphatic invasion, to generate a more
efficient predictor of survival (Shields et al., 2004). However, only 21 samples
were used, limiting the clinical value of this index. Further work is required to
assess the robustness of the Shields index to consider the use of it in clinical
settings. It would have been interesting to have assessed the prognostic value
of the Shields index in the current cohort – this could be carried out through
further work/investigations by others continuing the study.
In the present study, the presence of lymphatic vascular invasion was
associated with markers of tumour aggressiveness such as increased stage,
increased Breslow thickness, the presence of ulceration, increased Clark’s
level, high mitotic rate, the presence of microsatellites and nodular histological
subtype. When analysis was repeated using lymphatic vessel invasion detected
by IHC, significant association was observed with increased stage, increased
Breslow thickness, the presence of ulceration, increased Clark’s level and the
presence of microsatellites. This is in agreement with previous work that
reported significant associations of lymphatic vessel invasion with the presence
of ulceration and younger age (Niakosari et al., 2008). However, no significant
difference was observed with sentinel node biopsy or clinical outcome which
also has been reported by previous studies (Petitt et al., 2009; Sahni et al.,
2005). Lymphatic vessel invasion has been previously shown to be significantly
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associated with sentinel lymph node status, distant metastasis, overall survival
and disease free interval (Petersson et al., 2009). However, the Petersson
study utilised dual markers, LYVE-1 and S-100 and on a small cohort (n=36).
Whether the differences in these results are attributed to the small sample size
or related to the use of a different marker of lymphatic endothelium, is unclear.
In the current study, conducted in a robust fashion and in a large number of
patients, no association of vessel characteristic with relapse-free or overall
survival was observed. These results were unexpected due to their strong
association with poor prognostic histological features of melanoma which may
attest to the value of existing biomarkers. The mean follow up period of this
cohort is 38 months; if followed up long enough, positive relationship with
relapse-free or overall survival might be observed given the strong correlation of
vessels characteristics with poor prognostic features. In addition, more samples
could be added to the current cohort or using a different cohort altogether to
confirm the association of lymphatic and blood vessels characteristic with
clinical criterias.
The association of lymphatic vessel invasion with markers of tumour
aggressiveness and sentinel node biopsy in this study, and others, shows that
lymphovascular invasion by IHC should be routinely assessed clinically to
complement the determination of SLN biopsy in melanoma patients. However,
more studies need to be carried out in order to demonstrate a conclusive
relation between the prognostic values of lymphatic vessel invasion with patient
outcome.
It is unclear what factors drive lymphatic vessel invasion in a tumour rich in
blood vessels. However, it was observed that lymphatic vessel invasion by
tumour cells was associated with inflammatory cell infiltration around the
vessels. In this study, the presence of high macrophage count was significantly
associated with the presence of lymphatic vessel invasion, high microvessel
density and total IHC determined vascular invasion. This result is supported by
studies investigating the role of macrophages and inflammatory cells in inducing
lymphangiogenesis in tumours and other tissues (Ammar et al., 2011;
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Kerjaschki, 2005; Yano et al., 2006) and could be due to macrophages being a
source of angio- and lymphangiogenic growth factors (Schoppmann et al.,
2006). Tumour associated macrophage often accumulate in hypoxic regions of
tumours and trigger the production of pro-angiogenic growth factors, such as
9(*)SODWHOHWGHULYHGHQGRWKHOLDOFHOOJURZWKIDFWRUE)*)DQG71)Į6NREH
et al., 2001). Tumour associated macrophage also produce VEGF-C and
increased expression of this growth factor has been shown to increase in-vivo
lymphangiogenesis in murine models (Padera et al., 2002).
In conclusion, results from the current study show that, even though there is a
rich blood vessel network, vascular invasion in melanoma is essentially via
lymphatic vessels and that conventional assessment of vascular invasion
underestimates its incidence, which is significantly improved using IHC. The
presence of vascular invasion (both blood and lymphatic) was associated with
factors that indicate poor prognosis including increased stage, increased
Breslow thickness and the presence of ulceration. Similarly, lymphatic vessel
density was associated with Clark’s level whilest microvessel density and
macrophage count was associated with the presence of ulceration and
increased mitotic rate. However, these parameters; microvessel density,
lymphatic vessel density, lymphatic and blood vessel invasion were not
associated with clinical outcome of relapse-free survival or overall survival.
Interestingly, the association of macrophage count with microvessel density and
lymphatic vessel invasion, markers of neovascularisation and primary tumour
growth, suggest a role of macrophage and/or their associated factors in
metastatic cell dissemination via the lymphatic vessels. As will be described in
WKH QH[W FKDSWHU &KDSWHU  71)Į DQG ,/ȕ DUH WZR PDMRU F\WRNLQHV
produced by tumour associated macrophages that have been shown to facilitate
the invasion of tumour cells into the blood circulation. Subsequent chapters
GHVFULEHGH[SHULPHQWV WKDWZHUHFRQGXFWHG WRH[DPLQH WKH IXQFWLRQRI71)Į
DQG,/ȕ LQ LQIOXHQFLQJ WXPRXUFHOO PHODQRPDDQGEUHDVWDGKHVLRQ WREORRG
and lymphatic endothelium and to investigate if this may account for the
preferential invasion of lymphatics observed in patient tumours.
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CHAPTER 3: ADHESION OF TUMOUR CELLS TO
LYMPHATIC AND BLOOD ENDOTHELIUM
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3.1 Abstract
Background and Aims: Vascular invasion is an important step in the
metastatic cascade; tumour cell adhesion to blood and lymphatic vessels is
followed by penetration through the vessel wall and adaptation into the local
environment. Results from Chapter 2 show that, as we have also shown in
breast cancer, even though melanomas have rich vascular networks, vascular
invasion in melanoma is preferentially invasion of the lymphatics and that the
association between macrophage infiltrate with lymphatic vessel invasion
suggest a role for macrophage and/or their associated factors in cancer cell
dissemination via lymphatic vessels. The primary aims of the current chapter
were to compare the adhesion pattern of both melanoma and breast cancer cell
lines to blood and lymphatic endothelial cell models (large vessel versus
microvessel and primary versus immortalised cells) and to examine the effect of
PDFURSKDJHDVVRFLDWHGF\WRNLQHV71)ĮDQG,/ȕPDFURSKDJHFRQGLWLRQHG
media and tumour conditioned media on tumour-endothelial interactions. The
role of an adhesion molecule, preferentially expressed on the lymphatics (i.e
CLEVER-1 – common lymphatic endothelial and vascular endothelial receptor
1), might play in regulating lymphatic vessel invasion was also examined in
addition to ICAM-1 and VCAM-1 adhesion molecules (intracellular adhesion
molecule 1 and vascular cell adhesion molecule 1 respectively).
Methods: Melanoma (MeWo and SKMEL-30) and breast cancer (MDA-MB-
231, MCF7) cell adhesion to lymphatic (hTERT-LEC – human telomerase
reverse transcriptase lymphatic endothelial cells and hMVEC dLy Neo – human
neonatal dermal lymphatic microvascular endothelial cells) and blood (HUVEC
– human umbilical vein endothelial cells and hMEC-1 – human microvascular
endothelial cells) endothelial models was assessed using static adhesion
DVVD\V 7KH HIIHFW RI 71)Į DQG ,/ȕ VWLPXODWLRQ RQ HQGRWKHOLDO FHOOV DQG
tumour cells alone or both together on the adhesive process was examined. In
addition, the stimulatory effect on endothelial cells by tumour conditioned media
and macrophage conditioned media on tumour cell adhesion pattern were also
studied. ELISA (enzyme-linked immunosorbent assay) was used to examine the
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concentration of IL-1ɴ in both tumour conditioned media and macrophage
conditioned media. Surface and intracellular expression of CLEVER-1 on the
endothelial cells were examined by FACS (fluorescence activated cell sorting)
in addition to the surface expression of ICAM-1 and VCAM-1.
Results: Melanoma and breast cancer cells exhibited a higher level of adhesion
WREORRGFRPSDUHG WR O\PSKDWLFHQGRWKHOLDOFHOOV S71)ĮVWLPXODWLRQ
of endothelial cells alone, or of tumour cells alone, did not significantly alter
tumour-endothelial cell adhesion or patterns. However, when both tumour and
HQGRWKHOLDOFHOOVZHUHVWLPXODWHGZLWK71)ĮDVLJQLILFDQWLQFUHDVHGLQDGKHVLRQ
was observed (p<0.01). This increased tumour cell adhesion was most notably
REVHUYHGLQWKHO\PSKDWLFFHOOPRGHOVS,/ȕVWLPXODWLRQRIHQGRWKHOLDO
cells, tumour cells or both together showed a significant increase in the
percentage of adhered tumour cells to the endothelial cell models with a higher
increased adhesion to the lymphatic endothelial cells (p<0.001). In addition, no
significant changes in tumour-endothelial cell adhesion observed when the
endothelial cells were stimulated with tumour conditioned media. However,
there was a significant increased in the percentage of adhered tumour cells
(MDA-MB-231 and MeWo) to hMEC-1 and hTERT-LEC when both endothelial
models were stimulated with macrophage conditioned media (p<0.01) which
was significantly higher to the lymphatic endothelial cells. The effect of
increased adhesion to lymphatics by macrophage conditioned media seemed to
EHDVVRFLDWHGZLWKWKHDPRXQWRI,/ȕSUHVHQW:KHQLQWHUOHXNLQFRQYHUWLQJ
enzyme (ICE) inhibitor was used, with macrophage conditioned media, the
increased adhesion effect was removed.
CLEVER-1 was expressed intracellularly in both blood and lymphatic
endothelial cell lines, however significant surface expression was only observed
LQWKHLPPRUWDOLVHGO\PSKDWLFVK7(57/(&8SRQVWLPXODWLRQZLWK71)ĮRQO\
the primary lymphatic cells showed significant increased in surface expression
of CLEVER-1 to match that of hTERT-LEC. No significant surface expression
was ever observed with blood endothelium, even under stimulated conditions.
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Interestingly, stimulation of HUVEC, hMEC-1, hTERT-LEC and hMVEC-dLy
1HRZLWK,/ȕGLGQRWVKRZDQ\VLJQLILFDQWDOWHUHG&/(9(5H[SUHVVLRQ
ICAM-1 and VCAM-1 was expressed in HUVEC, hMEC-1 and hTERT-LEC with
the highest surface expression observed in HUVEC. Upon stimulation with TNF-
ĮDQG,/ȕERWK,&$0DQG9&$0H[SUHVVLRQLQFUHDVHGVLJQLILFDQWO\LQDOO
cell models.
Conclusions: Tumour-endothelial cell adhesion is modulated by cytokine
VWLPXODWLRQ ZLWK ERWK 71)Į DQG QRWDEO\ ,/ȕ SUHVXPDEO\ VHFUHWHG E\
macrophage, having strong influences in regulating adhesion particularly to the
lymphatics thus modulating lymphatic vessels invasion. Although CLEVER-1 is
an important lymphatic specific adhesion molecule, results from the current
study suggest that it may not be the principal regulator of macrophage, or
associated cytokine, up regulation of tumour cell lymphatic adhesion. This
process may be regulated by ICAM-1 and VCAM-1, which increased upon
VWLPXODWLRQZLWKWKHPDFURSKDJHDVVRFLDWHGF\WRNLQHV71)ĮDQG,/ȕ
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3.2 Introduction
3.2.1 Breast Cancer
Breast cancer is the most frequent cancer diagnosed in women around the
world which comprises 22.9% of all cancers (excluding non-melanoma skin
cancers because registrations for this cancer type is likely to be less complete
and less accurate compared to other cancers) with a 13.7% mortality rate
worldwide. There is a 0.5% overall increase in incidence annually. In spite of
such increasing incidence, mortality rates from breast cancer show a steady
decline, especially in developed countries, that is attributed to better screening
programmes, improved education and more effective treatments (Rosso et al.,
2010).
There are a number of risk factors that predispose to breast cancer such as
age, reproductive history (age of first birth, breast feeding and age of
menopause), hormonal status (including age of menarche and endo-/exo-
genous hormones), diet (high fat diet and alcohol consumption), environmental
influences (exposure to ionizing radiation), body weight, physical activity and
socioeconomic status. Familial breast cancer accounts 5-10% of total cases;
and involves germline mutations in penetrant breast cancer susceptibility genes
BRCA1 and BRCA2, amongst others such as p53, PTEN, ATM and RAD51
(Flanagan et al., 2010; Lose et al., 2006).
Histologically, breast cancer can be classified into (1) non-invasive carcinoma
in-situ, (2) invasive carcinoma and (3) rare and uncommon tumours
(inflammatory carcinoma and Paget’s disease). Histological types of breast
cancer, the frequency and the approximate 5-year survival rates are
summarised in Table 3-1.
As in melanoma, breast cancer staging uses the TNM classification system.
TNM staging categories for breast cancer are as shown in Appendix B-Table
B1. Based on the combination of tumour size, lymph node status and distant
metastasis, breast cancer is classified into four different stages as described in
Appendix B-Table B2.
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Table 3-1: Histological types of breast cancer, their frequency and the approximate 5-
year survival rates. Reproduced and adapted from (Li et al., 2005). Copyright© 2005 by
Cancer Research UK with permission conveyed through Copyright Clearance Center Inc.
Histological type Frequency
(%)
Approximate 5-year
survival (%)
Infiltrating ductal carcinoma 63.6 79
Infiltrating lobular carcinoma 5.9 84
Infiltrating ductal and lobular carcinoma 1.6 85
Medullary carcinoma 2.8 82
Mucinous carcinoma 2.1 95
Paget’s disease 1.0 79
Papillary carcinoma 0.8 96
Tubular carcinoma 0.6 96
Ductal carcinoma in-situ 3.6 >99
Lobular carcinoma in-situ 1.6 >99
Ductal and lobular carcinoma in-situ 0.2 >99
The prognosis of breast cancer is influenced by a number of factors such as
tumour size, age and menopausal status, histological types and grade, lymph
node involvement, lymphovascular invasion and hormone and growth factor
receptors. These factors will be discussed below.
3.2.1.1 Tumour size
The size of the primary tumour is an independent poor prognostic factor in
breast cancer. It has been established that the rate of distant recurrence
increases in patients with large tumours as opposed to smaller tumours
(Koscielny et al., 2009). Table 3-2 shows the 5-year overall survival of patients
with different tumour size.
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Table 3-2: Tumour size and the 5-year overall survival rates. Adapted from (McCready et
al., 2000).
Tumour size (cm) 5-year overall survival (%)
<1.00 99
1.01-3.00 89
3.01-5.00 86
3.2.1.2 Age and menopausal status
Only 5 to 7% of breast cancers are diagnosed in women below 40 years of age.
However, women in this group have a more aggressive cancer with higher
mortality and recurrence rates compared with older women. The poor prognosis
of younger patients is indication for adjuvant therapy which is offered to
approximately 80% of such patients (van der Sangen et al., 2008). The poor
prognosis breast cancers in younger women are more likely to be hormone
receptor negative, higher grade, poorly differentiated and have higher HER-
2/EGFR expression (Dobi et al., 2011).
3.2.1.3 Histological types and grade
A few histologic types of invasive carcinoma such as mucinous, tubular,
medullary and papillary carcinoma have better prognostic value than invasive
ductal carcinoma. Ductal carcinoma not otherwise specified (NOS) is the most
invasive histological types of breast carcinoma which accounts for 70% of all
breast carcinoma (Ellis et al., 1992).
Recently, gene expression profiling has been used to define breast cancer
subtypes based on the molecular characteristics and its association with clinical
outcome (van Veer et al., 2002; Weigelt et al., 2008). Based on the expression
profiles, invasive breast cancer has been categorised into five groups; (a)
luminal A (breast cancer with the highest expression of oestrogen receptor and
expression of keratin 18 and 19 in luminal mammary cells), (b) luminal B
(similar to luminal A but has moderate expression of oestrogen receptor), (c)
basal like (oestrogen receptor negative and expression of cytokeratin 5,
cytokeratin 17 and laminin), (d) normal breast like (expression of genes known
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to be expressed in normal mammary tissue) and (e) ERRB2+ (oestrogen
receptor negative and high expression of genes in the ERBB2 amplicons).
The grading system of breast cancer is based on the histological features of the
tumour. The Scarff-Bloom-Richardson (SBR) is a widely used system for breast
cancer which combined three histological characteristics of tumour to assign an
overall grade; tubule formation, nuclear pleomorphism and mitotic count
(Genestie et al., 1998; Zhang et al., 2010). In general, each factor is given the
score of 1 to 3 with 3 being the worst and the score of each factor are added
together to give the grade as shown in Table 3-3. In this grading system, score
of 3 to 5 is assign overall tumour grade of 1, score of 6 to 7 is assign grade 2
and score of 8 or 9 is assign overall tumour grade of 3 with 5 years survival rate
of 95, 75 and 50% in grade 1, 2 and 3 respectively.
Table 3-3: The Scarff-Bloom-Richardson grading system in breast cancer. Adapted from
(Genestie et al., 1998),
Tubule formation Score
>75% 1
10-75% 2
<10% 3
Nuclear pleomorphism Score
Uniform cells, small 1
Variation in cells, moderate size 2
Marked variation 3
Mitotic count (per 10 high power field) Score
<7 1
8 to 14 2
>15 3
In breast cancer, prognostic indices which combine different prognostic criteria
have been shown to be more powerful compared to using each of the factors
alone. The Nottingham Prognostic Index (NPI), first developed in 1982, is an
76
established and widely used index (developed by breast cancer specialists at
Nottingham University Hospital) which combines three prognostic factors of
breast carcinoma, the lymph node stage, histological grade and tumour size in
the following manner (Galea et al., 1992; Haybittle et al., 1982):
NPI = 0.2 x tumour diameter (cm) + lymph node stage (1=no nodes affected,
2=<3 glands affected, 3=>3 glands affected) + tumour grade (1=grade I,
2=grade II, 3=grade III).
The higher the NPI value, the worse the prognosis (Galea et al., 1992). By
applying this formula, scores fall into three bands; (a) a score of <3.4 suggests
a good prognosis group with the highest chance of a cure, with the same short
term survival of age-matched controls that have not had breast cancer but 15 to
20% of whom will experience metastasis and die of the disease over a 20-year
period. (b) a score between 3.4 to 5.4 suggests intermediate level of prognosis
with intermediate chance of a cure and (c) a score of >5.4 suggests the worse
prognosis with a small chance of a cure. NPI is an excellent index for stratifying
the prognosis of patients and in combination with oestrogen receptor status,
HER-2 status, menopausal status, vascular invasion and patient’s age, the NPI
is used as a tool in decision making about the choice of adjuvant systemic
therapy for early stage breast cancer patients after surgery. The absolute
survival benefit of adjuvant systemic treatment in each NPI group is
summarised in Table 3-4.
Table 3-4: The prognostic table. Adjuvant systemic treatment and 10-year survival.
Adapted from (Feldman et al., 2002).
NPI Percentage
survival,
no drug
Polychemotherapy Tamoxifen
(for 5 years)
all age
Age <50 50-59 60-69
Risk
reduction
27% 14% 8% 26%
<2.41 95%* - - - -
2.41-3.4 85% 89% 87% 86% 89%
3.41-4.4 70% 78% 74% 72% 78%
4.41-5.4 50% 64% 57% 54% 63%
>5.4 20% 42% 31% 26% 41%
*same as age-metched population without breat cancer.
77
3.2.1.4 Hormone and growth factor receptor
Oestrogen receptors (ER) and progesterone receptor (PR) located within the
cell nucleus has prognostic value in breast cancer patients. Patients with ER-
positive tumours have more favourable prognostic characteristics than patients
with ER-negative tumours which relapse earlier (Garicochea et al., 2009).
Patients with ER positive breast cancer will usually receive hormonal therapy.
Tamoxifen is widely used for the treatment of early and advanced ER positive
breast cancer in pre- and post-menopausal women. In addition, aromatase
inhibitors are also given to post-menopausal women to lower the amount of
oestrogen in their body. These treatments are usually given after surgery,
chemotherapy and radiation therapy to block/reduce the effect of oestrogen in
the body thus preventing disease recurrence.
3.2.1.5 Molecular marker
HER-2/neu also known as ErbB2 is a cell membrane surface receptor tyrosine
kinase normally involved in signal transduction pathway causing cell growth and
differentiation. This proto-oncogene is overexpressed in 25 to 30% of breast
cancer patients with a significant decrease in 5-year survival rates (Weigelt et
al., 2008). Besides HER-2/neu, mutation in tumour suppressor proteins such as
p53 and bcl-2 which regulates the cell cycle and apoptotic pathway also
influences the prognosis of breast cancer patients (Langerod et al., 2007). HER-
2 positive breast cancer patients are usually given the drug HerceptinTM
(trastuzumab) that interfere with HER-2/neu receptors causing cell cycle arrest
during the G1 phase.
3.2.1.6 Lymph node involvement
Involvement of axillary lymph nodes has been shown to be associated with
disease free survival and overall survival in breast cancer patients and has
been appreciated as the most reliable prognostic indicator. 50 to 70% of
patients with axillary node involvement will develop local recurrence compared
to 20 to 30% in node-negative patients (Fisher et al., 1983). The risk of
recurrence is related to the number of positive lymph nodes. Patients with four
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or more involved nodes have worse prognosis compared with patients with
fewer involved nodes (Veronesi et al., 2006). 5 years survival with lymph node
negative patients is 78% compared to 62 and 32% 5 years survival in patients
with 1 to 3 lymph nodes and >4 lymph nodes positivity respectively.
However, approximately one-third or 15 to 20% of lymph node negative patients
will ultimately develop distant metastasis if followed up long enough (Weigelt et
al., 2005). There is an urgent need, as conventional marker (such as NPI)
cannot stratify such patients, to identify new prognostic methods and markers in
such patients. Recent works suggest that assessment of lymphovascular
invasion may be able to stratify such lymph node patients (Abi-Raad et al.,
2011; Mohammed et al., 2011; Rakha et al., 2011).
3.2.1.7 Lymphovascular invasion
As in melanoma, the presence of tumour cells within blood or lymphatic vessels
detected microscopically is associated with poorer prognosis. Studies have
found that the presence of vascular invasion is associated with the presence of
axillary lymph nodes involvement, high risk of systemic relapse and increase
local recurrence after wide local excision or mastectomy (Gonzalez-Vela et al.,
2001). The identification of vascular invasion in the primary tumour has been
associated with the ability to metastasise; however standardisation and
adoption into clinical practice has not been achieved. As stated previously, the
conventional assessment of vascular invasion is based upon detection of
tumour cells within a vascular space lined with endothelial cells in tumour
sections stained with H&E; however the assessment of such vascular invasion
may be falsely reported due to retraction artifacts and may be missed if tumour
cells are packed within a vessel. In one study, there was a low level of
concordance (kappa=0.3) in the detection of vascular invasion by conventional
means between two observers (Ellis et al., 2006) and the use of
immunohistochemical marker such as D2-40 (reviewed in Section 1.4 -Chapter
1) demonstrated a very high level of concordance (kappa=0.9) between
observers (Mohammed et al., 2007).
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In a study from our group (Mohammed et al., 2008), using 177 well
characterised primary invasive breast cancer specimens, 96.4% of specimens
showed the presence of lymphatic vessel invasion while only 3.5% were blood
vessel invasion. The presence of lymphatic vessel invasion in this study was
significantly associated with the presence of lymph node metastasis,
development of distant metastasis, regional recurrence, worse disease free
interval and decreased overall survival. This is in accordance with other studies
reporting the association of lymphatic vessel invasion with larger tumour size,
lymph node metastasis and distant metastasis and also the independent role of
lymphatic vessel invasion as a poor prognostic factor in breast cancer (Bono et
al., 2004; Marinho et al., 2008; Viale et al., 2010).
Results from Chapter 1 showed that in melanoma, as also observed in breast
cancer, although a rich blood vascular network is present, vascular invasion
occurs predominantly via lymphatic vessels (85.5%) as opposed to blood
vessels (4.2%). Biologically, this process requires the tumour cells to migrate
toward the blood or lymphatic vessel; which is followed by tumour cell adhesion
and migration through the vessel. This process differs dependent upon the
vessel type, due to the presence or absence of basement membrane,
supporting structure such as pericytes and the thickness of the vessel wall
(Johnson and Jackson, 2008; Oliver and Detmar, 2002).
Although it was suggested that the metastatic spread of tumour cells via the
lymphatics follows the routes of natural lymph drainage (Fidler, 1997; Mandriota
et al., 2001), the exact mechanism of how tumour cells enter the lymphatic
capillaries is still uncertain. Chemokines was shown to aid the movement of
tumour cells towards lymphatic capillaries (Pepper and Skobe, 2003).
Chemokine receptor-ligand relationships are important for regulating leukocyte
trafficking and this relationship has been hypothesised to be exploited by cancer
cells to modulate entry into the lymphatics. An example is the CCR7-CCL21
interaction. Transduction of B16 murine melanoma cell lines with a retroviral
vector encoding the chemokine receptor CCR7 has shown an increased affinity
towards lymphatic endothelium (Muller and Luscinskas, 2008). This interaction
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could be blocked using neutralising antibodies against CCL21, which is
produced by lymphatic endothelial cells and that is specific towards CCR7;
suggesting that lymphatic vessels, through the action of chemokines, can attract
tumour cells and eventually promote lymph nodes metastasis.
The role of lymphatic specific adhesion molecules may also be important in
mediating tumour cells entry into and exit out of the lymphatics (Nathanson,
2003). Adhesion molecules are important because in order for tumour cells to
migrate and transmigrate into the lymphatic vessels, they first require an
adhesive interaction with lymphatic endothelial cells. To date, many adhesion
molecules preferentially expressed on the lymphatics have been discovered
and these adhesion molecules were reviewed in details in Section 1.5 -Chapter
1. The adhesive interaction between tumour cells and endothelial cells i.e
tumour-endothelial interaction will be the focus of this chapter.
3.2.2 In vitro models of tumour-endothelial interactions
In vitro, endothelial cell monolayers have been used as a model system to
investigate tumour-endothelial interactions to mimic interactions that occur in
vivo. Current knowledge of tumour-endothelial interaction is largely derived from
studies using blood endothelial cells. These studies use a range of endothelial
cells to investigate tumour cell adhesion; however the most widely used cell
type to investigate adhesion are large vein endothelial cells isolated from
human umbilical cords (HUVEC). Studies investigating tumour cell adhesion to
blood endothelium have identified a role for thrombospondin (TSP) in
potentiating tumour cell metastasis. Adhesion of the breast cancer cell line
MCF7 to HUVEC could be reduced by treatment with anti-TSP antibody
(Incardona et al., 1995). HUVEC have also been used to investigate the role of
intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) on the adhesion of breast cancer cells (MDA-MB-231) to
blood endothelium (Nizamutdinova et al., 2008). Pre-treatment with tanshinone-
1 significantly reduced adhesion of MDA-MB-231 to HUVEC through inhibition
of ICAM-1 and VCAM-1 expression. Changes in cell surface glycoproteins on
the breast cancer cell line, MDA-MB-231 can also change their adhesion to
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+89(& E\ GRZQUHJXODWLQJ WKH H[SUHVVLRQ RI Į/IXFRVH D PRQRVDFFKDULGH
overexpressed in many malignant tumours (Yuan et al., 2008). HUVEC have
been used to study tumour-blood endothelial adhesion of many tumour types
such as colon carcinoma (Gout et al., 2006); lung adenocarcinoma (Santoso et
al., 2005) and melanoma (Kim et al., 1993).
In addition to large vein HUVEC, human microvascular endothelial cells, hMEC
have also been used to study tumour-endothelial interactions. Increased
adhesion of melanoma cell lines, MeWo, SKMEL-28, JPC 298 and HT144,
occurs in Thy-1 activated human dermal microvascular endothelial cells
(hDMEC); which suggests an important role of Thy-1 in tumour-blood
endothelial interactions (Saalbach et al., 2005).
In contrast to blood endothelium, the mechanisms underlying the adhesion of
tumour cells to the lymphatic endothelium is still poorly understood. Very few
studies have utilised lymphatic endothelial cells, primarily due to the lack of
molecular tools which were able to specifically distinguish lymphatic from blood
endothelial cells. Studies investigating the interaction between tumour and
lymphatic endothelium interaction have, however, become possible over the
past 10 years following the discovery of lymphatic specific markers such as
those mentioned in section 1.4 i.e. VEGFR-3 (Laakkonen et al., 2007), LYVE-1
(Banerji et al., 1999a), Prox-1 (Wigle et al., 2002), podoplanin (Schacht et al.,
2005a) and D2-40 (Kahn and Alexander, 2002). Studies utilising primary
lymphatic endothelial cells have shown an increase in the attachment of breast
cancer cells (MCF7 and MDA-MB-231) following stimulation with anti-CCL-2
antibody which increases ICAM-1 expression on lymphatic endothelial cells
(Kawai et al., 2009). In addition, Danussi and colleagues (2009) showed that
the adhesion of breast cancer cells (MCF7) to human microvascular lung
lymphatic endothelial cells (HMVEC-LLy) was reduced following treatment with
an anti-Tn antibody, a common tumour associated carbohydrate antigen
present in most human carcinomas (Danussi et al., 2009).
Studies conducted so far utilised either blood or lymphatic endothelial cells to
study tumour-endothelial adhesion. No studies have conducted a direct side to
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side comparison of blood versus lymphatic adhesion. In light of the importance
of lymphatic invasion in the initial metastatic process, it is important to be able
to compare tumour-endothelial adhesion pattern in both blood and lymphatic
endothelial cell models. This knowledge is crucial towards understanding the
regulation of metastasis via lymphatic vessels.
The aims and objectives of the current chapter were to;
1. Compare the adhesion pattern of melanoma and breast cancer cell lines to
blood and lymphatic endothelial cell models. Different endothelial cell models
were used; vascular versus lymphatic models and primary cells versus
immortalised cell lines.
2. Investigate the stimulatory effect of macrophage associated cytokines; TNF-
ĮDQG,/ȕWXPRXUFRQGLWLRQHGPHGLDDQGPDFURSKDJHFRQGLWLRQHGPHGLDRQ
tumour-endothelial interactions and if these may account for the preferential
invasion of lymphatic vessels observed in tumours.
3. Study the surface and intracellular endothelial cell expression of CLEVER-1,
ICAM-1 and VCAM-1 in vascular versus lymphatic models and primary cells
versus immortalized cell lines; under control and stimulated conditions i.e. with
TNF-ɲ and IL-1ɴ to examine the role that these adhesion molecules might play
in regulating lymphatic vessel invasion.
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3.3 Materials and Methods
3.3.1 Cell lines and culture
3.3.1.1 Blood endothelial cells
HUVEC: Human umbilical vein endothelial cells were isolated from human
umbilical cords obtained from the Department of Obstetrics, City Hospital,
Nottingham using a collagenase digestion technique (Jaffe et al., 1973). Before
cell isolation, umbilical cords were stored in a sterile plastic container at 4oC
overnight or up to a maximum of one week. Trigene solution was used to wipe
the outer surface of the cord to remove excess blood and debris. The cord was
squeezed slightly to remove any clots forming inside the vein. To ensure
maximum sterility, 2cm of the cord from both ends and all areas with clamp
marks were cut off. The umbilical vein was cannulated using a sterile venflon®
and washed with RPMI medium to remove blood and debris using a 20ml
syringe inserted into the inlet pipe of the venflon®. 5ml of type I collagenase
were added into the vein where the free end of the cord was clamped and then
incubated at 37oC for 40 minutes. The vein was washed with 20ml of HUVEC
media (as described below) into a universal to stop the proteolytic activity of the
collagenase solution and centrifuged at 1500rpm for 5 minutes. The resultant
pellet was resuspended in 5ml of HUVEC medium (as described below) and
plated in a T25 tissue culture flask pre-coated with 0.2% gelatin (Sigma, UK) for
20 minutes at 37oC. Cells were incubated overnight and the media was
changed the next day to remove cells debris, such as erythrocytes and
leukocytes that remain floating, and these cells were grown to confluence. Cells
from three cords were pooled into a T175 flask to give a single batch of
experimental HUVEC. HUVEC were maintained in 37% nutrient mixture F-12
HAM media (Sigma, UK) in sterile water containing 3.7% 199 media (Sigma,
UK), 20% iron supplemented donor calf serum (PAA Laboratories, Austria), 1%
sodium bicarbonate (Sigma, UK), 14mM HEPES (Sigma, UK), 2mM L-
Glutamine (Sigma, UK), 1% penicillin/streptomycin (Sigma, UK), 7.5U/ml
heparin (CP Pharmaceuticals, UK), 25ng/ml EGF (Peprotech, UK) and
12.5ng/ml bFGF (Peprotech, UK). HUVEC were used between passage 2 and
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6. HUVEC, being a primary culture were used at short passage windows
because of the decrease expression of many proteins (for example angiotensin
I converting enzyme and prostacyclin) at each passage due to accelerated
senescence and spontaneous apoptosis. Upon recovery from liquid nitrogen,
HUVEC were characterized with endothelial cell marker, CD34 (AbD Serotec,
UK) using FACS to ensure specificity of the endothelial cells used in this study.
Subsequently, all experiments involving HUVEC were carried out on 0.2% pre-
gelatinised tissue culture flasks/plates.
hMEC-1: Human microvascular endothelial cells, obtained from ATCC, was the
first immortalised cell line derived from human dermal microvascular endothelial
cells (hDMEC), immortalised using SV40 large T-Antigen (Matsuo et al., 2006).
Cells were grown in endothelial basal medium (Lonza, USA) with 10% iron
VXSSOHPHQWHG GRQRU FDOI VHUXP ȝJPO K\GURFRUWLVRQH 6LJPD 8. QJPO
EGF and 1% penicillin/streptomycin. Cells were used between passage 4 and
17 and were characterized using CD34 and CD31 (AbD Serotec, UK) to ensure
pure working blood endothelial cells population.
3.3.1.2 Lymphatic endothelial cells
hTERT-LEC: Human telomerase reverse transcriptase lymphatic endothelial
cells (hTERT-LEC) were a kind gift from Professor M Pepper (Nisato et al.,
2004). These cells are an immortalised lymphatic endothelial cell line
established from human dermal microvascular endothelial cells (hDMEC)
following transfection with a retrovirus containing the coding region of human
telomerase reverse transcriptase. Cells were used between passage 27 and 34.
hTERT-LEC were characterised by FACS using commercially available
lymphatic marker, D2-40 (Covance, SIGNET, UK) to ensure pure working
lymphatic endothelial cells population. hTERT-LEC were cultured in endothelial
basal media (EBM) supplemented with the EGM-2 bullet kit (Lonza, USA).
hMVEC dLy Neo: Neonatal dermal lymphatic microvascular endothelial cells
(hMVEC-dLy Neo), obtained from Lonza, are a primary lymphatic cell line. The
medium for this cell line was prepared as hTERT-LEC. Cells were used
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between passage 4 and 6 because of accelerated senescence and
spontaneous apoptosis after passage 6.
3.3.1.3 Tumour cells
Two breast cancer cell lines; MCF7 (used between passage 23 and 35) and
MDA-MB-231 (used between passage 15 and 28) and two melanoma cell lines;
MeWo (used between passage 20 and 30) and SKMEL-30 (used between
passage 18 and 30) were used in this study. These cells were obtained from
ATCC. MCF7 and SKMEL-30 were maintained in RPMI-1640 (Sigma, UK), 10%
iron supplemented donor calf serum with 1% penicillin/streptomycin. MDA-MB-
231 were maintained in minimal essential medium EAGLE (Sigma, UK), 0.1mM
non-essential amino acids solution (Sigma, UK), 2mM L-glutamine, 1%
penicillin/ streptomycin and 1% iron supplemented donor calf serum . MeWo
were maintained in minimum essential medium EAGLE, 10% iron
supplemented donor calf serum, 2mM L-glutamine, 1% sodium bicarbonate,
0.1mM non-essential amino acids and 1mM sodium pyruvate (Sigma, UK).
3.3.2 Subculture of adherent cell lines
Adherent cells were cultured in tissue culture flasks with routine culture media
(section 3.3.1) until 80 to 90% confluent. To subculture, complete medium was
removed and cells washed with PBS (without Ca2+ and Mg2+). Cells were
detached from the flask by adding 5ml of 0.5mg/ml trypsin-EDTA (Sigma, UK)
and incubated for 5 minutes at 37oC. Complete media was used to deactivate
the trypsin prior to centrifugation at 170g for 5 minutes to remove residual
trypsin. The pellet was resuspended in complete media, mixed well and split
into a new tissue culture flask.
3.3.3 Cryopreservation of cell lines
Cells were frozen to keep them at low passage number. Adherent cells lines
were brought into suspension using trypsin-EDTA (section 3.3.2) and counted
using haemocytometer or cell countess/automatic cell counter system (Life
Technologies, NY). Cells were then centrifuged at 170g for 5 minutes. 1x106
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were resuspended in 1ml of freezing medium (heat inactivated fetal calf serum
or complete medium + 10% DMSO) and stored in a cryovial. Cells were placed
at -80oC overnight before transferring to liquid nitrogen until further use.
3.3.4 Peripheral blood mononuclear cells (PBMC) isolation
PBMC were isolated from whole blood using a density-gradient centrifugation
method (Sheikh et al., 2004). Blood was collected, under informed consent from
healthy donors, in a vacutainer tube (BD, UK) containing 170 IU heparin as
anticoagulant. 2.5ml histopaque 1119 (Sigma, UK) was added to a 15ml tube to
separate the granulocytes, followed by histopaque 1077 (Sigma, UK) to
separate the mononuclear cells. 5ml of heparinised blood was layered on top of
the histopaque 1119 and histopaque 1077 and centrifuged for 30 minutes at
670g followed by the removal of the PBMC at the second layer (Figure 3-1).
Cells were washed twice in washing buffer (0.1% bovine serum albumin in iron
supplemented donor calf serum) and counted by haemocytometer or cell
countess prior to usage.
3.3.5 Generation of tumour conditioned media
In the tumour environment, tumour cells produce many cytokines and growth
factors that are used for tumour expansion and tumour growth. Hewett and
Murray (1996) developed a method to generate tumour conditioned media
Figure 3-1 PBMC separation using
density-gradient centrifugation
method. Left tube represents 5ml
of blood layered on top of
histopaque 1077 and 1119. Right
tube represents the layer of cells
and liquid formed after
centrifugation.
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which was used to mimic tumour microenvironment in vitro. In the current study,
breast cancer (MDA-MB-231 and MCF7) and melanoma (MeWo and SKMEL-
30) cell lines were used to generate tumour conditioned media. These cells
were grown in T175 flasks until 90 to 100% confluent. Routine culture media
was renewed overnight. The following day, media was removed, cells washed
twice with PBS and 20ml of tumour conditioning media was added to each flask.
Tumour conditioning media consists of HUVEC media or LEC basal media
without serum or growth factors. Serum was not added to avoid possible loss of
serum nutrients by tumour cells and to prevent a probable effect of conditioned
serum metabolites on endothelial cells (Hewett and Murray, 1996). After 24
hours, media was collected and centrifuged at 670g for 10 minutes to remove
cell debris prior to freezing at -80oC. Tumour cells was washed with PBS, re-fed
with their routine culture medium overnight before another batch of tumour
conditioned media was harvested. Tumour conditioned media was harvested
three times from each flask.
Prior to experimental use, the tumour conditioned media was supplemented
with heat inactivated fetal calf serum to fulfill endothelial cells growth
requirements (20%, 10%, 5% and 5% serum added prior to use on HUVEC,
hMEC-1, hTERT-LEC and hMVEC dLy Neo respectively). 50U/ml of sterile
polymyxinB-sulphate (Sigma, UK) was also added to neutralise any
contaminating endotoxin present in the conditioned media. Proliferation assays
were carried out by culturing tumour cells with normal cell culture media and
with generated tumour conditioned media to ensure that such media was
bioactive - results are shown in Appendix C-Figure C1.
3.3.6 Generation of macrophage conditioned media
Human monocytes were isolated from PBMC using a CD14+ selection method.
This procedure was conducted by Mohamad El-Refaee (PhD student,
University of Nottingham). PBMC were isolated from buffy coats by density
gradient centrifugation as in Section 3.3.4. First, 90ml of PBS was added to
50ml of blood in a T75 flask. 35ml of the blood/PBS mixture was gently layered
on top of a 15ml histopaque 1077 in a 50ml centrifuge tube which was
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centrifuged at 670g for 30 minutes with no brakes applied. PBMC were
harvested from the interphase of red blood cell layer and the histopaque layer.
For washing, 10ml of PBS was added to the PBMC which were centrifuged at
170g for 10 minutes. Supernatant was discarded and the cell pellet was
resuspended in 10ml PBS. Washing steps were repeated 3 times. After the third
wash, a small sample was removed and counts using haemocytometer.
Monocytes were purified from PBMC using magnetic microbeads conjugated
ZLWK DQWL &' 0LOWHQ\L %LRWHF 3%0& ZHUH UHVXVSHQGHG LQ ȝO 0$&6
EXIIHU PDJQHWLF FHOO VRUWLQJ EXIIHU 3%6   )&6  ȝ0 ('7$ DQG WKH
PDJQHWLF PLFUREHDGVZHUH DGGHG DW ȝO SHU [7 PBMC. The mixture was
incubated at 4ȠC in the dark for 15 mins. Cells were centrifuged at 170g for 10
minutes, the pellet resuspended in 3ml MACS buffer and added to a negative
depletion column. The column was washed 3 times with MACS buffer in which
the CD14 negative cells were discarded. The column was removed from the
magnet and placed over a fresh collection tube. 5ml of MACS buffer was added
to the column and a plunger applied to elute CD14+ monocytes.
For macrophage preparation, 1x107 CD14+ monocytes were cultured for six
days in RPMI-1640 + 5% FCS in the presence of 50ng/ml of macrophage-
colony stimulating factor (M-CSF) (Peprotech, UK) in a Teflon flask (Thermo
Scientific, UK). At day 7, this macrophage co-cultured conditioned media was
harvested and stored at -20ȠC until further use.
7R VWXG\ WKH SURGXFWLRQ RI ,/ȕ LQ GLIIHUHQW VWLPXODWRU\ FRQGLWLRQV [6
macrophages per well were cultured (RPMI-1640 + 5% FCS) in a 12-well plate
for 48 hours under following conditions;
(1) resting macrophage – unstimulated,
(2) tumour derived lysate (TDL) stimulation (MDA-MB-231 lysate). Cell lysates
were prepared in RIPA buffer (20 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-
40, 0.5% sodium deoxycholate, 1 mM EDTA and 0.1% SDS) containing
protease inhibitors (2 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 130 µm
Bestatin, 14 µm E-64, 1 µm Leupeptin, 0.3 µm Aprotinin, Sigma) and
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phosphatase inhibitor cocktails 1 and 2 (Sigma, UK). Cell lysates were stored at
-80oC until further used.
/LSRSRO\VDFFKDULGHJDPPD/36Ȗ3HSURWHFK8.VWLPXODWLRQQJPO
LPS acts as an endotoxin, which could promote the secretion of pro-
LQIODPPDWRU\F\WRNLQHV,QWKLVVWXG\/36ȖZDVXVHGWRLQGXFHWKHSURGXFWLRQ
RI,/ȕDQGWKHUHVXOWLQJVXSHUQDWDQWZDVXVHGWRVWLPXODWHWKHHQGRWKHOLDODQG
tumour cells in the in-vitro assays.
(4) TDL + interleukin converting enzyme (ICE) inhibitor (R&D Systems, UK)
(250 mM).
/36Ȗ,&(LQKLELWRU
ICE is a cysteine protease responsible for proteolytic activation of the
ELRORJLFDOO\ LQDFWLYH ,/ȕ SUHFXUVRU WR WKH SURLQIODPPDWRU\ DFWLYH F\WRNLQH
(Livingston, 1997). In this study, ICE inhibitor was used to inhibit the production
RI PDWXUH ,/ȕ WR VWXG\ WKH HIIHFW RI ,/ȕ LQKLELWLRQ LQ WKH LQYLWUR DVVD\
Optimisation of ICE inhibitor concentration needed to inhibit the production of
,/ȕE\/36ȖVWLPXODWHGPDFURSKDJHVZDVFDUULHGRXWEHIRUHEHLQJXVHG LQ
the actual experiment. Optimisation result was shown in Appendix C –Figure
C2.
These 5 different conditions of supernatants were harvested after 48 hours and
stored at -20oC until further used in the in-vitro assays.
3.3.7 Static adhesion assay
Endothelial cells were grown to confluence in a 24 well plate (optimised seeding
density; 0.75x105 cells/ml, 1.3x105 cells/ml, 1.3x105 cells/ml and 1.5x105 cell/ml
for HUVEC, hMEC-1, hTERT-LEC and HMVEC-dLY cells respectively).
Complete media was removed and replaced with growth factor free media in
FRQWURO ZHOOV RU JURZWK IDFWRU IUHH PHGLD VXSSOHPHQWHG ZLWK  71)Į
QJPO QJPO QJPO 3HSURWHFK 8.  ,/ȕ QJPO QJPO
QJPO5	'6\VWHPV8.71)Į,/ȕQJPOQJPOWXPRXU
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conditioned media or (4) macrophage conditioned media and incubated for 24
hours.
PBMC adhesion was determined by adding 4x105 cells/well for 5 minutes. Non-
adherent cells were washed from the endothelial layer with washed buffer (0.1%
bovine serum albumin in PBS) and assessed visually by counting adherent cells
in the central area of the well with a phase contrast microscopy at 10x
PDJQLILFDWLRQ3%0&DGKHVLRQ WR WKHHQGRWKHOLDOFHOOVZLWKDQGZLWKRXW71)Į
DQG,/ȕVWLPXODWLRQZDVFDUULHGRXWLPPHGLDWHO\SULRUWRFRPPHQFLQJWXPRXU
cell adhesion experiments to assess immune cell-endothelial cell interactions, in
addition to acting as a control to demonstrate that the endothelial cells and the
cytokines were responding appropriately.
For tumour cell adhesion assays, tumour cells were trypsinised to prepare
single cell suspensions. The effect of trypsin on tumour cell adhesion was
further investigated as described in section 3.3.8 and results are shown in
VHFWLRQ7KHFHOOVZHUH ODEHOHGZLWKȝ0RI&HOO7UDFNHU*UHHQ&0)'$
(Invitrogen, USA) at 1x106 per ml for 30 minutes at 37ȠC. This concentration
was shown not to affect cell viability and proliferation up to 24 hours (section
3.4.2). After labelling, tumour cells were resuspended in RPMI-1640 containing
10% iron supplemented donor calf serum. 0.5x105 cells per well were incubated
for 35 minutes at 37ȠC on the different endothelial cell monolayers. Tumour cell
adhesion time was optimised between 5 to 60 minutes and the results shown in
section 3.4.2)
Non adherent cells were washed with RPMI-1640. Adherent tumour cells were
counted using a fluorescence microscope (Nikon, Japan), in the central area of
the well which was marked manually with grid lines on the bottom of the plate. 2
fields of view were counted in each well at 20x magnification. Experiments were
conducted twice, both in triplicate. Results were expressed as the absolute
number of cells adhered to the endothelial layer and as the percentage of cells
adhered relative to control. Static adhesion assays were also performed under
WKH IROORZLQJ FRQGLWLRQV  VWLPXODWLQJ WXPRXU FHOOV ZLWK 71)Į   DQG
QJPO RU ,/ȕ QJPO QJPO DQG QJPO  VWLPXODWLQJ ERWK
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HQGRWKHOLDO DQG WXPRXU FHOOV VLPXOWDQHRXVO\ ZLWK 71)Į QJPO RU ,/ȕ
QJPO  VWLPXODWLQJ WKH HQGRWKHOLDO FHOOV ZLWK 71)Į QJPO  ,/ȕ
(10ng/ml), (4) stimulating the endothelial cells with tumour conditioned media
and (5) stimulating the endothelial cells with macrophage conditioned media.
3.3.8 Effect of trypsin dissociation on tumour cell adhesion
Trypsin-EDTA was used to dissociate adherent cells from tissue culture flasks
to prepare cell suspension. However, this type of enzymatic treatment may
affect tumour cell adhesion to the endothelium. To investigate the effect of the
trypsin dissociation method on these cells, a direct comparison between
trypsinised tumour cells or cells treated with EDTA was carried out. A confluent
T75 flask of MCF7 cells was split 1:2 and cells were allowed to adhere
overnight. Cells from one flask were trypsinised as in Section 3.3.2 and cells
from the other flask were detached using 5mM of EDTA for 15 minutes and
resuspended in RPMI-1640 + 10% serum. These two cells populations were
labeled with cell tracker green and the adhesion pattern to the endothelial cells
were compared as in Section 3.3.7.
3.3.9 Effect of gelatin on tumour cell adhesion
HUVEC cells were cultured on gelatin coated flasks to facilitate cell attachment.
To investigate the effect of gelatin on tumour cell adhesion assay, a direct
comparison of MDA-MB-231 adhesion to HUVEC and hTERT-LEC, both
cultured with and without gelatin was carried out. The adhesion assay protocol
was carried out as in Section 3.3.7.
3.3.10 ELISA
Enzyme-linked immunosorbent assay (ELISA) is a biochemical method used to
detect the presence of an antibody or an antigen in a sample. In the current
VWXG\ WKLV WHFKQLTXH ZDV XVHG WR GHWHFW WKH SUHVHQFH RI ,/ȕ LQ WXPRXU
FRQGLWLRQHG PHGLD DQG PDFURSKDJH FRQGLWLRQHGPHGLD XVLQJ KXPDQ ,/ȕ,/
1F2 Duoset ELISA Development kit (R&D System, UK). A 96 well microplate
was coated with capture antibody overnight at room temperature. Next day,
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each well was aspirated and washed with wash buffer (0.05% Tween® 20 in
PBS). Washing was carried out three times. After the last wash, any remaining
wash buffer was removed by inverting the plate and blotting it against clean
paper towel. Non specific binding was blocked by adding 300µl of reagent
diluents (1% BSA in PBS, pH 7.2-7.4, 0.2µm filtered) in each well. The plate
was covered with an adhesive strip and incubated at room temperature for one
hour. 100µl of samples and standards, diluted in reagent diluents, were added
to the test wells before incubation at room temperature for 2 hours. 100µl of
detection antibody was added to the wells and incubated for 2 hours at room
temperature before addition of 100µl of strepavidin-HRP (1:50 dilution in
reagent diluents) for 20 minutes. Washing was conducted three times after each
incubation. 100µl of substrate solution (1:1 of substrate reagent A and substrate
reagent B; BDBioSciences, CA) was added to each well to allow colour change
in response to HRP levels for 15 minutes. 50µl of sulphuric acid (2M) was then
added to stop this reaction. The plate was lightly tapped to ensure thorough
mixing. The optical density of each well was determined using a plate reader
(Fluorostar Optima, BMG LabTech) at 450nm using Fluorostar Optima software
version 1.30 R3.
3.3.11Western blot
The specificity of the ICAM-1 and VCAM-1 antibodies was determined by
Western blotting as described below (specificity of CLEVER-1 had been
completed previously (Ammar et al., 2011).
(A) Cell lysate preparation
Endothelial cells and PBMC cell lysates were used to determine ICAM-1 and
VCAM-1 antibody specificity. Endothelial cells (HUVEC and hMEC-1) were
grown to confluence in 3 x T75 tissue culture flasks. Upon confluence, one flask
RI HQGRWKHOLDO FHOOV ZDV VWLPXODWHG ZLWK 71)Į QJPO RQH ZLWK /36Ȗ
(500ng/ml) diluted in growth factor free media and one flask acted as a control
with only growth factor free media used. PBMC were isolated from fresh blood
using the density gradient centrifugation method as described in Section 3.3.1.
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The PBMC were incubated in T75 flasks at 37ȠC for 24 hours in RPMI medium
KHDWLQDFWLYDWHGIHWDOFDOIVHUXPZLWKRXW/36ȖQJPO6LJPD8.
These cells (endothelial cells and PBMC) were trypsinised as described in
Section 3.3.2. Cells were washed with 1ml PBS to remove any residue of serum
proteins and centrifuged at 690g for 10 minutes. The supernatant was
discarded and 1ml lysis buffer (2mM Tris-HCl, 135mM NaCl, 1.5mM MgCl2, 1%
Triton X-100 and 10% glycerol) added to the cell pellet with 10µl of protease
inhibitor cocktail (Sigma, UK) to maintain and preserve protein functionality
following cell lysis. Cell lysates were stored at -20ȠC.
(B) Protein measurement by Bio-Rad protein assay kit (Bio-Rad
Laboratories, USA)
The Bio-Rad protein assay is a colourimetric method to measure the
concentration of solubilised protein in cell lysates. It involves the addition of an
acidic dye to the protein solution and a differential color change occurs in
response to the protein concentration. The absorbance value was determined
by a microplate reader. A protein standard curve was generated using bovine
serum albumin diluted in lysis buffer by plotting the absorbance values against
corresponding protein concentrations. The absorbance readings of unknown
protein lysates at 650nm were plotted on the standard curve to determine the
protein concentration in each cell lysate - this was carried out in triplicate. The
determination of the protein concentration, in respective cell lysates, was
carried out to ensure equal loading of protein in the wells of the SDS-PAGE
Western blot gel.
(C) Buffers used in Western Blot
x 4X SDS/sample buffer: To prepare a non-reducing sample buffer, 1.52g
Tris base (Sigma, UK), 60% glycerol (Sigma, UK), 8% SDS (Sigma, UK)
and 10mg bromophenol blue (Sigma, UK) were diluted in 100ml ultrapure
water. The pH was adjusted to 6.8 with 1M hydrochloric acid (HCl). To
SUHSDUH D UHGXFLQJ VDPSOH EXIIHU OPO RI ȕPHUFDSWRHWKDQRO
(Sigma, UK) was added to the above mixture.
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x 0.5M Tris-HCl/SDS pH 6.8: 6.05g Tris base and 0.4% SDS were mixed
with 50ml ultrapure water. The pH was adjusted to 6.8 with 1M HCl and
ultrapure water was added to 100ml total volume.
x 1.5M Tris-HCl/SDS pH 8.8: 18.2g Tris base and 0.4% SDS were mixed
with 50ml ultrapure water. The pH was adjusted to 8.8 with 1M HCl and
ultrapure water was added to 100ml total volume.
x Electrode buffer/10X Tris-Glycine: 30.3g Tris-base and 144g glycine
(Sigma, UK) were mixed in 1L distilled water.
x 1X running buffer: 100ml 10X Tris-Glycine, 10ml 10% SDS and 900ml
distilled water.
x Transfer buffer: 50ml 10X Tris-Glycine, 100ml methanol and 350ml
distilled water.
(D) Gel preparation and electrophoresis
12% SDS-PAGE resolving gels and 5% stacking gels were prepared using the
recipes described in Table 3-5. Gels were left to set for 30 minutes each at
room temperature. 25µg of protein from each sample was loaded into the wells
of the Western blot gel. Before loading, cell lysates were mixed with 4X SDS
sample buffer (1 volume of sample to 3 volume of sample buffer) and incubated
at 100ȠC for 5 minutes to denature the proteins. These protein samples were
loaded at equal amounts in the wells of the SDS-PAGE gel (total volume 20µl).
1.5µl of Western blot molecular weight marker (rainbow marker) (GE
Healthcare, UK) with 1.5µl of Western blot magic marker (Invitrogen, NY, USA)
were also loaded and the gel was run on 125V for 90 minutes. Following
electrophoresis, the stacking gel was removed and the gel blotted on a
nitrocellulose membrane (Millipore, MA, USA) at 25V for 90 minutes. The
membrane was then blocked overnight in blocking buffer (5% milk (SMA First
Infant Milk, Ireland) in 0.1% PBS-Tween) at 4ȠC. The blocking buffer was
removed and the membrane incubated with either ICAM-1 or VCAM-1 anti-
antibody (1:100 in blocking buffer) (Thermo Scientific, UK) for 1 hour at room
temperature. The membrane was washed 3 x 5 minutes with 0.1% PBS/Tween
EHIRUH LQFXEDWLRQ ZLWK VHFRQGDU\ ĮPRXVH +53DQWLERGLHV  5	'
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System, UK) for 1 hour at room temperature. Washing was carried out 3 x 5
minutes and Amersham ECL reagent (GE Healthcare, UK) was added to the
membrane for 1 minute. An Amersham hyperfilm ECL (GE Healthcare, UK) was
H[SRVHGRQWRSRIWKHPHPEUDQHIRUPLQXWHVDQGGHYHORSHGWRYLHZEDQGVȕ
actin antibody was used to ensure equal loading of sample in the gel. The
QLWURFHOOXORVHPHPEUDQHZDV LQFXEDWHGZLWKȕDFWLQ+53FRQMXJDWHGDQWLERG\
(1:1000 in blocking buffer) (Invitrogen, UK) for 1 hour at room temperature and
the membrane was developed as above.
Table 3-5: Recipe for 12% resolving gel and 5% stacking gel used in
western blot
Reagents 12% resolving
gel (ml)
Reagents 5% stacking
gel (ml)
H2O 6.6 H2O 3
30% acrylamide-bis 8.0 30% acrylamide-bis 0.65
1.5M Tris-HCl/SDS pH 8.8 5.2 0.5M Tris-HCl/SDS pH 6.8 1.25
10% APS 0.2 10% APS 0.05
TEMED 0.008 TEMED 0.0005
3.3.12 Flow cytometry of endothelial cell CLEVER-1, ICAM-1 and VCAM-1
expression
Flow cytometry was carried out to detect surface or intracellular expression of
FHOOXODU SURWHLQV ,QGLUHFW IORZ F\WRPHWU\ ZDV FDUULHG RXW XVLQJ PRXVH Į
CLEVER-1 antibody (obtained via collaboration with Dr Marco Salmi, Finland),
anti-ICAM-1 and anti-VCAM-1 antibody (R&D System. UK) and a FITC-labelled
rabbit anti-mouse antibody (DAKO, Denmark). Both surface and intracellular
expression of CLEVER-1 was assessed on four endothelial cell models;
HUVEC, hMEC-1, hTERT-LEC and hMVEC dLy Neo. In addition, the influence
RI 71)Į DQG ,/ȕ RQ &/(9(5 H[SUHVVLRQ LQ WKHVH FHOO OLQHV ZDV
investigated. Surface expression of ICAM-1 and VCAM-1 were assessed on
three endothelial cell models; HUVEC, hMEC-1 and hTERT-LEC. WinMDI 2.8
(Purdue University Cytometry Laboratories, Indiana) and FlowJo software
version 7.6.1 was used to analyse flow cytometry results.
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(A) Surface staining
Endothelial cells were trypsinised and counted using a haemocytometer. 2 x 105
cells were aliquoted into a 10ml FACS tube and centrifuged at 170g for 5
PLQXWHV 7KH VXSHUQDWDQW ZDV UHPRYHG DQG FHOOV UHVXVSHQGHG LQ ȝO RI
CLEVER-1 antibody diluted in FACS buffer (PBS + 0.1% bovine serum
DOEXPLQ%6$ EULQJLQJ WKH WRWDO FRQFHQWUDWLRQ RI DQWL&/(9(5 WR  ȝJPO
5µg/ml of ICAM-1 and VCAM-1 antibody were also used to asses expression of
these adhesion molecules using this procedure. For controls, cells were either
incubated in FACS buffer alone or with IgG isocontrol (20µg/ml). These cells
were incubated on ice for one hour in the dark. 1ml FACS buffer was added to
wash the cells (to remove any unbound antibody) and then centrifuged (170g, 5
minutes). Supernatant was discarded and the cell pellet was resuspended in
ȝO RI VHFRQGDU\ DQWLERG\ UDEELW DQWLPRXVH ),7&  GLOXWLRQ LQ )$&6
buffer) prior to incubation on ice for 1 hour in the dark. Washing steps followed
DQGILQDOO\FHOOVZHUH UHVXVSHQGHG LQȝORI)$&6EXIIHUDQG IOXRUHVFHQFH
readings were measured using FACS scan (Becton Dickinson, Sunnyvale Ca,
USA).
(B) Intracellular staining
Endothelial cells were trypsinised and fixed with 1ml 4% formaldehyde (diluted
in PBS) for 30 minutes at room temperature. The cells were centrifuged at
1000rpm for 5 minutes and supernatant discarded. 1ml FACS buffer then added
to wash the cells, centrifuged at 170g for 5 minutes and supernatant discarded.
The cells were permeabilised in 70% methanol for 10 minutes and centrifuged
(170g, 10 minutes). Supernatant was removed and cells resuspended in 1.5ml
FACS buffer. The cells were evenly distributed into three FACS tubes;
XQODEHOOHGFHOOVFHOOVZLWK,J*LVRFRQWURO'$.2'HQPDUNȝJPODQGFHOOV
with CLEVER-1 antibody and centrifuged at 170g for 10 minutes. The cells were
then treated as in the surface staining procedures
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3.3.13 Statistical analysis
For flow cytometry, results were reported as geometric mean ± standard
deviation. The student t-test was used to calculate the significance value of
CLEVER-1, ICAM-1 and VCAM-1 expression between endothelial cell models
DQG EHWZHHQ XQVWLPXODWHG FRQWUROV ZLWK 71)Į,/ȕ VWLPXODWHG HQGRWKHOLDO
cells.
For adhesion assays, the student t-test was used to evaluate variation between
HQGRWKHOLDO FHOO PRGHOV DQG LQGLYLGXDO WUHDWPHQWV FRQWURO DQG 71)Į,/ȕ
stimulated conditions). A p value <0.05 defined significant relationships. All
statistical analysis was carried out using GraphPad Prism version 3.02 and
Microsoft Excel 2007.
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3.4 Results
3.4.1 The effect of cell tracker green labeling on tumour cell viability and
proliferation
To assess the effect of fluorescent labelling on cell viability and proliferation, the
trypan blue exclusion viability assay was used. Trypan blue is a vital stain used
to selectively colour dead tissues or cells blue without killing living cells. No
difference in MDA-MB-231 cells viability count between the labelled and
unlabelled cells was observed (Figure 3-2). There was also no difference in the
proliferative rate between the labeled and unlabelled cells up to 72 hours. The
same effect was also observed with MeWo cell line (Figure 3-3). Therefore, cell
tracker green was used for tumour cell labeling in subsequent adhesion assays.
Figure 3-2 The effect of cell tracker green labelling on MDA-MB-231 cell viability (A) and
cell proliferation (B). There was no significant different in MDA-MB-231 cell viability (at
24 hours) and proliferation (up to 72 hours) between the fluorescently labeled and
unlabelled cells. Pooled data from 2 independent experiments, each carried out in
triplicate (n=6).
Figure 3-3 The effect of cell tracker green labelling on MeWo cell viability (A) and cell
proliferation (B). There was no significant different in MeWo cell viability (at 24 hours) and
proliferation (up to 72 hours) between the fluorescently labelled and unlabelled cells.
Pooled data from 2 independent experiments, each carried out in triplicate (n=6).
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3.4.2 Optimisation of tumour cell adhesion assay
MDA-MB-231 and MCF7 cell lines were used to determine the optimal adhesion
time of tumour cell adhesion. Each cell line was left to adhere to HUVEC,
hMEC-1 and hTERT-LEC for 5, 15, 35, 45 and 60 minutes and the number of
adhered cells compared at the end of the assay. Results show that the number
of adhered MDA-MB-231 cells increased significantly up to 35 minutes and then
plateaud in all endothelial cell models used. If there was an increased in the
number of adhered tumour cells after 35 minutes, this increased is non-
significant. Similar adhesion patterns were also observed with MCF7 cells in
which no significant increase in the number of adhered cells was observed after
35 minutes for HUVEC and hMEC-1 cells. However, the adhesion of MCF-7
cells to hTERT-LEC increased significantly up to 45 minutes and plateaud at 60
minutes. Yet, based on MDA-MB-231 and MCF-7 adhesion results, 35 minutes
was used as the adhesion time for subsequent tumour cell assays (Figure 3-4).
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Figure 3-4 Optimisation of MDA-MB-231 (A) and MCF7 (B) adhesion time to HUVEC,
hMEC-1 and hTERT-LEC. The number of adhered tumour cells to the endothelial cells
was assessed at different incubation time. Both tumour cells showed significant
increased in the number of cells adhered between 5 to 35 minutes and plateau thereafter.
Pooled data from 2 independent experiments, each carried out in triplicate (n=6).
*represents significant difference (p<0.05) between two time points.
3.4.3 The effect of trypsin dissociation method on tumour cell adhesion
To assess the effect of trypsin on the adhesive property of tumour cells,
adhesion assays were conducted using cells detached using either trypsin or
EDTA. There was no difference in MCF7 cell adhesion to HUVEC between the
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two dissociation methods as shown in Figure 3-5. Therefore, tyrpsin was used
to detach adherent tumour cells in this study.
3.4.4 The effect of gelatin on tumour cell adhesion
To assess the effect of gelatin coating (used to culture HUVEC cells) on tumour
cell adhesion, adhesion assays were carried out with MDA-MB-231 cells on
HUVEC or hTERT-LEC cells cultured on tissue culture plates coated with and
without gelatin. It was observed that coating tissue culture flask/well with gelatin
has no significant effects on tumour cell adhesion as shown in Figure 3-6 and
that, as will be discussed in greater detail later (Section 3.4.6), tumour cells
exhibited a preference for blood endothelial cells adherence as opposed to
lymphatic endothelial cells adherence.
Figure 3-6 The effect of gelatin coating on MDA-MB-231 adhesion to HUVEC under
FRQWURODQG71)ĮVWLPXODWHGFRQGLWLRQV7KHUHZDVQRVLJQLILFDQWGLIIHUHQWLQ0'$0%
231 adhesion to HUVEC or hTERT-LEC; with or without gelatin. Pooled results from two
independent experiments each carried out in triplicate (n=6).
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Figure 3-5 Effect of trypsin
dissociation method on MCF7
adhesion to HUVEC under
FRQWURO 71)Į DQG ,/ȕ
stimulated conditions. Pooled
results from two independent
experiments each carried out in
triplicate (n=6).
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3.4.5 PBMC adhesion to HUVEC, hMEC-1, hTERT-LEC and hMVEC dLy
Neo.
3%0&DGKHVLRQWRXQVWLPXODWHGDQG71)Į,/ȕVWLPXODWHG+89(&K0(&
1, hTERT-LEC and HMVEC-dLy Neo was conducted prior to conducting any
WXPRXUFHOODGKHVLRQH[SHULPHQWV(QGRWKHOLDOFHOOVSUHVWLPXODWLRQZLWK71)Į
DQG ,/ȕ IRU  KRXUV FDXVHG D VLJQLILFDQW LQFUHDVHG LQ 3%0& DGKHVLRQ
compared to the unstimulated controls (p<0.0001 and <0.01 respectively)
(Figure 3-7). PBMC adhesion to all endothelial cell models increased with
LQFUHDVLQJ71)ĮFRQFHQWUDWLRQDQGDSODWHDXZDVREVHUYHGDWQJPO)RU,/
ȕ D SODWHDX ZDV REVHUYHG DW QJPO 3%0& DGKHVLRQ WR 71)Į,/ȕ 
stimulated HUVEC was more than that to hMEC-1 but was not significantly
different (p>0.05). There was no significant difference in the number of cells
adhered to either of the lymphatic endothelial models, hTERT-LEC and
HMVEC-dLY Neo. However, adhesion of PBMC was significantly higher to
stimulated blood endothelial cells (HUVEC and hMEC-1) than to the lymphatic
endothelial cells (hTERT-LEC and HMVEC-dLy Neo), (p<0.05) for both
cytokines, except when the endothelial cells were stimulated with 15ng/ml of IL-
ȕZKHUHWKHGLIIHUHQFHVZHUHQRWVWDWLVWLFDOO\VLJQLILFDQW
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Figure 3-7 PBMC adhesion to HUVEC, hMEC-1, hTERT-LEC and HMVEC-dLy Neo under
$71)ĮDQG%,/ȕVWLPXODWLRQ6WLPXODWLRQRIHQGRWKHOLDOFHOOVZLWK71)ĮRU,/ȕ
caused a significant increase in the number of PBMC adhered to all endothelial cell
models compared to the unstimulated controls (p<0.0001 and p<0.01 respectively). PBMC
adhesion to all endothelial cell models increased with increasing concentrations of both
F\WRNLQHVZKLFKSODWHDXDWDQGQJPO IRU71)ĮDQG ,/ȕUHVSHFWLYHO\(UURUEDUV
represent standard deviation in 28 independent experiments, each in duplicate (n=56). P
value was assessed by paired T-test, * represent statistical significant compared to
control groups (p<0.05).
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3.4.6 Tumour cell adhesion to HUVEC, hMEC-1, hTERT-LEC and hMVEC
dLy Neo under control conditions
MCF7, MDA-MB-231, MeWo and SKMEL-30 showed similar overall adhesion
patterns to all four endothelial cell models, under control conditions, however
with different affinity as shown in Figure 3-8. Of the four tumour cell lines, MDA-
MB-231 cells had the highest affinity towards the blood endothelium (HUVEC
110.88±14.95 and hMEC-1 90.63±6.00) while SKMEL-30 had the highest
affinity towards lymphatic endothelial cells (hTERT-LEC 74.67±5.76 and
HMVEC-dLy Neo 72.00±4.84). Both the breast cancer cell lines showed
relatively less adherence to the lymphatic rather than the blood endothelial cells
in comparison to the melanomas. Although MDA-MB-231, MCF7, MeWo and
SKMEL-30 showed preferential adhesion towards the blood endothelial cells as
opposed to lymphatic endothelial cells, only the breast cancer cell lines shows
significant difference (p<0.001). There was no significant difference in the
tumour cell adhesion patterns between the primary and the immortalised cell
lines of the same origin; blood and lymphatics.
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MDA-MB-231 MCF7 MeWo SKMEL-30
HUVEC 110.88 ±14.95 79.75 ±4.50 71.75 ±3.86 98.92 ±6.68
hMEC-1 90.63 ±6.00 64.88 ±3.27 56.25 ±5.19 90.67 ±6.68
hTERT-LEC 39.38 ±4.37 35.88 ±5.00 50.42 ±3.06 74.67 ±5.76
hMVEC dLy Neo 37.50 ±5.45 37.75 ±5.15 44.08 ±4.94 72.00 ±4.84
Figure 3-8 Tumour cell adhesion to HUVEC, hMEC-1, hTERT-LEC and HMVEC-dLy Neo
under control conditions. All endothelial cell models show the same adhesion pattern
with the 4 tumour cells used, MDA-MB-231, MCF7, MeWo and SKMEL-30; in which higher
adherence to the blood endothelial models, HUVEC is observed. Pooled results from 28
independents experiments, each in triplicate (n=84). * significant difference within group,
+ significant difference between groups)
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 7KHHIIHFWRI71)ĮDQG,/ȕRQWKHDGKHVLRQRIWXPRXUFHOOVWRWKH
different endothelial models
The percentage adhesion of each of the tumour lines; MDA-MB-231, MCF7,
0H:RDQG6.0(/WR71)ĮVWLPXODWHG+89(&K0(&K7(57/(&DQG
HMVEC-dLy Neo was not significantly increased when compared to the
unstimulated endothelial models as shown in Figure 3-9.
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)LJXUH0'$0% $0&) %0H:R&DQG6.0(/ 'DGKHVLRQ WR71)Į
VWLPXODWHG +89(& K0(& K7(57/(& DQG +09(&G/\ 1HR DW GLIIHUHQW 71)Į
concentrations relative to the unstimulated controls. Pre-stimulation of the endothelial
FHOOV ZLWK 71)Į IRU  KRXUV GLG QRW KDYH DQ\ VLJQLILFDQW HIIHFW RQ WKH DGKHVLRQ RI
tumour cells to either blood (HUVEC and hMEC-1) and lymphatic (hTERT-LEC and
HMVEC-dLy Neo) endothelial cell models. Pooled results from two independent
experiments, each carried out in triplicate (n=6).
Pre-stimulation of the tumour cell lines, MDA-MB-231, MCF7, MeWo and
6.0(/ ZLWK 71)Į GLG QRW VLJQLILFDQWO\ LQFUHDVHG WKHLU DGKHVLRQ WR
XQVWLPXODWHG EORRG HQGRWKHOLDO FHOO PRGHOV H[FHSW IRU WKH DGKHVLRQ RI71)Į
stimulated MDA-MB-231 to HUVEC (p<0.001). However, pre-stimulation of the
WXPRXU FHOO OLQHV ZLWK 71)Į VKRZV VLJQLILFDQW LQFUHDVHG RI 0'$0%
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MCF7 and MeWo cells adhesion to the unstimlated lymphatic endothelial cells,
hTERT-LEC (p<0.05) as shown in Figure 3-10.
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)LJXUH  $GKHVLRQ RI 71)Į VWLPXODWHG WXPRXU FHOOV 0'$0% $ 0&) %
MeWo (C) and SKMEL-30 (D) to unstimulated HUVEC, hMEC-1, hTERT-LEC and HMVEC-
dLy Neo. Percentage of tumour cell adhesion to all endothelial cell lines did not vary
significantly under control and stimulated conditions with the exception of MDA-MB-231
adhesion to HUVEC (p<0.001) and the adhesion of MDA-MB-231, MCF7 and MeWo to
hTERT-LEC (p<0.05). Pooled results from two independent experiments, each carried out
in triplicate (n=6). P value was assessed by paired T-test, * represent statistical
significant compared to control groups (p<0.05). ! represent statistical significant
FRPSDUHGWRQJPORI71)ĮDQGUHSUHVHQWVWDWLVWLFDOVLJQLILFDQWEHWZHHQEORRGDQG
lymphatic endothelial cell models.
3UHVWLPXODWLRQRIWKHHQGRWKHOLDOFHOOVZLWK,/ȕVKRZVVLJQLILFDQWLQFUHDVHGLQ
MDA-MD-231, MCF7, MeWo and SKMEL-30 cells adhesion towards HUVEC,
hMEC-1, hTERT-LEC and hMVEC dLy Neo, with a more pronounced
percentage increased observed in both breast cancer cell lines compared to the
melanomas. In MDA-MB-231 and MCF7, the percentage increased was higher
towards the lymphatic endothelial cells compared to the blood endothelial cells
(p<0.001 and p<0.0001 respectively) as shown in Figure 3-11.
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)LJXUH0'$0% $0&) %0H:R&DQG6.0(/ 'DGKHVLRQ WR ,/ȕ
stimulated HUVEC, hMEC-1, hTERT-LEC and HMVEC-dLy Neo relative to the
XQVWLPXODWHG FRQWUROV 3UHVWLPXODWLRQ RI WKH HQGRWKHOLDO FHOOV ZLWK ,/ȕ IRU  KRXUV
significantly affect the adhesion of tumour cells to both blood (HUVEC and hMEC-1) and
lymphatic (hTERT-LECand hMVEC dLy Neo) endothelial cell models. Increased was more
significant in breast cancer cell lines compared to the melanoma cell lines. In breast
cancer cell lines, percentage increased was more to the lymphatic cell models compared
to the blood endothelial models (p<0.001 and p<0.0001 respectively). Pooled results from
two independent experiments, each carried out in triplicate (n=6). * represent statistical
significant compared to control groups (p<0.05). ! represent statistical significant
FRPSDUHG WR QJPO RI ,/ȕ DQG  UHSUHVHQW VWDWLVWLFDO VLJQLILFDQW EHWZHHQ EORRG DQG
lymphatic endothelial cell models.
When the tumour cells: MDA-MB-231, MCF7, MeWo and SKMEL-30 were
VWLPXODWHG ZLWK ,/ȕ WXPRXUHQGRWKHOLDO DGKHVLRQ LQFUHDVHG VLJQLILFDQWO\
across the four unstimulated endothelial cell models; HUVEC, hMEC-1, hTERT-
LEC and hMVEC dLy Neo. In MDA-MB-231 and SKMEL-30 adhesion, the
percentage adhesion was higher towards the lymphatic endothelial cells
opposed to the blood endothelial cells as shown in Figure 3-12.
106
0 5 10 15
0
100
200
300
(A)
* *
*!
*!*!
*! *!
*!
+ +
IL-1E concentration (ng/ml)
Pe
rc
en
ta
ge
of
ad
he
re
d
ce
lls
(%
)
0 5 10 15
0
100
200
300
(B)
IL-1E concentration (ng/ml)
Pe
rc
en
ta
ge
of
ad
he
re
d
ce
lls
(%
)
*!
**
*!*!
*!
0 5 10 15
0
100
200
300
(C)
IL-1E concentration (ng/ml)
Pe
rc
en
ta
ge
of
ad
he
re
d
ce
lls
(%
)
*!*!
*!**!
*!
*!*!
0 5 10 15
0
100
200
300
HUVEC
hMEC-1
hTERT-LEC
hMVEC dLy Neo
(D)
*
**!*!
*!
*!*!*!
**
*
*
+
+
IL-1E concentration (ng/ml)
Pe
rc
en
ta
ge
of
ad
he
re
d
ce
lls
(%
)
)LJXUH$GKHVLRQRI,/ȕVWLPXODWHGWXPRXUFHOOV0'$0%$0&)%0H:R
(C) and SKMEL-30 (D) to unstimulated HUVEC, hMEC-1, hTERT-LEC and HMVEC-dLy Neo
UHODWLYHWRWKHXQVWLPXODWHGFRQWUROV3UHVWLPXODWLRQRIWKHWXPRXUFHOOVZLWK,/ȕIRU
hours significantly affect the adhesion of tumour cells to blood (HUVEC and hMEC-1) and
lymphatic (hTERT-LECand hMVEC dLy Neo) endothelial cell models. Increased was more
significant to the lymphatic endothelial cells compared to the blood endothelial cells in
MDA-MB-231 and SKMEL-30. Pooled results from two independent experiments, each
carried out in triplicate (n=6). * represent statistical significance compared to control
JURXSV S  UHSUHVHQW VWDWLVWLFDO VLJQLILFDQW FRPSDUHG WR QJPO RI ,/ȕ DQG 
represent statistical significant between blood and lymphatic endothelial cell models.
As both breast cancer and both melanoma cell lines showed a similar adhesion
pattern with similar affinity to the endothelial cell models of the same origin,
GRXEOHVWLPXODWLRQRI71)ĮERWKWXPRXUDQGHQGRWKHOLDOFHOOVZHUHVWLPXODWHG
simultaneously) was conducted using one breast cancer (MDA-MB-231) and
one melanoma cell line (MeWo) to study the adhesion patterns towards the
immortalised endothelial cells; hMEC-1 and hTERT-LEC. When MDA-MB-231
DQGWKHHQGRWKHOLDOFHOOVZHUHERWKVLPXOWDQHRXVO\VWLPXODWHGZLWK71)ĮWKHUH
was a significant increased in tumour cell adhesion to hMEC-1 (p=0.02) and
hTERT-LEC (p<0.001). The relative percentage of adhered tumour cells was
significantly higher to the lymphatic compared to the blood endothelial cell
models (p<0.05). Similar results were also observed with melanoma where
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there was a significant increased in adhesion of MeWo to hMEC-1 (p<0.001)
and hTERT-LEC (p<0.0001); as with the breast line the percentage adhesion of
MeWo cells were also higher in the lymphatic compared to the blood endothelial
cell model (Figure 3-13).
When MDA-MB-231 and the endothelial cells (hMEC-1 and hTERT-LEC) were
ERWKVLPXOWDQHRXVO\VWLPXODWHGZLWK ,/ȕ WKHUHZDVDVLJQLILFDQW LQFUHDVHG LQ
tumour cell adhesion to hMEC-1 and hTERT-LEC (p<0.001 and p<0.0001
respectively). Interestingly, the relative percentage of adhered tumour cells was
significantly higher to the lymphatic compared to the blood endothelial cell
models (p<0.0001). With the melanoma cell line (MeWo), although significant
increased in adhesion to hMEC-1 (p<0.001) and hTERT-LEC (p<0.001) was
observed, the percentage adhesion was of similar affinity towards both
lymphatic and blood endothelial cells (Figure 3-13).
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Figure 3-13 MDA-MB-231 (A) and MeWo (B) cell adhesion to hMEC-1 and hTERT-LEC
ZKHQERWKWKHWXPRXUFHOOVDQGWKHHQGRWKHOLDOFHOOVZHUHVWLPXODWHGZLWK71)Į,/ȕ
Significantly increased tumour-endothelial adhesion was observed in both tumour cell
lines with higher percentage adhesion to the lymphatic compared to the blood
endothelial cells. Pooled results from two independent experiments, each carried out in
triplicate (n=6). P value was assessed by paired T-test, * represent statistical significance
compared to control groups (p<0.05). + represent statistical significant between blood
and lymphatic endothelial cell models.
)LJXUHVKRZVWKHDGKHVLRQSDWWHUQRI0'$0%DQG0H:RWR71)Į
,/ȕ DQG 71)Į,/ȕ VWLPXODWHG K0(& DQG K7(57/(& $V VHHQ
SUHYLRXVO\DQG LQ WKLVDVVD\71)ĮDQG ,/ȕVWLPXODWLRQRIHQGRWKHOLDO FHOOV
tumour cells or both together increased MDA-MB-231 adhesion to both blood
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and lymphatic endothelial cell models with a preferential increased to the
O\PSKDWLF HQGRWKHOLDO FHOOV ZLWK ,/ȕ LQGXFLQJ JUHDWHU DGKHVLRQ WKDQ 71)Į
&RPELQLQJ 71)Į DQG ,/ȕ VWLPXODWLRQ RQ K0(& DQG K7(57/(& GLG QRW
significantly affect the adhesion pattern of MDA-MB-231 cells to both
HQGRWKHOLDOFHOOPRGHOVFRPSDUHGWRVWLPXODWLRQZLWK,/ȕDORQH
A different pattern was observed with MeWo in which no significant increased
ZDVREVHUYHGZLWK71)ĮVWLPXODWLRQ+RZHYHUZLWK,/ȕVWLPXODWLRQDOWKRXJK
a significant increased was observed, there was no significant different between
blood and lymphatic endothelial cell models i.e between hMEC-1 and hTERT-
/(& $V REVHUYHG ZLWK 0'$0% FHOOV FRPELQLQJ 71)Į DQG ,/ȕ
stimulation of endothelial cells did not significantly increased MeWo cell
DGKHVLRQ WR EORRG RU O\PSKDWLF HQGRWKHOLDO FHOOV LQ FRPSDULVRQ WR ,/ȕ
stimulation alone.
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Figure 3-14 0'$0%$DQG0H:R%FHOODGKHVLRQWR71)Į ,/ȕDQG71)Į
,/ȕ VWLPXODWHG K0(& DQG K7(57/(& UHODWLYH WR WKH XQVWLPXODWHG FRQWUROV 3UH
VWLPXODWLRQRIWKHHQGRWKHOLDOFHOOVZLWK71)ĮIRUKRXUVFDXVHVLJQLILFDQWLQFUHDVHGLQ
0'$0% DGKHVLRQ WR K7(57/(& S ZKLOH ,/ȕ VWLPXODWLRQ IRU  KRXUV
significantly affect the adhesion of both tumour cells to hMEC-1 and hTERT-LEC, which
ZHUHKLJKHUWRWKHO\PSKDWLFHQGRWKHOLDOFHOOV8SRQVWLPXODWLRQZLWK71)Į,/ȕQR
VLJQLILFDQW FKDQJHV REVHUYHG FRPSDUHG WR ZKHQ WKH FHOOV ZHUH VWLPXODWHG ZLWK ,/ȕ
alone. Pooled results from two independent experiments, each carried out in triplicate
(n=6). P value was assessed by paired T-test, * represent statistical significance
compared to control groups (p<0.05). + represent statistical significant between blood
and lymphatic endothelial cell models.
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3.4.8 The effect of tumour conditioned media on the adhesion of tumour
cells to the endothelium
To study the effect of tumour conditioned media on the adhesion of tumour cells
to lymphatic and blood endothelium, hMEC-1 and hTERT-LEC were incubated
for 24 hours with tumour conditioned media. As observed in Figure 3-15, there
was no significant increased in the adhesion of MDA-MB-231 when the
endothelial cells were pre-incubated with MDA-MB-231 tumour conditioned
media. Similarly, there was no effect in the percentage adhesion of MCF7,
MeWo and SKMEL-30 cells towards the pre-incubated endothelial cells with
tumour conditioned media.
To ensure that the adhesive effect observed in this assay is a true effect,
proliferation assays were carried out by culturing tumour cells with normal cell
culture media and with the tumour conditioned media used to in this assay to
ensure that these media ware bioactive - results are shown in Appendix C-
Figure C1.
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Figure 3-15 MDA-MB-231, MCF7, MeWo and SKMEL-30 adhesion to hMEC-1 and hTERT-
LEC stimulated with tumour conditioned media relative to the unstimulated control.
Tumour conditioned media stimulation for 24 hours did not have any significant effect on
the four tumour cell adhesion to the endothelial cells. Pooled results from two
independent experiments each carried out in triplicate (n=6).
110
3.4.9 The effect of macrophage conditioned media on the adhesion of
tumour cells to the endothelium
Macrophage conditioned media from day 7 monocyte-macrophage cultured was
obtained from three different donors. Pre-incubation of the endothelial cells
(hMEC-1 and hTERT-LEC) with this conditioned media for 24 hours caused a
significant increased in the adhesion of MDA-MB-231 and MeWo cells to both
hTERT-LEC and hMEC-1 cells relative to the controls (p<0.05). The percentage
increased in the adhesion of MDA-MB-231 cells was higher to the tumour
conditioned media stimulated hTERT-LEC compared to the tumour conditioned
media stimulated hMEC-1 across the three donors (p<0.001, p=0.008, p<0.001
for donor 1, donor 2 and donor 3 respectively) (Figure 3.16A). Similar results
were also observed in MeWo-endothelial adhesion in which the percentage
increased were higher to the tumour conditioned media stimulated lymphatic
endothelial cells opposed to the tumour conditioned media stimulated blood
endothelial cells in the three donors (p<0.01, p<0.01 and p=0.001 for donor 1,
donor 2 and donor 3 respectively)(Figure 3.16B).
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Figure 3-16 MDA-MB-231 (A) and MeWo (B) cells adhesion to tumour conditioned media
stimulated hMEC-1 and hTERT-LEC relative to the unstimulated controls. Pre-stimulation
of the endothelial cells for 24 hours caused significant increase in both tumour cells
adhesion to hMEC-1 and hTERT-LEC which was notably higher to the lymphatic
endothelial cells. Pooled results from two independent experiments each carried out in
triplicate (n=6). P value was assessed by paired T-test, * represent statistical significance
compared to control groups (p<0.05). + represent statistical significant between blood
and lymphatic endothelial cell models.
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,/ȕFRQFHQWUDWLRQLQWXPRXUFRQGLWLRQHGPHGLDDQGPDFURSKDJH
conditioned media
An ELISA was conducted (as in Section 3.3.10) to determine the concentration
RI ,/ȕ LQ PDFURSKDJH DQG WXPRXU FRQGLWLRQHG PHGLD XVHG LQ WKH VWDWLF
DGKHVLRQDVVD\VDERYH6HFWLRQDQG1R,/ȕZDVGHWHFWHGLQDQ\
of the tumour conditioned media used. However, the macrophage conditioned
media from the three different donors showed 69.7, 131.8 and 88.8 pg/ml of IL-
ȕLQGRQRUGRQRUDQGGRQRUUHVSHFWLYHO\7KHVHUHVXOWVZHUHVKRZQLQ
Figure 3-17.
Figure 3-17 ,/ȕFRQFHQWUDWLRQ LQPDFURSKDJHFRQGLWLRQHGPHGLD IURPWKUHHGLIIHUHQW
donors) and tumour conditioned media used to stimulate endothelial cells in static
DGKHVLRQ DVVD\ ,/ȕ ZDV GHWHFWHG LQ PDFURSKDJH FRQGLWLRQHG PHGLD EXW QRW WXPRXU
conditioned media.
3.4.11 The effect of macrophage conditioned media (5 different conditions
with/out ICE inhibitors on the adhesion of tumour cells to the
endothelium.
In unstimulated conditions, MDA-MB-231 cells adhered with similar affinity to
hMEC-1 and hTERT-LEC across all three donors. These donors are different
than the one used in previous adhesion assay and were designated donor 4, 5
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and 6. Upon stimulation with macrophage conditioned media generated from
/36ȖVWLPXODWHGPDFURSKDJHVWKHUHZDVDQLQFUHDVHGLQWKHQXPEHURI0'$
MB-231 cells adhered to both hMEC-1 (p<0.001, p<0.0001 and p<0.001 in
donor 4, donor 5 and donor 6 respectively) and hTERT-LEC (p<0.001,
p<0.0001 and p<0.001 in donor 4, donor 5 and donor 6 respectively) with no
preferential adhesion to either hMEC-1 or hTERT-LEC. The adhesion of MDA-
MB-231 cells to hMEC-1 and hTERT-LEC stimulated with macrophage
conditioned media generated from TDL stimulated macrophages was not
statistically significant compared to the control condition. However, there was a
significant decreased in the adhesion of MDA-MB-231 cell when the endothelial
cell models were stimulated with macrophage conditioned media generated
IURP /36Ȗ,&( LQKLELWRU DQG /36Ȗ7'/,&( LQKLELWRU VWLPXODWHG
macrophages across the three donors (Figure 3-18).
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Figure 3-18 Adhesion of MDA-MB-231 cells to hMEC-1 and hTERT-LEC stimulated with
macrophage conditioned media from 3 different donor; (A) Donor 4, (B) Donor 5 and (C)
Donor 6. Under control conditions, MDA-MB-231 cells shows similar adhesive ability and
affinity across both endothelial cells. Adhesion of MDA-MB-231 cells increased
significantly across hMEC-1 and hTERT-LEC when they were stimulated with
PDFURSKDJH FRQGLWLRQHG PHGLD JHQHUDWHG IURP /36Ȗ VWLPXODWHG PDFURSKDJHV 0'$
MB-231 cells adhesion decreased significantly across hMEC-1 and hTERT-LEC in
PDFURSKDJH FRQGLWLRQHG PHGLD JHQHUDWHG IURP /36Ȗ,&( DQG /36Ȗ7',&(
stimulated macrophages in all 3 donors. Pooled data from two independent experiments,
each carried out in duplicate (n=4). (*significant difference compared to unstimulated
FRQWUROVÁVLJQLILFDQWGLIIHUHQWFRPSDUHGWR/36ȖVWLPXODWHGJURXS
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,/ȕFRQFHQWUDWLRQLQPDFURSKDJHFRQGLWLRQHGPHGLD
$VCSUHYLRXVO\DQ(/,6$ZDVFRQGXFWHGWRGHWHUPLQHWKHFRQFHQWUDWLRQRI,/ȕ
in macrophage conditioned media used in the adhesion assay as described
DERYH6HFWLRQ1R,/ȕZDVGHWHFWHGLQWKHXQVWLPXODWHGPDFURSKDJH
VXSHUQDWDQWDFURVV WKH WKUHHGRQRUVXVHG8SRQVWLPXODWLRQZLWK/36Ȗ WKHUH
ZDVDVLJQLILFDQWLQFUHDVHGLQWKHFRQFHQWUDWLRQRI,/ȕGHWHFWHGLQDOOGRQRUV
166.29, 270.36 and 118.24 pg/ml for donor 4, donor 5 and donor 6 respectively
in which the highest increased was observed in donor 5. When ICE inhibitor
ZDV DGGHG WR WKH /36Ȗ VWLPXODWHGPDFURSKDJH WKH SHUFHQWDJH UHGXFWLRQ RI
,/ȕFRQFHQWUDWLRQZDVUHVSHFWLYHO\)LJXUH
Figure 3-19 ,/ȕ FRQFHQWUDWLRQ LQ PDFURSKDJH FRQGLWLRQHG PHGLD  FRQGLWLRQV
generated from three donors used to stimulate hMEC-1 and hTERT-LEC cells in
transendothelial migration assay.
3.4.13Western blot result for ICAM-1 and VCAM-1 expresion
Figure 3-20 shows ICAM-1 and VCAM-1 protein expression by Western blot.
Anti ICAM-1 and anti VCAM-1 bands were detected at 90 and 80 kDa
respectively. HUVEC, hMEC-1 and PBMC lysates expressed low level of ICAM-
 XQGHU FRQWURO FRQGLWLRQ ,&$0 H[SUHVVLRQ OHYHO ZDV KLJKHU LQ 71)Į
stimulated HUVEC and hMEC-1 cells as well as LPS stimulated PBMC.
Similarly, VCAM-1 was expressed in lower level in HUVEC and hMEC-1 lysates
DQG WKH H[SUHVVLRQ ZDV KLJKHU LQ 71)Į VWLPXODWHG FHOOV +RZHYHU XQGHU
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control condition, HUVEC expressed lower level of ICAM-1 compared to hMEC-
1 lysate. No non-specific bands were detected indicating that the anti-ICAM-1
and anti-VCAM-1 antibodies used were specific and detected the correct protein
bands. These antibodies were therefore used to assess ICAM-1 and VCAM-1
protein expression via FACS analysis.
Figure 3-20 ICAM-1 and VCAM-1
expression in HUVEC, hMEC-1 and PBMC
cell lysate in control and cytokine
stimulated conditions. 25µg of protein
were loaded into each well. Native ICAM-1
and VCAM-1 expression was detected in
PBMC lysate with stronger expression in
71)Į/36 VWLPXODWHG O\VDWHV ǺDFWLQ
bands show equal protein loading into
each well.
3.4.14 Endothelial cell expression of CLEVER-1, ICAM-1 and VCAM-1
FACS was used to examine both surface and intracellular expression on
XQVWLPXODWHG DQG 71)Į,/ȕ VWLPXODWHG HQGRWKHOLDO FHOOV 5HVXOWV VKRZ WKDW
CLEVER-1 was expressed intracellularly in both blood and lymphatic
endothelium with the highest expression in hTERT-LEC (geometric mean (GM)
±SD 36.46±9.33). The GM of HUVEC, hMEC-1 and HMVEC-dLy Neo were
18.65±1.49, 14.67±1.03 and 13.87±0.56 respectively (Figure 3-21).
Interestingly, as seen in previous studies (Ammar et al., 2011) CLEVER-1
surface expression was only detected on hTERT-LEC in comparison with low
expression on HUVEC, hMEC-1 and HMVEC-dLy Neo (12.11±3.86, 1.43±1.15,
 DQG  UHVSHFWLYHO\ 8SRQ VWLPXODWLRQ ZLWK 71)Į RQO\
HMVEC-dLy Neo showed a significant increase of CLEVER-1 expression on
both surface (17.91±0.59) and intracellular staining (26.35±1.59). No significant
increase in CLEVER-1 expression was observed in any of the endothelial cell
OLQHVVWLPXODWHGZLWK,/ȕ)LJXUH
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Figure 3-21 CLEVER-1 surface (A) and intracellular (B) expression on HUVEC, hMEC-1,
K7(57/(&DQGK09(&G/\1HRXQGHUFRQWURODQG71)Į,/ȕVWLPXODWLRQ&/(9(5
surface expression was only detected on hTERT-LEC in comparison with low expression
on HUVEC, hMEC-1 and HMVEC-dLy. Only HMVEC-dLy Neo showed significant increased
of CLEVER-1 expression on both surface and intracellular staining upon stimulation with
71)Į1RVLJQLILFDQW LQFUHDVH LQ&/(9(5 H[SUHVVLRQREVHUYHG LQDOO HQGRWKHOLDO FHOO
OLQHV VWLPXODWHG ZLWK ,/ȕ 3RROHG UHVXOWV IURP WKUHH LQGHSHQGHQW H[SHULPHQWV HDFK
carried out in duplicate (n=6).
Surface expression of ICAM-1 and VCAM-1 was also examined by FACS
analysis. Under control conditions, the expression of ICAM-1 was the highest in
HUVEC (14.55+1.12) compared to hMEC-1 (2.44+0.25) and hTERT-LEC
8SRQVWLPXODWLRQZLWK71)Į,/ȕWKHUHZDVDQLQFUHDVHLQ,&$0
1 expression observed across blood and lymphatic endothelial cells (Figure 3-
  9&$0 H[SUHVVLRQ ZDV DOVR LQFUHDVHG LQ 71)Į,/ȕ VWLPXODWHG
HUVEC, hMEC-1 and hTERT-LEC (Figure 3-22).
Figure 3-22 Surface expression of (A) ICAM-1 and (B) VCAM-1 on HUVEC, hMEC-1 and
K7(57/(&XQGHUFRQWURODQG71)Į,/ȕVWLPXODWLRQ9&$0VXUIDFHH[SUHVVLRQZDV
GHWHFWHGLQDOOHQGRWKHOLDOFHOOOLQHV8SRQVWLPXODWLRQZLWK71)ĮDQG,/ȕWKHUHZDVDQ
increase in ICAM-1 surface expression. VCAM-1 expression of endothelial cells also
LQFUHDVHG ZKHQ +89(& K0(& DQG K7(57/(& ZHUH VWLPXODWHG ZLWK 71)Į,/ȕ
Pooled results from two independent experiments each carried out in duplicate
(n=4).(*significant different compared to unstimulated controls).
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3.5 Discussion
In the present chapter, the adhesion pattern of breast cancer and melanoma
cell lines to blood and lymphatic endothelial models (large vessel versus
microvessel and primary versus immortalised cells) was compared. The
VWLPXODWRU\ HIIHFW RI PDFURSKDJH DVVRFLDWHG F\WRNLQHV 71)Į DQG ,/ȕ
macrophage conditioned media and tumour conditioned media on tumour-
endothelial adhesion was also compared to study whether these may account
for the preferential invasion of lymphatic observed in both melanoma (Chapter
2) and breast cancer (Mohammed et al., 2008) patients. The role of CLEVER-1,
which is an adhesion molecule preferentially expressed on lymphatic
endothelial cells, in terms of regulating lymphatic vessel invasion was studied,
LQ DGGLWLRQ WR WKH VWLPXODWRU\ HIIHFW RI 71)Į DQG ,/ȕ RQ &/(9(5
expression on the blood and lymphatic endothelial cell models. ICAM-1 and
VCAM-1 expression on the endothelial cell models under control and cytokines
stimulated conditions were also investigated.
3%0& DGKHVLRQ WR WKH XQVWLPXODWHG DQG 71)Į,/ȕ VWLPXODWHG +89(&
hMEC-1, hTERT-LEC and HMVEC-dLy Neo was assessed. Adhesion of PBMC
was greater to vascular than lymphatic endothelial cells under control
conditions. As PBMC were of blood origin, it may be that they are programmed
to interact more with blood endothelial barrier compared to the lymphatic
EDUULHU3%0&DGKHVLRQWR71)ĮVWLPXODWHGHQGRWKHOLDOFHOOVZDVVLJQLILFDQWO\
KLJKHU WKDQ WKH XQVWLPXODWHG FRQWUROV 6DOPL HW DO  6LPLODUO\ ,/ȕ
stimulated HUVEC have been shown to increase PBMC adhesion compared to
the unstimulated controls (de Oca et al., 2005). This may be due to increased
expression of adhesion molecules such as ICAM-1 and VCAM-1 in inflamed
HUVEC and human dermal lymphatic endothelial cells in order to recruit
immune cells to the site of inflammation (Louise et al., 2006; Sun et al., 2010;
van Grevenstein et al., 2007); which was also shown in this study showing that
the expression level of ICAM-1 and VCAM-1 on HUVEC, hMEC-1 and hTERT-
/(&ZDVXSUHJXODWHGXSRQVWLPXODWLRQZLWK71)Į,/ȕ7KHQXPEHURI3%0&
DGKHUHG WR DOO 71)Į VWLPXODWHG HQGRWKHOLDO FHOOV ZDV VLJQLILFDQWO\ KLJKHU
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FRPSDUHG WR ,/ȕ VWLPXODWHG HQGRWKHOLDO FHOOV ZKLFK LV LQ DFFRUGDQFH ZLWK
SUHYLRXV VWXGLHV FRPSDULQJ 3%0& DGKHVLRQ WR 71)Į ,/ȕ DQG LQWHUIHURQȖ
stimulated human skin microvascular endothelial cells from adults (HMVEC-Ad)
and human coronary arterial endothelial cells (HCAEC) (Watabe et al., 2007).
The adhesion of PBMC to the endothelial models was used as an internal
experimental control prior to the assessment of tumour cell adhesion to ensure
that both cytokines and endothelial cell models were behaving as expected.
When PBMC adhesion was compared against tumour cell adhesion to HUVEC,
hMEC-1, hTERT-LEC and hMVEC dLy Neo, results shows that tumour cells
have different adhesion kinetics than leukocytes. This may partially attributed to
size differences between tumour cells and leukocytes (Wu et al., 2001). The
optimal adhesion time for tumour cells was 35 minutes which is in accordance
with previous tumour cell adhesion studies where 30 minutes and 1 hour
adhesion times were used (Carrire et al., 2005; Jurisic et al., 2010).
In tumour cell adhesion, the breast cancer cell lines, MDA-MB-231 and MCF7,
and the melanoma cell lines, MeWo and SKMEL-30, showed different adhesive
affinity towards the endothelial cell models, which demonstrated the
heterogenous nature of tumour cell adhesion (Eccles and Welch, 2007). Of the
four tumour cell lines, MDA-MB-231 had the highest affinity towards all
endothelial cell models, which may be related to the highly invasive and
aggressive nature of this tumour (Kim et al., 2010; Walter-Yohrling et al., 2003),
which expressed high level of vimentin, a marker of mesenchymal phenotype.
MCF7 on the other hand expresses markers of luminal epithelial phenotype;
estrogen and progesterone receptors positive and HER2/Neu negative, and are
less aggressive compared to MDA-MB-231 (Mladkova et al., 2010). Although
the four tumour cell lines showed differences in terms of adhesive potential,
they all showed preferential adhesion to unstimulated blood endothelial cells as
opposed to the lymphatic endothelial cells (Figure 3-8). This is interesting in
light of current observations and others (Doeden et al., 2009b; Kuroda et al.,
2010; Mohammed et al., 2007) in breast cancer and melanoma that show
vascular invasion in these tumour types is principally of lymphatic vessels.
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Experiments comparing the adhesion of a panel of breast cancer and
melanoma cells on blood and lymphatic endothelial cells have not previously
been reported. However, the preferential adhesion of colon carcinoma cells,
HT29, to lung microvascular endothelial cells (HMVEC) as opposed to large
vein endothelial cells (HUVEC) has been reported (ten Kate et al., 2006). This is
in contrast to our current observations made using breast cancer and
melanoma cells, in which preferential adhesion of all four cell lines, MDA-MB-
231, MCF7, MeWo and SKMEL-30 was observed on HUVEC, reflecting diverse
nature of endothelial cells arising from different vascular beds or different
adhesion patterns of various tumour types (Murakami et al., 2001; Swerlick et
al., 1992). Although the Kate et al (2006) study used fluorescently labeled
tumour cells to differentiate them from the endothelial cells, as in the current
study, the end measurement to assess adhesion differs as their study used total
fluorescence, assessed using a plate reader, to measure cell adhesion rather
than counting total number of fluorescent cells.
There was no difference in tumour cell adhesion to primary lymphatic cells
(HMVEC-dLy Neo) and immortalised lymphatic cells (hTERT-LEC), suggesting
that despite the immortalisation procedure, hTERT-LEC retain a phenotype
similar to the primary cells from which they were derived (Nisato et al., 2004).
Therefore, hTERT-LEC is a useful in-vitro model to study lymphatic-endothelial
interactions, which can overcome the problem of a short passage window when
using primary lymphatics.
The preferential adhesion of tumour to blood rather than lymphatic endothelial
cells was unexpected, considering our previous histopathology based findings
in tumour specimens. This may be due to cells being exposed to inflammatory
FRQGLWLRQVDQGDVVRFLDWHGF\WRNLQHVLQWKHWXPRXUPLOLHX71)ĮDQG,/ȕERWK
are multifunctional cytokines have been known to stimulate angiogenesis,
growth, proliferation and invasion of tumour cells via various signaling pathways
VXFKDV WKH1)Ʉ%DQG0$3.SDWKZD\ &KHQDQG*RHGGHO:DMDQWHW
DO  7XPRXU FHOO DGKHVLRQ WR 71)ĮVWLPXODWHG +89(& K0(&
hTERT-LEC and HMVEC-dLy Neo did not vary significantly when compared to
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the unstimulated endothelium. Similar results have been described, in which no
significant changes are observed in the adhesion of melanoma cell lines; WM9,
:0DQG:0WRXQVWLPXODWHGRU71)ĮVWLPXODWHG+89(&9RXUDHWDO
1998). However, others have shown that tumour cell adhesion increases with
71)ĮVWLPXODWLRQ 7KH FRORQ FDQFHU FHOO OLQH +7 DGKHUHG PRUH WR 71)Į
stimulated HUVEC and lung microvascular endothelial cells than the
unstimulated controls. The adhesion of breast MDA-MB-231 cancer cells to
+89(& ZDV VKRZQ WR LQFUHDVH DSSUR[LPDWHO\ VL[ IROG IROORZLQJ 71)Į
stimulation compared to the unstimulated counterpart (Nizamutdinova et al.,
2008). No such increased was observed in the current study, using similar cell
PRGHOVKRZHYHUERWKWKH71)ĮFRQFHQWUDWLRQVDQGWKHLQFXEDWLRQWLPHGLIIHU
In their study, HUVEC cells were stimulated for 4 hours in which significant
increase in the adhesion molecules, ICAM-1 and VCAM-1 was observed
compared to the unstimulated control. In this study, the endothelial cells were
LQFXEDWHG IRU  KRXUV ZLWK 71)Į DW ZKLFK WLPH WKH PD[LPDO LQFUHDVH LQ
adhesion molecules such as E-selectin, ICAM-1 and VCAM-1 was reported
(Hagi-Pavli et al., 2004).
+RZHYHUXSRQ,/ȕVWLPXODWLRQDVLJQLILFDQWLQFUHDVHGRIWXPRXUFHOODGKHVLRQ
was observed which was notably higher to the lymphatic endothelial cells,
VXJJHVWLQJ D QRYHO DQG LPSRUWDQW UROH IRU ,/ȕ LQ FDQFHU FHOO DGKHVLRQ WR
lymphatic vessels. Pre-stimulation of either endothelial cells or tumour cells with
,/ȕ LQFUHDVHG WKHSHUFHQWDJHDGKHVLRQRI0'$0%0&)0H:RDQG
SKMEL-30 towards HUVEC, hMEC-1, hTERT-LEC and hMVEC dLy Neo with
similar adhesive affinity towards the endothelial of the same origin i.e. blood and
lymphatics. Dejana and colleague (1998) have also reported similar results.
Using three human colorectal carcinoma (HT-29, HCC-P2988, and HCC-
M1410) and one human melanoma (A-375) cell line, a significant increase in the
DGKHVLRQSDWWHUQRIWKHVHFHOOVWRZDUGV,/ȕVWLPXODWHG+89(&FRXOGDOVREH
observed (Dejana et al., 1998).
As the two breast (MDA-MB-231 and MCF7) and the two melanoma (MeWo
and SKMEL-30) cell lines showed a similar adhesion pattern towards blood and
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lymphatic endothelial cells, experiments were therefore conducted to examine
WKH HIIHFW RI 71)Į DQG ,/ȕ DFWLYDWHG 0'$0% DQG 0H:R FHOOV LQ
LQIOXHQFLQJ WKH DGKHVLRQ WRZDUGV 71)Į DQG ,/ȕ DFWLYDWHG K0(& DQG
hTERT-LEC. A significant increased was observed when both the tumour and
WKHHQGRWKHOLDOFHOOVZHUHVLPXOWDQHRXVO\VWLPXODWHGZLWK71)ĮVXJJHVWLQJWKDW
GXDO DFWLYDWLRQ ZLWK 71)Į PLJKW EH QHFHVVDU\ WR SURPRWH WXPRXUHQGRWKHOLDO
FHOODGKHVLRQ,QWXPRXUFHOOV71)ĮDQG,/ȕDFWVWKURXJK1)Ʉ%LQGXFWLRQRI
chemokine receptor CXCR4 and up-regulation of molecules such as monocyte
chemoattractant protein-1 (MCP-1), IL-8 and ICAM-1. In endothelial cells, both
cytokines up-regulate various receptors such as lectin-like oxidized low-density
lipoprotein (oxLDL) receptor-1 (LOX-1) (Choo et al., 2006; Katerinaki et al.,
2003; Liang et al., 2007; Wang and Lin, 2008). Interestingly, the percentage
adhesion of both MDA-MB-231 and MeWo was higher to the lymphatic
endothelial model (hTERT-LEC), as opposed to the blood endothelial cells
(hMEC-1). Such results suggest that although in control conditions, tumour cells
DGKHUHGPRUH WR WKHEORRGHQGRWKHOLXP71)ĮDQG,/ȕDFWLYDWLRQ LQFUHDVHV
the percentage of adherent cells, which was higher to lymphatic endothelial
cells. Such results support the hypothesis that in melanoma and breast cancer,
lymphatic adhesion, and subsequently metastasis by this route, can be
modulated by cytokine stimulation.
Results from current experiments suggested that macrophage secreted
F\WRNLQHV LH 71)Į DQG PRUH LPSRUWDQWO\ ,/ȕ KDYH VWURQJ LQIOXHQFHV LQ
regulating adhesion of tumour cells to the lymphatic endothelial cells and thus
PD\PRGXODWH O\PSKDWLFYHVVHO LQYDVLRQ ,QYROYHPHQWRI71)Į LQPDOLJQDQF\
FRPHV IURP WKH REVHUYDWLRQ WKDW PLFH ZKLFK ODFN WKH JHQH IRU 71)Į DUH
resistant to skin cancer (Moore et al., 1999). Similarly, in melanoma cell models
as well as breast and prostate cancer, the absence of metastasis was observed
LQ PLFH PRGHOV ODFNLQJ ,/ȕ JHQH 3ROODUG  ,Q DGGLWLRQ LQWHUOHXNLQ
receptor antagonist (IL-1ra) inhibits the increased adhesion of A375M
PHODQRPD FHOOV RQ ,/ȕ DFWLYDWHG +89(& VXSSRUWLQJ WKH IDFW WKDW ,/ȕ
mediated tumour-endothelial interaction is involved in the adhesion and thus
metastatic process (Chirivi et al., 1993).
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When both blood (HUVEC and hMEC-1) and lymphatic models (hTERT-LEC
and HMVEC-dLy Neo) were stimulated with tumour conditioned media or
macrophage conditioned media, only the macrophage conditioned media
stimulated endothelial cells exhibited increased tumour cell adhesion. These
results suggest that cytokines secreted by macrophages, rather than tumour
cells, may contribute to the increased invasiveness of tumour cells - this is
VXSSRUWHG E\ WKH (/,6$ UHVXOWV ZKHUH ,/ȕ ZDV GHWHFWHG LQ PDFURSKDJH
FRQGLWLRQHGPHGLDEXWQRWWXPRXUFRQGLWLRQHGPHGLD7KHIDFWWKDW,/ȕLVQRW
detected in tumour conditioned media used in this study is interesting because
WXPRXU FHOOV EHVLGHVPDFURSKDJHVFRXOGDOVRSURGXFHG ,/ȕ LQERWKQRUPDO
settings and in the tumour microenvironment. This may be due to the effect of
,/RU,/ZKLFKFRXOGVXSSUHVV,/ȕSURGXFWLRQ LQWKHWXPRXU%RJGDQHW
al., 1992; Jensen et al., 2009). IL-6 and IL-10 ELISA’s could be carried out on
tumour conditioned media to confirm the expression of these cytokines, and
GHWHUPLQHKRZ,/ȕLVUHJXODWHGLQWKHVHFHOOV+RZHYHU ,/ȕFRQFHQWUDWLRQ
from the macrophage media, seemed to correlate with the number of cells
DGKHUHG WR WKHHQGRWKHOLDOFHOOPRGHOV ,/ȕKDVEHHQVKRZQ WR LQFUHDVH WKH
expression of a number of adhesion molecules which eventually promotes
tumour-endothelial cell adhesion (Pollard, 2008) as observed in this study.
:KHQ ,&( LQKLELWRU ZDV XVHG ZLWK WKH /36Ȗ VWLPXODWHG PDFURSKDJHV WKH
increased adhesion effect was removed and may be due to the fact that there
was a decreased in the expression of cell adhesion molecules on both blood
and lymphatic endothelial cells.
Therefore, the role that adhesion molecules preferentially expressed on the
lymphatic endothelial cells play in regulating lymphatic vessel invasion was also
examined. Adhesion molecules are of particular interest as they regulate tumour
cell entry into, and exit out of, the lymphatics. Based on our historical, and
current, data, CLEVER-1 is preferentially expressed on the surface of lymphatic
endothelial cells (hTERT-LEC). Interestingly, CLEVER-1 expression in
lymphatic vessels was associated with lymph node metastasis (Ammar et al.,
2011). In this chapter, we compared CLEVER-1 expression between blood and
lymphatic endothelial cells, and between primary and immortalised cell lines,
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showing that although all endothelial cell models expressed CLEVER-1
intracellularly, only the immortalised lymphatics, hTERT-LEC showed significant
surface expression of CLEVER-1. Similar results have been published showing
that CLEVER-1 is differentially expressed in lymphatic, but not vascular
endothelial cells in normal skin in-vivo (Salmi et al., 2004). Upon stimulation
ZLWK71)ĮRQO\WKHSULPDU\O\PSKDWLFV+09(&G/\1HRVKRZHGDVLJQLILFDQW
increase in CLEVER-1 expression; both total and surface, suggesting that
hTERT-LEC represent an activated LEC model, at least in terms of CLEVER-1
expression. Stimulation of HUVEC, hMEC-1, hTERT-LEC and HMVEC-dLy Neo
ZLWK ,/ȕ GLG QRW VKRZ DQ\ VLJQLILFDQW DOWHUHG &/(9(5 H[SUHVVLRQ 6XFK
results, in light of the adhesion assay results, suggest that although CLEVER-1
may be an important lymphatic specific adhesion molecule, it may not be a
principal regulator of lymphatic vessel invasion. In tumour sections CLEVER-1
expression was observed in blood vessels, lymphatic vessels and
macrophages, however, only CLEVER-1 expression in lymphatic vessels was
associated with lymph nodes metastasis (Ammar et al., 2011). Based on these
results, CLEVER-1 knockdown in lymphatic cells would be required to further
examine the role that this molecule plays in mediating tumour cell trafficking via
lymphatic vessels. However, at this stage, studying CLEVER-1 was
discontinued from the current study.
Surface expression of adhesion molecules, ICAM-1 and VCAM-1 were also
H[DPLQHG 8SRQ VWLPXODWLRQ ZLWK 71)Į,/ȕ LQFUHDVHG H[SUHVVLRQ RI WKHVH
adhesion molecules could be observed in HUVEC, hMEC-1 and hTERT-LEC
cells which is in accordance with other studies (Brigati et al., 2002; Hayes and
Seigel, 2009), suggesting that these adhesion molecules might play important
role in regulating tumour-endothelial adhesion processes. As in CLEVER-1,
ICAM-1 and VCAM1 knockdown would be required to examine the role of these
molecules in mediating tumour cell trafficking into the circulation.
In summary, our previous translational investigations as discussed in Chapter 2,
and by others (Mohammed et al., 2008), have demonstrated that lymphatic
vessels play an important role in metastatic disease. We have shown in the
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FXUUHQW FKDSWHU WKDW 71)Į DQG PRUH LPSRUWDQWO\ ,/ȕ VWLPXODWLRQ RI ERWK
tumour and endothelial cells causes a significant increase in adhesion, of which
the highest increase is observed on lymphatic endothelial cell models. A
suitable in vitro lymphatic endothelial cell system is important to understand the
complex mechanisms governing tumour cell adhesion and migration towards
the lymphatics, which in some tumour types, occurs more frequently than
invasion of blood vessels. Current results suggest that metastasis resultant from
lymphatic vessel-tumour cell adhesion is modulated by cytokine stimulation,
which may represent an important therapeutic target in breast cancer and
melanoma.
In addition to tumour-endothelial adhesion, tumour cells migration through the
extracellular matrix and tumour cell transendothelial migration is a pre-requisite
for metastatic dissemination into the circulation. Therefore, we next sought to
VWXG\ZKHWKHU71)ĮDQG,/ȕKDYHDQ\HIIHFWXSRQWXPRXUFHOOPLJUDWLRQDQG
endothelial transmigration, which is the focus of Chapter 4.
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CHAPTER 4: TUMOUR CELL MIGRATION AND BLOOD
VERSUS LYMPHATIC ENDOTHELIAL
TRANSMIGRATION
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4.1 Abstract
Background and Aims: In the initial metastatic process, the capability of
cancer cells to metastasise depends on their ability to detach from the tumour
mass, migrate through the extracellular matrix, adhere to the endothelium and
transmigrate between blood and/or lymphatic endothelial cells into the
circulation. Results in Chapter 3 demonstrated that tumour-endothelial cell
DGKHVLRQFDQEHPRGXODWHGE\F\WRNLQHVWLPXODWLRQDQGWKDW71)ĮDQGPRVW
LPSRUWDQWO\ ,/ȕ VHFUHWHG E\ PDFURSKDJH VWURQJO\ LQIOXHQFHG WXPRXU FHOO
adhesion to lymphatic endothelial cells; thus potentially modulating lymphatic
endothelial transmigration. The aim of the current chapter was to investigate the
HIIHFWRI71)Į,/ȕWXPRXUFRQGLWLRQHGPHGLDDQGPDFURSKDJHFRQGLWLRQHG
media stimulation on breast cancer and melanoma cell migration. In addition,
the transmigration pattern of both melanoma and breast cancer cell lines across
blood and lymphatic endothelial cell models were compared following
VWLPXODWLRQZLWKHLWKHU,/ȕRUPDFURSKDJHFRQGLWLRQHGPHGLD
Methods: 7KH HIIHFW RI 71)Į ,/ȕ WXPRXU FRQGLWLRQHG PHGLD DQG
macrophage conditioned media stimulation on melanoma (MeWo and SKMEL-
30) and breast cancer (MDA-MB-231 and MCF7) cell migration was
investigated using scratch wound assays. Melanoma (MeWo) and breast
cancer (MDA-MB-231) transmigration across the lymphatic (hTERT-LEC) and
blood (hMEC-1) endothelial cell models was assessed using Boyden chamber
WUDQVPLJUDWLRQDVVD\V7KHHIIHFWRI ,/ȕDQGPDFURSKDJHFRQGLWLRQHGPHGLD
stimulation of endothelial cells on the transmigratory process was also
examined.
Results: The percentage reduction of scratch area at different time points
represented tumour cell migration in the scratch wound migration assay. MDA-
MB-231 showed the highest percentage of wound closure followed by MCF7,
6.0(/DQG0H:RXQGHU FRQWURO FRQGLWLRQV)ROORZLQJH[SRVXUH WR71)Į
DQG ,/ȕ WKHPLJUDWLRQRIDOO IRXU WXPRXUFHOO OLQHVZDV LQFUHDVHG ,QFUHDVHG
migration was higher in IL-1ɴ VWLPXODWHG FHOOV FRPSDUHG WR 71)Į VWLPXODWHG
cells for all of the tumour cell lines assessed. There was no significant
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difference in the migration ability of MDA-MB-231, MCF7, MeWo and SKMEL-
30 when the cells were stimulated with tumour conditioned media compared to
the unstimulated controls. A significant increase in the percentage of wound
closure was observed at 24 hours post-wounding when the cells were
stimulated with macrophage conditioned media from donor 2 (p<0.0001) and
donor 3 (p=0.023).
Results from the static transendothelial migration assay, show that MDA-MB-
231 cells exhibit similar transmigratory abilities across both hMEC-1 and
K7(57/(&ZKLFKLQFUHDVHGVLJQLILFDQWO\XSRQVWLPXODWLRQZLWK,/ȕSYDOXHV
<0.001 and <0.001 for hMEC-1 and hTERT-LEC respectively). MeWo cell
transmigration under control conditions showed similar affinity across both
hMEC-1 and hTERT-LEC, however with a lower number of cells migrating
across the endothelium compared to MDA-MB-231 cells. However, upon
VWLPXODWLRQ ZLWK ,/ȕ WKHUH ZDV DQ LQFUHDVHG LQ WKH WUDQVPLJUDWRU\ DELOLW\ RI
MeWo cells across hMEC-1 and hTERT-LEC (p-values <0.00001 and <0.0001
respectively) which was notably observed across hMEC-1 cells. When hMEC-1
DQG K7(57/(& ZHUH VWLPXODWHG ZLWK /36Ȗ VWLPXODWHG PDFURSKDJH
conditioned media, there was an increased in the number of cells transmigrated
across the endothelial cell monolayer; hMEC-1 and, particularly, hTERT-LEC.
However, when hMEC-1 and hTERT-LEC were stimulated with macrophage
FRQGLWLRQHGPHGLDJHQHUDWHGZLWK/36Ȗ,&(DQG/36Ȗ7'/,&(VWLPXODWLRQ
the number of transmigrated MDA-MB-231 cells decreased significantly
compared to both control and LPS stimulated macrophages suggesting that it
was IL1E in the macrophage lysate that was responsibe for the increased
transmigration.
Conclusions: Tumour cell migration and transmigration across the lymphatic
DQGEORRG HQGRWKHOLXP FDQ EHPRGXODWHGE\ F\WRNLQH VWLPXODWLRQ71)Į DQG
HVSHFLDOO\,/ȕDUHLQIODPPDWRU\F\WRNLQHVVHFUHWHGE\PDFURSKDJHWKDWKDYH
strong influences in regulating tumour cell migration and transmigration across
endothelial cells, particularly across lymphatic endothelium.
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4.2 Introduction
Tumour cell adhesion to blood or lymphatic vessels is an important step in the
process of vascular invasion and entry into the circulation. Results presented in
Chapter 2 showed that in melanoma, vascular invasion is principally of
lymphatic vessels opposed to blood vessels even though a rich vascular
network was present. Similar patterns were also observed in breast cancer
patients, where 85.5% vascular invasion occurs via lymphatic vessels
(Mohammed et al., 2008). A highly significant association between high
macrophage counts and the presence of lymphatic vessel invasion was also
observed, which may suggest that macrophage, or macrophage associated
factors, play a role in promoting invasion through lymphatic vessels. In vitro
results, from Chapter 3, show that TNF-ɲ DQG ,/ȕ, which are cytokines
secreted by macrophage, can influence tumour cell adhesion to lymphatic and
blood endothelial cell models, but with a preferential increase observed to
lymphatic endothelial cells.
In addition to tumour cell adhesion, the migration of tumour cells through the
extracellular matrix is also a pre-requisite in the initial metastatic progression.
Cell migration is a cyclic process involving continuous formation and
disassembly of matrix adhesions (Etienne-Manneville, 2008). This multistep
model of cell migration has been investigated in non-neoplastic cells such as
fibroblasts and keratinocytes during normal physiological processes including
wound healing and immune cell trafficking. However, studies on tumour cells
show that these cells use similar migratory mechanisms to those that occur in
normal cells. In response to migratory and chemotactic stimuli, cells form a
membrane protrusion which is driven by actin polymerization and assembly of
cell filaments. Cell protrusions attach to the surrounding tissue structure or
extracellular matrix, contract and subsequently generate a traction force that
leads to forward gliding of the cells. The molecular mechanisms of cell migration
are summarised in Figure 4-1.
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The process of migration can be studied using a wound healing assay which is
a convenient and inexpensive method for the analysis of cell migration in vitro.
This assay involves creating a wound or a scratch in a cell monolayer and
capturing an image of wound closure at regular intervals before quantifying the
rate of migration. Wound healing assays have been used to study the ability of
cells to polarise and migrate and to study the effect of cell-matrix and cell-cell
interactions in the migratory process (Etienne-Manneville and Hall, 2001; Nobes
and Hall, 1999).
Transmigration of cancer cells across the endothelium follows migration and
adhesion steps in the initial metastatic cascade. This process, termed
Figure 4-1 A five step model of cell migration. (A) Formation of cell protusions is driven
by actin polymerization which binds to ARP2/3 and Wiscott-Aldrich protein (WASP).
ARP2/3/WASP complex binds to inner leaflet of the plasma membrane via
phosphoinosites (PIPs) and CDC42 inducing pseudopod extension. (B) Formation of
focal contact. Integrins cluster in the cell membrane and come into contact with ECM
inducing phosphorylation and dephosphorylation signals into the cell. (C) Surface
proteases cleave ECM components (collagen, fibronectin, laminins, pro-MMPs). (D)
Active myosin II binds to actin filaments generating actomyosin contraction. (E)
Detachment of the trailing edge. Focal contact disassembly occurs at the trailing edge
leading to integrin detachment from the substrate. Integrins detached from the substrate
become internalised by endocytotic vesicles to be recycled towards the leading edge or
deposited onto the substrate. Reproduced and adapted from (Friedl and Wolf, 2003).
Copyright© by Nature Publishing Group with permission conveyed through Copyright
Clearance Center Inc.
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intravasation i.e the entry of cells into the vasculature is less well characterised
than extravasation i.e the movement of cells from the circulation into the tissue
which mimics leukocytes extravasation following inflammation. Controversy
exists in relation to whether tumour cells actively transmigrate across blood or
lymphatic vessels in response to chemokines/growth factors or whether they
passively enter the circulation without active migratory mechanisms (van Zijl et
al., 2011). In term of lymphatic capillaries, the suggestion has been put forward
that transmigration may be predominately a passive process due to the
structure of the lymphatic vessels which lack basement membrane and inter-
endothelial tight junctions. In addition, tumour lymph/angiogenesis generates
immature and poorly organised vessels that might allow shedding cancer cells
to pass. Yet, many studies have supported the hypothesis that intravasation is
an active process involving the interactions between tumour cells, endothelial
cells and the microenvironment with expression of growth factors and adhesion
molecules and secretion of various chemokines playing an important role.
The tumour microenvironment consists of many cell types, the population of
which is determine by the types of tumour (Pollard, 2008). Examples of cells
present in the tumour environment include fibroblasts, adipocytes and
haematopoietic and immune cells such as leukocytes, lymphocytes, mast cells
and macrophages.
4.2.1 The involvement of macrophage in tumour cell invasion
Tumour associated macrophage (reviewed in Section 1.6.1 -Chapter 1) which
populate the microenvironment of most tumours have been shown to promote
and enhance tumour cell invasion. Studies using human and mouse mammary
carcinoma have shown that tumour associated macrophage are present in at
least three separate populations in the tumour microenvironment; (1) in the
stroma surrounding tumour cells, (2) accumulating around the edge of dying
cells in necrotic areas and (3) aligned along the abluminal side of vessels
(Sahai, 2007). Such tumour associated macrophages produce epidermal
growth factor (EGF) and those that are clustered around vessels may establish
EGF gradients that attract tumour cells towards the vessels thus promoting
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intravasation. A paracrine signaling loop was identified between carcinoma cells
and macrophages, where tumour cell EGF receptors and macrophage CSF-1
receptors are activated by macrophage-produced EGF and tumour cell-
produced CSF-1 respectively, leading to increased migration and invasion
:\FNRIIHWDO,QVHSDUDWHH[SHULPHQWVWKHSURGXFWLRQRI71)Į,/ȕ
MMP-2, -3, -7 and -9 have been shown to be upregulated in macrophages
when co-cultured with breast cancer cells (Pollard, 2008). However, the authors
did not discuss on how breast cancer could promote such an effect. Therefore,
questions exist on how breast cancer could promote such an effect and whether
the increase in these cytokines in macrophages could increase tumour cells
metastatic capacity.
Although not widely studied, similar to the tumour-endothelial adhesion
(discussed in Chapter 3), reports thus far have utilised either blood endothelial
cells, mostly HUVEC, or very occassionaly lymphatic endothelial cells to
examine the transmigration of tumour cells across the endothelium. The focus
of the current chapter was to conduct a side to side comparison of tumour cell
transendothelial migration across blood versus lymphatic endothelial cells and
determine what factors might influence this process.
The aims and objective of the current chapter were to;
,QYHVWLJDWHWKHHIIHFWRIPDFURSKDJHDVVRFLDWHGF\WRNLQHV71)ĮDQG,/ȕ
and the effect of tumour conditioned media and macrophage conditioned media
on breast cancer (MDA-MB-231 and MCF7) and melanoma (SKMEL-30 and
MeWo) cell migration.
2. Compare the transmigration pattern of melanoma (MeWo) and breast
cancer (MDA-MB-231) cell lines across blood and lymphatic endothelial cell
PRGHOV K0(& DQG K7(57/(& UHVSHFWLYHO\ XQGHU FRQWURO DQG ,/ȕ
stimulated conditions in addition to the effect of macrophage conditioned media
in this process.
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4.3 Materials and Methods
4.3.1 Optimisation of seeding density for scratch wound migration assay
Optimisation of tumour cells seeding density was carried out before carrying out
scratch wound migration assay to ensure 100% confluent monolayer prior to
wounding. MDA-MB-231, MCF7, MeWo and SKMEL-30 was added at 1x105,
2x105, 3x105, 4x105 and 5x105 per well in duplicate wells. The tumour cells
were incubated at 37oC for 24 hours. After 24 hours, the tumour cells were
observed under the microscope to determine their confluency.
Photomicrographs of the cells were also taken at 10x microscopic
magnification. Optimisation was carried out twice for each tumour cell line, each
in duplicate.
4.3.2 Scratch wound migration assay
Scratch wound migration assays were conducted by plating 4x105 MDA-MB-
231cells/well in a 12 well tissue culture plate and incubating for 24 hours prior to
wounding to ensure a confluent monolayer (as optimised in Section 4.3.1). 24
hours post-plating, the standard culture media was removed and replaced with
JURZWKIDFWRUDQGVHUXPIUHHPHGLDZLWKRUZLWKRXW71)ĮDQGQJPORU
IL-1ɴ (5, 10 and 15ng/ml) for a further 24 hours. Confluent cell monolayers were
scratched with a p20 pipette tip done at a 90 degree angle to create a wound,
devoid of adherent cells. Wound scratch at 90 degree angle to the tissue culture
plate was shown to produce a more consistent and reproducible width as shown
by Yimin Zhang in a separate PhD project.
Cell debris was washed away twice with PBS and cells were cultured in growth
factor and serum free media with 10µg/ml of mytomycin-c (Sigma, UK) for the
duration of this assay to inhibit cellular proliferation. Wound closure was
monitored by photomicrographs taken at predetermined time points (0, 2, 4, 6
and 24 hours) after the scratch was made. Figure 4-2 shows representative
photomicrograph of MDA-MB-231 scratch wound migration assay taken at 0, 4,
6 and 24 hours after the scratch was made on a confluent cell monolayer.
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Figure 4-2 MDA-MB-231 scratch wound migration assay. Confluent cell monolayers were
scratch with a pipette tip to create a wound, devoid of adherent cells. Photomicrographs
were then taken at (A) 0, (B) 4, (C) 6 and (D) 24 hours. Percentage reduction of the
scratch area at different time points represented the rate of tumour cell migration. (100x
magnification).
The percentage reduction of the scratch area at different time points
represented the tumour cells migratory ability and was measured using ImageJ
1.43u software (National Institute of Health, USA). Experiments were conducted
twice, each in triplicate.
As 5ng/ml TNF-ɲ and 10ng/ml IL-1ɴ was determined to be an optimal
concentration used to stimulate MDA-MB-231 cells in initial adhesion assays
(mentioned above), these concentrations were also used to examine MCF7,
MeWo and SKMEL-30 cell migration. Scratch wound migration assays were
also conducted to examine the effect of tumour conditioned media (generated
as described in Section 3.3.5) on MDA-MB-231, MCF7, MeWo and SKMEL-30
and the effect of macrophage conditioned media (generated as described in
section 3.3.6) on MDA-MB-231 cells migration. These macrophage conditioned
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PHGLDZHUHIURPWKUHHQHZGRQRUVDQGZHUHGHVLJQDWHGGRQRUDQG,/ȕ
levels in these media; the macrophage and tumour conditioned media, was
determine by ELISA as described in Section 3.3.10.
4.3.3 Optimisation of coating agents and endothelial cell seeding density
for transmigration assay
The transmigration assay was carried out using Transwell chambers (Costar,
CA, USA) with 6.5mm diameter polycarbonate membrane filters of 8µm pore
size which were used to form dual compartments in a 24 well tissue culture
plate. Prior to transmigration assay experiments, the total number of endothelial
cells (hMEC-1) to be added per transwell was optimised so that a confluent
intact cell monolayer was obtained. A confluent cell monolayer is essential for
transendothelial migration assay. In addition to the seeding density, the
concentrations and the types of coating on which to grow the endothelial cells
was also optimised. The Transwell inserts are made of polycarbonate
membrane on which it is difficult to culture the endothelial cells on, to obtain a
cell monolayer. Cell attachment can be improved by coating the culture surface
with matrix constituents. Coating agents used in this optimisation procedure
were gelatin (0.2%) (Sigma, UK) and rat tail collagen type I (GIBCO, Paisley,
UK) in 3 different concentrations; 5, 10 and 15µg/cm3.
To coat the polycarbonate membrane with gelatin, 0.2% gelatin diluted in PBS
was added to the inserts and incubated at 37oC for 30 minutes. The media was
then removed and washed twice with PBS prior to the addition of endothelial
cells. To coat the polycarbonate membrane with collagen, 5, 10 and 15µg/cm3
rat tail collagen type I diluted in 0.02M acetic acid was added to the inserts and
incubated at 37oC for 1 hour. The remaining solution was aspirated from the
inserts, washed twice with PBS to remove all the acid and air dried for 30
minutes in the fume hood prior to usage.
hMEC-1 cells at different seeding densities (5x104, 7.5x104, 1x105 and 2x105)
were then added to the coated inserts and incubated at 37oC for 24 hours after
which time the media was removed and cells washed twice with PBS. To check
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for an intact cell monolayer, 100µg/ml of Lucifer yellow was added to the inserts
or to Transwell inserts without cells as control. 600µl of PBS was added to the
lower wells. The plate was incubated at 37oC for 30 minutes. Fluorescence
leakage of each well was determined using a plate reader (Fluorostar Optima,
BMG LabTech) (excitation 458nm, emission 520nm) using Fluorostar Optima
software version 1.30 R3. The lucifer yellow leakage range for an intact cell
monolayer is typically 0.3% to 2% reduction of control. A leakage value of >2%
of control suggests that cell monolayer was likely compromised during the
assay (Costar, USA).
4.3.4 Optimisation of tumour cell labeling for transmigration assay
Tumour cells used in the transmigration assay were fluorescently labeled to
differentiate them from the endothelial cells. Optimisation was carried out using
MDA-MB-231 and MeWo cells labeled with different concentrations of Cell
Tracker Green CMFDA (Invitrogen, USA). MDA-MB-231 and MeWo cells in
suspension were labeled with 1nm, 2.5nm, 5nm, 10nm and 15nm of cell tracker
green diluted in RPMI serum free media at 1x106 cells per ml for 30 minutes at
37oC. Labeled cells were centrifuged at 170g for 10 minutes. Supernatant
discarded and cells resuspended in RPMI media and cultured in a 12 well plate
at 37oC. After 24 hours, the fluorescently labeled tumour cells were viewed
under the fluorescence microscope to access their fluorescence signal. The
labeled cells were also trypsinised and counted to assess their viability and
proliferation. The labeled cells also were monitored at 48 and 72 hours post
labeling.
4.3.5 Transmigration assay
In the transmigration assay optimisation (Section 4.3.3), coating the upper
compartment (insert) of the Boyden chamber Transwell system with rat tail
collagen type I gave more reproducible and consistent results in generating
endothelial cell monolayers. So, this coating agent was used in all subsequent
transmigration assay experiments.
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Endothelial cells (seeding density: 2x105 for both hMEC-1 and hTERT-LEC
cells in 100µl cultured media) were added to the coated insert and grown to
confluence by incubating them at 37oC for 24 hours with 600µl of complete
media in the lower compartment. After 24 hours, complete media was removed
and replaced with growth factor free media in control wells or growth factor free
PHGLDVXSSOHPHQWHGZLWK,/ȕQJPODQGLQFXEDWHGDWoC for a further 24
hours.
Prior to conducting the transmigration assay, lucifer yellow leakage was used to
check for intact endothelial cells monolayers (Section 4.3.3). If an intact
endothelial cell monolayer was obtained, the transmigration assay would
proceed by first labelling tumour cells. The tumour cells were trypsinised to
produce a single cell suspension and then counted using the cell countess
system. Cells at 1x106 per ml were then labeled with 5nM of Cell Tracker Green
CMFDA (Invitrogen, USA) for 30 minutes at 37ȠC. This concentration was
shown not to affect cell viability and proliferation up to 72 hours (section 4.4.7).
After labelling, tumour cells were resuspended in RPMI-1640. 1x105 cells per
well (100µl volume) were seeded on top of the endothelial cell monolayer. 600µl
of RPMI-1640 was added to the lower compartment. As a positive control, 600µl
of heat inactivated fetal calf serum was added to the lower chamber and these
cells were left to transmigrate for 16 hours at 37oC (Tumour cell transmigration
time was optimized between 4 to 24 hours and the results shown in Section
4.4.8)
At the end of the assay, the endothelial cells and the non-migrated tumour cells
in the upper chamber were cleansed with a cotton swab. Tumour cells that had
transmigrated to the lower face of the filter were manually counted using a
fluorescence microscope (Nikon, Japan). 2 fields of view were counted in each
well at 10x magnification. Experiments were conducted twice, both in duplicate.
Results were expressed as the absolute number of cells transmigrated and as
the percentage of cells transmigrated relative to control. Transmigration assays
were also performed by stimulating the endothelial cells with macrophage
conditioned media.
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4.3.6 Statistical analysis
All data are represented as mean + standard deviation (SD) of two independent
experiments each performed in duplicate/triplicate. In both migration and
transmigration assays, the student t-test was used to evaluate variation
EHWZHHQFRQWURODQGLQGLYLGXDOWUHDWPHQWV71)Į,/ɴ stimulated conditions).
A p-value less than 0.05 was used to define significant relationships. All
statistical analysis was carried out using GraphPad Prism software version 3.02
(GraphPad Software Inc.).
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4.4 Results
4.4.1 Optimisation of seeding density for scratch wound migration assay
In a scratch wound migration assay, cultured cells need to be 100% confluent
prior to wounding to ensure accurate results. Results from the optimisation
experiments show that 4x105 MDA-MB-231 cells per well in a 12 well plate is
the appropriate seeding density for the cells to be 100% confluent after 24
hours incubation at 37oC (Figure 4-3). At 5x105 cells/well, MDA-MB-231 was too
confluent and the cells started to lift off from the tissue culture plate, and
therefore failed to develop an intact monolayer. For MCF7, MeWo and SKMEL-
30, 5x105 cells per well was the appropriate seeding density to ensure confluent
monolayers after 24 hours incubation at 37oC (Figure 4-4).
Figure 4-3 Optimisation of MDA-MB-231 cells seeding density for scratch wound
migration assay. MDA-MB-231 were seeded at (A)1x105, (B)2x105, (C)3x105 and
(D)4x105 cells per well in a 12 well plate. Cells were incubated at 37oC for 24 hours
after which time, photomicrographs of the cells were taken to assess confluency.
Cells need to be 100% confluent prior to wounding. Optimisation was carried out
twice, each in duplicate (200x magnification).
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Figure 4-4 Confluent cell monolayer of (A) MCF7, (B) MeWo and (C) SKMEL-30 for scratch
wound migration assay. Cells were seeded at 5x105 per well to ensure confluent
monolayer after 24 hours incubation at 37oC (200x magnification)
4.4.2 Optimisation of TNF-ɲ and IL-1ɴ concentration for scratch wound
migration assay
7KH0'$0%FHOOOLQHZDVXVHGWRGHWHUPLQHWKHRSWLPDO71)ĮDQG,/ȕ
concentration to stimulate tumour cells in the scratch wound migration assay.
Confluent MDA-MB-231 cells were stimulated with 3 different concentrations of
71)ĮDQGQJPODQGWKHVFUDWFKZRXQGPLJUDWLRQDVVD\ZDVFDUULHG
out as in Section 4.3.2.
Results show that there was no significant increased in the percentage of
ZRXQGFORVXUHZKHQ0'$0%FHOOVZHUHVWLPXODWHGZLWKQJPO71)ĮDW
any time point accessed. The percentage of wound closure increased
significantly when MDA-MB-231 cells were stimulated with 5 and 10ng/ml TNF-
Į DW   DQG  KRXUV SRVW ZRXQGLQJ FRPSDUHG WR WKH XQVWLPXODWHG FRQWURO
cells (Figure 4-5). No significant increased was observed in the percentage of
ZRXQG FORVXUH EHWZHHQ  DQG QJPO 71)Į VWLPXODWLRQ 7KHUHIRUH QJPO
71)ĮZDVXVHGWRVWLPXODWHWXPRXUFHOOVLQVXEVHTXHQWPLJUDWLRQDVVD\V
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7KUHH GLIIHUHQW FRQFHQWUDWLRQV RI ,/ȕ LH   DQG QJPO ZHUH XVHG WR
stimulate confluent MDA-MB-231 cells for 24 hours to determine the optimal IL-
ȕFRQFHQWUDWLRQ WRVWLPXODWH WXPRXUFHOOV LQVFUDWFKZRXQGPLJUDWLRQDVVD\V
The scratch wound migration assay was carried out as described as in Section
4.3.2.
Results show that the percentage of wound closure increased significantly when
0'$0%FHOOVDUHVWLPXODWHGZLWKDQGQJPO,/ȕDWDOOWLPHSRLQWV
assessed, as shown in Figure 4-6. A significant increased of wound closure was
observed when comparing between 5 and 10ng/ml of MDA-MB-231 stimulation
at the 24 hours time point. However, no significant increased in the percentage
RIZRXQGFORVXUHZDVREVHUYHGEHWZHHQDQGQJPO,/ȕDWDOOWLPHSRLQWV
DVVHVVHG 7KHUHIRUH QJPO ,/ȕ ZDV XVHG WR VWLPXODWH WXPRXU FHOOV LQ
subsequent migration assays.
Figure 4-5 The effect of TNF-ĮRQ0'$-MB-231 cell migration. The percentage of wound
FORVXUH LQFUHDVHG VLJQLILFDQWO\ ZKHQ FHOOV DUH VWLPXODWHG ZLWK  DQG QJPO 71)Į
compared to the unstimulated control. No significant increased in the percentage of
ZRXQG FORVXUH ZDV REVHUYHG EHWZHHQ  DQG QJPO 71)Į. Pooled data from 2
independent experiments each carried out in triplicate (n=6).(* significant difference of
QJPO71)ĮVWLPXODWLRQFRPSDUHGWRFRQWUROJURXSsignificant difference of 10ng/ml
71)ĮVWLPXODWLRQFRPSDUHGWRFRQWUROJURXS
141
0
*† ‡
*† ‡
*† ‡
*† ‡
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Pe
rc
en
ta
ge
o
fw
o
u
n
d
cl
o
su
re
(%
)
Time (hours)
Ctrl
5
10
15
4.4.3 The effect of TNF-ɲ and IL-1ɴ on tumour cell migration
 7KHHIIHFWRI71)ĮDQG,/ȕRQWXPRXUFHOOPLJUDWLRQ
The percentage reduction of the scratch area at different time points represents
the rate of tumour cell migration. Under control conditions, MDA-MB-231 shows
the highest percentage of wound closure (67.43 ±9.85%) followed by MCF7
(55.67 ±6.91%), SKMEL-30 (27.68 ±6.91%) and MeWo (18.42 ±5.72%).
)ROORZLQJ H[SRVXUH WR 71)Į WKH PLJUDWLRQ RI DOO IRXU WXPRXU FHOO OLQHV
increased which was particularly noticeable with MDA-MB-231. MDA-MB-231
VWLPXODWHGZLWK71)ĮKDGDVLJQLILFDQWO\KLJKHUPLJUDWLRQUDWHFRPSDUHGWRWKH
unstimulated control at all time points assessed (2 to 24 hours post wounding).
$W  KRXUV WKH ZRXQG FORVXUH RI 71)ĮVWLPXODWHG 0'$0% FHOOV ZDV
89.42 ±16.70% compared to the unstimulated control i.e, 67.43 ±9.85%. MCF7
FRQWURODQG71)Į0H:RFRQWURO
DQG71)ĮDQG6.0(/FRQWURODQG71)Į
35.56 ±6.23%) cells also showed significantly higher migratory ability at 24
hours post wounding; p-value <0.01, <0.01 and 0.014 respectively.
Figure 4-6 The effect of IL1-ȕRQ0'$-MB-231 cell migration. The percentage of wound
closure increased significantly when cells were stimulated with 5, 10 and 15ng/ml IL-ȕ
No significant increased in the percentage of wound closure was observed between 10
DQG QJPO ,/ȕ. Pooled data from 2 independent experiments each carried out in
WULSOLFDWH Q  VLJQLILFDQW GLIIHUHQFH RI QJPO ,/ȕstimulation compared to control
JURXSVLJQLILFDQWGLIIHUHQFHRIQJPO,/ȕVWLPXODWLRQFRPSDUHGWRFRQWUROJURXS‡
VLJQLILFDQWGLIIHUHQFHRIQJPO,/ȕVWLPXODWLRQFRPSDUHGWRFRQWUROJURXS
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)ROORZLQJH[SRVXUHWR,/ȕWKHPLJUDWLRQRIDOOIRXUWXPRXUFHOOOLQHVLQFUHDVHG
which was significant at 2 hours post wounding in MDA-MB-231 and MeWo cell
OLQHVFRPSDUHGWRFRQWUROFHOOV6LPLODUWR71)ĮVWLPXODWLRQ,/ȕVWLPXODWLRQRI
MDA-MB-231 cells had significantly higher migratory ability compared to the
other tumour cell lines used in this study. The percentage cell migration of these
tumour cell lines was 89.20 ±1.57%, 71.57 ±6.04%, 33.82 ±5.75% and 39.34
±5.03% for MDA-MB-231, MCF7, MeWo and SKMEL-30 respectively
Figure 4-7 The effect of TNF-ɲDQG ,/ȕVWLPXODWLRQRQ$0'$0% %0&) &
0H:RDQG'6.0(/FHOOPLJUDWLRQ6WLPXODWLRQRIDOOWXPRXUFHOOVZLWK71)ĮDQG,/
ȕ FDXVHG VLJQLILFDQW LQFUHDVHG LQ WKH PLJUDWRU\ DELOLW\ RI DOO WXPRXU FHOOV DW  KRXUV
ZKLFKZDVQRWDEO\KLJKHUZLWK,/ȕVWLPXODWLRQ0'$0%VWLPXODWHGZLWK71)ĮDQG
,/ȕKDGDVLJQLILFDQWO\KLJKHUPLJUDWLRQUDWHFRPSDUHGWRWKHXQVWLPXODWHGFRQWURODWDOO
time points assessed (p<0.001). MCF7, MeWo and SKMEL-30 showed significantly higher
migratory ability at 24 hours with TNF-ɲ (p value =0.01, =0.0054 and 0.014 respectively)
DQG,/ȕVWLPXODWLRQSYDOXHSDQGS UHVSHFWLYHO\3RROHGGDWD
from two independent experiments, each carried out in triplicate (n=6). (*significant
difference of TNF-ɲ stimulation compared to control group; significant difference of IL-
1ɴ stimulation compared to control group).
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4.4.5 The effect of tumour conditioned media stimulation on tumour cell
migration
To study the effect of tumour conditioned media on tumour cell migration, MDA-
MB-231, MCF7, MeWo and SKMEL-30 were incubated with the cells’ own
tumour conditioned media generated as described in Chapter 3. There was no
significant different in the migration rate of MDA-MB-231 cells compared to the
unstimulated controls and this effect was observed across all cell lines used in
this study (Figure 4-8).
Figure 4-8 The effect of tumour conditioned media stimulation on (A) MDA-MB-231, (B)
MCF7, (C) MeWo and (D) SKMEL-30 cell migration. Stimulation of tumour cells with
tumour conditioned media caused no significant effect in the migratory ability across the
cell lines used compared to the unstimulated controls. Pooled data from two
independent experiments, each carried out in triplicate (n=6).
4.4.6 The effect of macrophage conditioned media stimulation on tumour
cell migration
To study the effect of macrophage conditioned media on tumour cell migration,
MDA-MB-231 cells were incubated with macrophage conditioned media
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generated from three different donors as described in Chapter 3 (donor 7, donor
8 and donor 9). Under control condition, the percentage cell migration of MDA-
MB-231 was 67.63 +4.82 which is in accordance with previous migration assay
experiments.
There was no significant difference in the migration rate of MDA-MB-231 cells
compared to the unstimulated controls when cells were stimulated with
macrophage conditioned media generated from donor 1. A significant difference
in the percentage of wound closure was, however, observed when cells were
stimulated with macrophage conditioned media generated from donor 3 but only
at the 24 hour time point (p=0.023) whereas media generated from donor 2
showed a significant difference at 4, 6 and 24 hours post wounding (p=0.04,
p=0.01, p<0.001 respectively) (Figure 4.9).
Figure 4-9 The effect of macrophage conditioned media stimulation on MDA-MB-231 cell
migration. MDA-MB-231 cells were stimulated with macrophage conditioned media
generated from three different donors for 24 hours post wounding. Macrophage
conditioned media generated from donor 7 caused no significant effect in the migratory
ability of MDA-MB-231 cells compared to control. Significant different in the percentage
of wound closure was observed when cells were stimulated with macrophage
conditioned media from donor 8 (at 4, 6 and 24 hours) and donor 9 (at 24 hours). Pooled
results from 2 independent experiments each carried out in duplicate (n=4). † and ‡
represent statistical significant of macrophage conditioned media generated from donor
8 and donor 9 respectively.
$Q (/,6$ ZDV FRQGXFWHG WR GHWHUPLQH WKH FRQFHQWUDWLRQ RI ,/ȕ LQ
macrophage conditioned media used in the haplotaxis migration assay
GHVFULEHG DERYH   DQG  SJPO RI ,/ȕ ZDV GHWHFWHG LQ
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macrophage conditioned media generated from donor 7, donor 8 and donor 9
respectively (Figure 4-10).
Figure 4-10 ,/ȕ FRQFHQWUDWLRQ LQ
macrophage conditioned media
generated from three donors (donor 7,
donor 8 and donor 9) used to stimulate
MDA-MB-231 cells in scratch wound
migration assay.
4.4.7 Optimisation of coating agents and endothelial cells seeding
density for transmigration assay
Optimisation of coating agents and endothelial cell seeding density was carried
out prior to transmigration assay experiments so that a confluent cell monolayer
could be obtained (Section 4.3.3). Results show that the most suitable coating
agent, agent concentration and cell seeding density to obtain a cell monolayer
is 10µg/cm3 of rat tail collagen I using 2x105 cells per well because at this
concentration, there was <4% reduction in Lucifer yellow flux to the bottom well
(Figure 4-11). Although from the manufecturer’s recommendation that Lucifer
yellow leakage for an intact cell monolayer is typically 2% reduction of control,
4% reduction is the lowest value that could be optained from the optimisation
experiments in this study. Therefore, it was decided that all subsequent
transmigration assay experiments would use 10µg/cm3 of rat tail collagen I as
coating agent with 2x105 endothelial cells per well.
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Figure 4-11 Optimisation of coating agents and endothelial cell seeding density on
tranwell inserts for transmigration assay in order to obtain a cell monolayer. 10µg/cm3 of
collagen at 2x105 cells per well were used in the subsequent transmigration assay as
there was <4% reduction in Lucifer yellow flux to the bottom well at this concentration
and density opposed to Lucifer yellow flux in control wells. Error bars represents
standard deviation from two independent experiment, each carried out in duplicate (n=4).
4.4.8 The effect of cell tracker green labeling on tumour cell viability and
proliferation
In the static transmigration assay, tumour cells usually take up to 24 hours to
transmigrate across endothelial monolayers. Therefore, fluorescently labeled
tumour cells need to be viable for the duration of the assay. To assess the
effect of fluorescent dye on cell viability, the trypan blue exclusion method was
used. This method is based on the principle that viable cells possess an intact
cell membrane which does not take up the blue dye. Dead cells will take up the
dye as their membrane can no longer control the passage of macromolecules.
Cell counting was used to assess the effects on cell proliferation (all cells were
counted to give a total cell count, including viable and non-viable cells).
Results show that there was no difference in MDA-MB-231 cell viability between
the labelled and unlabelled cells across the range of concentrations i.e 1, 2.5, 5,
10 and 15nm up to 48 hours (Figure 4-12). However, at 72 hours post labeling,
there was a reduction in MDA-MB-231 cell viability at 5nm to 15nm
concentrations. There was also no difference between the total cell count i.e cell
proliferation between the labelled and unlabelled cells at 1, 2.5, 5 and 10nm
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concentrations up to 72 hours time point. The total cell count of MDA-MB-231
decreased significantly at 72 hours post labeling with 15nm dye concentrations.
Similar effects were also observed with MeWo cells in which there was no
significant different in MeWo cell viability up to 24 hours post labeling at all
concentrations used compared to the unlabelled cells. However, at 48 and 72
hours post labeling, there was a reduction in MeWo cell viability at 10 to 15 nm
concentrations. There was no significant difference in MeWo proliferation rate at
1nm to 5nm concentrations. However, at 48 and 72 hours post labeling with 10
and 15nm concentrations, the total cell count of MeWo significantly decrease as
compared to the unlabelled cells (Figure 4-13).
Therefore, based on the results from these two cell lines i.e. MDA-MB-231 and
MeWo, 5nm cell tracker green was used for tumour cell labeling in subsequent
transmigration assays.
Figure 4-12 The effect of cell tracker green labelling on MDA-MB-231 cell viability (A) and
cell proliferation (B). There was no significant different in MDA-MB-231 cell viability up to
48 hours across the range of concentration compared to the unlabelled cells. At 72 hours
post labeling, there was a reduction in MDA-MB-231 cell viability at 5nm to 15nm
concentrations. There was no significant different in MDA-MB-231 proliferation rate at
1nm to 10nm concentrations. The proliferation rate decrease at 15nm concentration at 48
and 72 hours opposed to unlabelled cells. *represent significant difference compared to
control group. Pooled data from 2 independent experiments, each carried out in triplicate
(n=6).
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Figure 4-13 The effect of cell tracker green labelling on MeWo cell viability (A) and cell
proliferation (B). There was no significant different in MeWo cell viability up to 24 hours
across the range of concentration used compared to the unlabelled cells. However, at 48
and 72 hours post labeling, there was a reduction in MeWo cell viability at 10nm to 15 nm
concentrations. There was no significant different in MeWo proliferation rate at 1nm to
5nm concentrations. However, the proliferation rate decrease at 10nm and 15nm dyes
concentrations at 48 and 72 hours opposed to unlabelled cells. * represent significant
difference compared to control group. Pooled data from 2 independent experiments,
each carried out in triplicate (n=6).
4.4.9 Time point optimisation for tumour cell migration across
endothelial cell monolayers
The MDA-MB-231 breast cancer cell line was used to optimise the adhesion
time required for tumour cell transmigration. This tumour cell line was left to
transmigrate across hMEC-1 cells for 4, 8, 16 and 24 hours and the number of
transmigrated tumour cells attached to the lower face of the polycarbonate
membrane filters between the negative control and the positive control wells
were compared at the end of the assay (Figure 4-14 and 4-15).
The number of MDA-MB-231 cells that has transmigrated across hMEC-1 cells
increased significantly from 4 to 24 hours in both negative and positive control
wells. At 4 and 8 hours, the number of tumour cells that has transmigrated
across hMEC-1 cells was less than 50 cells and if this time point was chosen,
the accuracy of the statistical analysis could be debated. At 24 hours time point,
more than 200 MDA-MB-231 cells had transmigrated, which would affect the
counting accuracy because the cells were very close together (Figure 4-14).
Therefore, the 16 hour time point was chosen as the incubation time for
subsequent tumour cell transendothelial migration assays.
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Figure 4-14 The number of transmigrated MDA-MB-231 cells attached to the lower face of
the polycarbonate membrane filters between negative (wells without serum) and positive
(wells with 100% heat inactivated fetal calf serum) control wells at 4, 8, 16 and 24 hours.
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Figure 4-15 Optimisation of MDA-MB-231 transmigration time across hMEC-1 cells. The
number of MDA-MB-231 cells migration across hMEC-1 cells was assessed at different
incubation time. Both negative (wells without serum) and positive (well with 100% heat
inactivated fetal calf serum) controls showed significant increase in the number of
tumour cells migrated across hMEC-1 cells between 4 to 24 hours. Pooled data from two
independent experiments, each carried out in duplicate (n=4). * represent significant
difference compared to 4 hours time point and + represent significant difference between
negative and positive control group.
4.4.10 Tumour cell migration across hMEC-1 and hTERT-LEC under
control and IL-1ɴ stimulation
Under unstimulated conditions, MDA-MB-231 show similar transmigratory
abilities across both hMEC-1 and hTERT-LEC, in that there was no significant
difference in the number of MDA-MB-231 cells that transmigrated between
hMEC-1 and hTERT-LEC. The transmigratory ability of MDA-MB-231 increased
VLJQLILFDQWO\LQUHVSRQVHWR,/ȕVWLPXODWLRQRIWKHHQGRWKHOLDOFHOOVDFURVVERWK
hMEC-1 and hTERT-LEC monolayers (p-value <0.001 and <0.001 respectively)
with similar affinity across both endothelial models (139.5+ 6.1 cells vs
149.5+5.3 cells across hMEC-1 and hTERT-LEC respectively). MeWo cell
transmigration under control conditions showed similar transmigratory ability
across both hMEC-1 (11.3+ 0.7 cells) and hTERT-LEC (11.8+1.4 cells),
however with a lower number of cells migrating across the endothelium
compared to MDA-MB-231 cells. However, upon stimulation with IL-1ɴ, there
was an increased in the transmigratory ability of MeWo cells across hMEC-1
and hTERT-LEC (p value <0.00001 and <0.0001 respectively) which was more
notable across hMEC-1 (Figure 4-16).
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Figure 4-16 The number of MDA-MB-231 (A) and MeWo (B) cells migration across hMEC-1
DQGK7(57/(&XQGHUFRQWURODQG ,/ȕVWLPXODWHGFRQGLWLRQV3RVLWLYHFRQWUROV ZHOOV
with 100% heat inactivated fetal calf serum) shows that the assays were in working
conditioned as expected. MDA-MB-231 cells shows an increased migration across both
hMEC-1 and hTERT-LEC cells with similar affinity to both endothelial cells (p value
<0.001 and <0.001 respectively). Transmigration of MeWo cells were also significantly
LQFUHDVHG DFURVV ,/ȕ VWLPXODWHG K0(& DQG K7(57/(& S YDOXH  DQG
p<0.0001). Pooled data from two independent experiments, each carried out in duplicate
(n=4). (* significant different compared to negative controls).
4.4.11 The effect of macrophage conditioned media stimulation on MDA-
MB-231 transmigration across hMEC-1 and hTERT-LEC
The 5 conditions of macrophage conditioned media used in this assay were
generated from 3 donors as described in Chapter 3. Under control conditions,
MDA-MB-231 showed similar transmigratory ability across hMEC-1 and hTERT-
LEC across all 3 donors. When hMEC-1 and hTERT-LEC were stimulated with
PDFURSKDJH FRQGLWLRQHG PHGLD JHQHUDWHG IURP /36Ȗ VWLPXODWHG
macrophages, there was an increased in the number of cells transmigrated
across the endothelial cell monolayer. It should be remembered (Section
WKDWWKH,/ȕFRQFHQWUDWLRQVLQFRQGLWLRQHGPHGLDIURP/36VWLPXODWHG
macrophages) for these donors were as follows; 166.29 pg/ml for donor 4,
270.36 pg/ml for donor 5 and 118.24 pg/ml for donor 6. In donor 5 and donor 6,
the increased was significantly noted with the lymphatic endothelial cells,
hTERT-LEC opposed to hMEC-1 cells (p=0.03 and p<0.001 in donor 5 and
donor 6 respectively). Supernatants generated with TDL stimulated
macrophages showed no significant difference in term of the number of
WUDQVPLJUDWHG FHOOV DFURVV ERWK K0(&DQG K7(57/(& LQ DOO GRQRUV ,/ȕ
concentrations were 23.23, 24.31 and 24.96pg/ml for donor 4, donor 5 and
donor 6 respectively). However, when hMEC-1 and hTERT-LEC were
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VWLPXODWHG ZLWK PDFURSKDJH FRQGLWLRQHG PHGLD JHQHUDWHG ZLWK /36Ȗ,&(
LQKLELWRUDQG/36Ȗ7'/,&(LQKLELWRUVWLPXODWLRQWKHQXPEHURIWUDQVPLJUDWHG
0'$0%FHOOVGHFUHDVHGVLJQLILFDQWO\FRPSDUHGWRERWKFRQWURODQG/36Ȗ
stimulated macrophages in all the 3 donors (Figure 4-17). ELISA results
VKRZHG WKDW WKH ,/ȕ FRQFHQWUDWLRQ LQ WKHVH PDFURSKDJH FRQGLWLRQHG PHGLD
ZHUH   DQG SJPO IURP /36Ȗ,&( VWLPXODWHG PDFURSKDJHV
DQG   DQG SJPO IURP /36Ȗ7'/,&( VWLPXODWHG
macrophages (donor 4, 5 and 6 respectively)
Figure 4-17 MDA-MB-231 cells migration across hMEC-1 and hTERT-LEC stimulated with
macrophage conditioned media from; (A)donor 4, (B)donor 5 and (C) donor 6. Under
control conditions, MDA-MB-231 cells shows similar transmigratory ability across the
endothelial cells. Transmigration of MDA-MB-231 cells increased significantly across
K0(& DQG K7(57/(& ZLWK PDFURSKDJH FRQGLWLRQHG PHGLD VWLPXODWLRQ IURP /36Ȗ
stimulated macrophages, which decreased significantly in macrophage conditioned
PHGLD IURP/36Ȗ,&(DQG/36Ȗ7'/,&(VWLPXODWHGPDFURSKDJHV3RROHGGDWD IURP
two independent experiments, each in duplicate (n=4). *represent significant difference
compared to controls. †represent significant difference between hMEC-1 and hTERT-LEC
of the same group and ‡represent significant difference compared to LPS stimulated
hMEC-1 and hTERT-LEC.
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4.5 Discussion
In the initial metastatic process, cancer cells must break from the primary
tumour mass, migrate through the extracellular matrix, adhere and transmigrate
across blood or lymphatic endothelial cells before entering the circulation and
extravasating into the tissue to establish a secondary tumour site. Each of these
steps is multi-component processes with regulation dependent upon different
molecules and proteins that co-operate to ensure cancer cells survival and
spread. Results from Chapter 3 demonstrated that tumour-endothelial cell
DGKHVLRQ FDQ EH PRGXODWHG E\ F\WRNLQH VWLPXODWLRQ DQG WKDW 71)Į DQG
HVSHFLDOO\ ,/ȕ VHFUHWHG E\ PDFURSKDJHV VWURQJO\ LQIOXHQFH DGKHVLRQ WR
lymphatic endothelial cells; thus potentially modulating lymphatic vessel
invasion. The aim of the current chapter was to study the migratory ability of
four tumour cell lines; MDA-MB-231, MCF7, MeWo and SKMEL-30 under
FRQWUROFRQGLWLRQVDQGH[DPLQHWKHHIIHFWRI71)Į ,/ȕ WXPRXUFRQGLWLRQHG
media and macrophage conditioned media stimulation. The transmigration
pattern of both melanoma (MeWo) and breast cancer (MDA-MB-231) cell lines
across blood (hMEC-1) and lymphatic (hTERT-LEC) endothelial cell models
ZHUH DOVR VWXGLHG DQG FRPSDUHG 7KH HIIHFW RI ,/ȕ DQG PDFURSKDJH
conditioned media upon tumour cell migration across blood and lymphatic
endothelial cells were also examined.
5HVXOWVIURPWKHVFUDWFKZRXQGPLJUDWLRQDVVD\VVKRZHGWKDW71)ĮDQG,/ɴ-
stimulation altered the migratory ability of all tumour cell lines used in this study
(MDA-MB-231, MCF7, MeWo and SKMEL-30), which was observed at
numerous time points. These observations are in agreement with other studies
showing that migration of human cutaneous melanoma and cervical cancer cell
lines (HBL and HW756) is increased by these pro-inflammatory cytokines. Both
71)ĮDQG,/ɴ have been shown to upregulate integrin expression in human
melanoma cells thus increasing the ability of cells to bind to extracellular
substrate and increase invasion via fibronectin binding (Katerinaki et al., 2003).
A maximal effect on cell migration, with the cell lines used in this study, was
observed at 20-24 hours which in accordance with other studies (Hidalgo et al.,
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2005; Katerinaki et al., 2003), during which an increase in ICAM-1, VCAM-1
(Morandini et al., 1998) and integrin (Zhu et al., 2002) expression on the tumour
cells was observed. Of the four tumour cell lines used in this study, MDA-MB-
231 had significantly higher migratory rate compared to the other tumour cell
lines both in control and TNF-ɲ/IL-1ɴ stimulated conditions followed by MCF7,
SKMEL-30 and MeWo. The differences in migratory ability of these tumour lines
demonstrated the heterogenous nature of tumour cell migration. MDA-MB-231
cells originated from a highly invasive and aggressive tumour which might
explain the high motility rate (Swamydas et al., 2011).
When the tumour cells were stimulated with tumour conditioned media, there
were no significant changes in the migratory ability of MDA-MB-231, MCF7,
MeWo and SKMEL-30 observed across all time points assessed. Tumour
conditioned media consists of various proteins, cytokines, chemicals and growth
factors; all of which may influence the migration rate of tumour cell lines but no
effect was observed in this current study. It could be argued that the tumour
conditioned media used is not biologically active, thus the observed results.
However, as described in Chapter 3, when tumour cells were cultured with the
same tumour conditioned media, they still proliferated at the same rate as those
cultured with normal media.
When MDA-MB-231 cells were stimulated with macrophage conditioned media,
there was an increased in the percentage of wound closure and the migratory
DELOLW\REVHUYHGFRPSDUHGWRWKHXQVWLPXODWHGFRQWURO7KHIDFW WKDW ,/ȕZDV
GHWHFWHG LQ WKHPDFURSKDJHFRQGLWLRQHGPHGLDDQGQR ,/ȕZDVGHWHFWHG LQ
WKHWXPRXUFRQGLWLRQHGPHGLDPD\VXJJHVWWKDW,/ȕFRXOGSOD\DUROHLQVXFK
tumour cell migration and the initial metastatic process. In a previous study, IL-
ȕ VWLPXODWHG 0&) FHOOV ZHUH VKRZQ WR H[SUHVV 6$ ZKLFK LV D
metastasis promoting protein, as well as increase secretion of MMP-9 and
MMP-2, which are capable of degrading extracellular matrix proteins during cell
migration (Franco-Barraza et al., 2010).
It may be argued that results from the scratch wound migration assays are not
based on cell migration alone but could be affected by cell proliferation. The use
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of mitomycin-C for the duration of the assay from 0 hour post wounding ensures
that the effect observed is a true migratory effect. Mitomycin-C is an antibiotic
that can exerts anti-proliferative effect in living cells by arresting cells in the
G2/M phase of the cell cycle (Granada et al., 2005) up to 48 hours following
exposure to a single dose of mitomycin-C (Lama and Fechtner, 2003).
Transmigration of tumour cells across the endothelial cells follows on from
migration and adhesion in the metastatic cascade. Therefore, tumour
transendothelial migration was also off interest in this study. The Boyden
chamber system is a dual compartment system assay and the most commonly
used model to study tumour cell transmigration in-vitro (Okada et al., 1994).
Both hMEC-1 and hTERT-LEC endothelial cells were cultured on collagen
coated surfaces as they did not form monolayers when cultured directly on the
polycarbonate membrane surface of the transwell inserts. The use of
extracellular constituents such as collagen, laminin, gelatin, fibronectins and
others help to facilitate endothelial cell attachment to the membrane surface.
Most studies involving culture of endothelial cells have utilised rat tail collagen
type I as the coating agent which not only helps the endothelial cells to attach to
the cultured surface but also maintain their native differentiation characteristics
and functions (Ghislin et al., 2011; Voura et al., 1998).
In the assay used in the current study, tumour cells were labeled with a
fluorescent dye; cell tracker green CMFDA, which is a fluorescent chloromethyl
derivative that can diffuse through live cell membranes. This dye reacts with the
intracellular components inside the cells to emit fluorescent signals which,
reportedly, do not affect cell viability up to 72 hours. The use of fluorescent dye
in this assay helps to differentiate between tumour and endothelial cells, and in
doing so, improves the accuracy of quantifying the number of transmigrated
cells across the endothelium (Wu et al., 2010).
Experiments comparing transendothelial migration of tumour cell lines; MDA-
MB-231 and MeWo across blood and lymphatic endothelial cells in a single
experiment have not been reported previously. As in the adhesion assay
described in Chapter 3, most transendothelial migration assays have used large
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vein endothelial cells (HUVEC) to study tumour cell transmigration. Under
control conditions, MDA-MB-231 and MeWo show similar transmigratory
abilities across both blood and lymphatic endothelial cells however with different
affinity. MDA-MB-231, which is a more aggressive tumour type, transmigrated in
higher numbers compared to MeWo cells. One previous study has shown that
human fibrosarcoma HT-1080 and lung carcinoma Calu-1 cells exhibit
significantly higher transmigration across bovine aortic endothelial cells (BAEC)
monolayers compared to the colon carcinoma cell lines (SW620, SW480, HT29
and Colo 205) (Li and Zhu, 1999). They concluded that the HT-1080 and Calu-1
cells may associate with a higher capacity to spread in-vivo.
8SRQVWLPXODWLRQZLWK,/ȕWKHUHZDVDVLJQLILFDQWLQFUHDVHGLQWKHQXPEHURI
MDA-MB-231 cells that transmigrated across both hMEC-1 and hTERT-LEC
with similar affinity to both endothelial cell types. Similarly, upon stimulation with
IL-1ɴ, there was also an increased in the transmigratory ability of MeWo cells
across hMEC-1 and hTERT-LEC which was more notably observed across
hMEC-1 cells. Such results, with IL-1 altering transmigration across
endothelium, may be due to enhanced contractile force generation and
cytoskeletal remodeling which can increase transmigration and invasion
efficiency across the endothelial barrier, as has been observed with chemokines
such as Gro-ɴ and IL-8 (Claudia et al., 2008).
8SRQ VWLPXODWLRQ ZLWK PDFURSKDJH VXSHUQDWDQW JHQHUDWHG IURP /36Ȗ
stimulated macrophages, an increased transmigratory effect was observed with
hTERT-LEC cells compared to hMEC-1 cells and was statistically significant in
donor 2, the donor with the highest level of IL-1E. The differences in these
UHVXOWV PD\ EH GXH WR WKH GLIIHUHQFHV LQ ,/ȕ LH RQH LV UHFRPELQDQW ,/ȕ
whereas that from macrophage is naturally occurring. Many studies have also
UHSRUWHG FRQWUDVWLQJ UHVXOWV LQ UHODWLRQ WR ,/ȕ LQ WXPRXU PLFURHQYLURQPHQW
tumour promoting and tumour regression and they conclude that the biological
HIIHFWRI,/ȕPD\GHSHQGRQWKHGRVHVRIWKLVF\WRNLQHDQGWKHFRQGLWLRQRI,/
ȕDGPLQLVWUDWLRQ6DLMRHWDOD
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When both hMEC-1 and hTERT-LEC cells were stimulated with macrophage
FRQGLWLRQHG PHGLD JHQHUDWHG IURP /36Ȗ,&( LQKLELWRUV VWLPXODWHG
macrophages, the number of cells transmigrated across both endothelial cells
GHFUHDVHGVLJQLILFDQWO\DFURVVDOOWKUHHGRQRUVFRPSDUHGWRXVLQJ/36ȖDORQH
,/ȕ(/,6$UHVXOWVIURPWKHPDFURSKDJHPHGLDVHHPHGWRFRUUHODWHZLWKWKH
QXPEHURI FHOOV WUDQVPLJUDWHG ,/ȕKDVEHHQVKRZQ LQ VHSDUDWH VWXGLHV WR
decrease the amount of p125FAK molecules in HUVEC which eventually blocked
the formation of focal contacts, resulting in decreased strength of endothelial
cell attachment with the extracellular matrix. The decreased adhesiveness
might enable tumour cells to migrate beneath the endothelial cells more easily
(Iwaki et al., 1997). It remains to be seen if this explanation applies to current
UHVXOWV ,/ȕ VWLPXODWLRQ RQ HQGRWKHOLDO FHOOV LQFUHDVHG WKH H[SUHVVLRQ RI
adhesion molecules such as ICAM-1 and VCAM-1 resulting in the increased of
tumour-endothelial cell adhesion eventually leading to increased tumour
transendothelial migration.
In addition, when both hMEC-1 and hTERT-LEC were stimulated with
PDFURSKDJHFRQGLWLRQHGPHGLDJHQHUDWHGIURP/36Ȗ,&(LQKLELWRUVVWLPXODWHG
macrophages,it was also observed that the number of MDA-MB-231 cells
transmigrated was lower than the controls (endothelial cells without any
stimulation). As stated earlier, ICE is a cysteine protease with its predominant
UROHLQFOHDYLQJLPPDWXUH,/ȕLQWRLWVDFWLYHPDWXUHIRUPUHYLHZLQ&KDSWHU
Section 1.6.2). However, ICE could also cleaved IL-18, a pro-inflammatory
cytokine produce by cells of haematopoietic lineage including
monocyes/macrophage hence, the effect observed in this transwell migration
assay might be due to this fact. IL-18 ELISA should be carried out if this assay
was to be repeated to confirm on this information.
It would also be good however, to carried out Lucifer yellow test on the
HQGRWKHOLDO FHOOV PRQROD\HU DIWHU  KRXUV VWLPXODWLRQ ZLWK ,/ȕ DQG
macrophage conditioned media to show that the integrity of the monolayers are
not affected with both stimulation. However, in the adhesion assay (described in
Chapter 3), when the endothelial cell monolayers were stimulated with either IL-
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ȕRUPDFURSKDJHFRQGLWLRQHGPHGLD WKH LQWHJULW\RIFHOOVPRQROD\HUZDVQRW
compromised as observed under the light microscope. Such result reflected that
WKHHIIHFWREVHUYHGZLWK,/ȕDQGPDFURSKDJHPHGLDVWLPXODWLRQLQWKHWUDVZHOO
migration assay is a true effect and not as a result of non-intact cells.
In summary, results in the current chapter show that pro-inflammatory
F\WRNLQHV 71)Į DQG ,/ȕ PD\ SOD\ LPSRUWDQW UROHV LQ UHJXODWLQJ PHODQRPD
DQGEUHDVWFDQFHUFHOOPLJUDWLRQDQGWUDQVPLJUDWLRQLQYLWUR,/ȕVWLPXODWLRQRI
endothelial cells increased both melanoma and breast cancer cell
WUDQVPLJUDWLRQDFURVVK0(&DQGK7(57/(&,QWKHFDVHRI,/ȕJHQHUDWHG
from macrophage supernatant, the transmigration of MDA-MB-231 cells was
more notably observed across hTERT-LEC. This study is important as it
optimised various factors involved in the transmigration protocol to create a fully
working transendothelial transmigration assay procedures to be used in the
near future. In terms of the tumour transendothelial migration, additional
experiments need to be carried out to validate the results observed using MDA-
MB-231 by using more tumour cell lines. Transendothelial migration under flow
conditions would also be useful as it more closely replicates in vivo processes.
Due to the findings, as discussed in Chapter 3 and the present chapter, that IL-
1ɴ ?particularly macrophage derived, modulates lymphatic vessel adhesion,
migration and transmigration, it was interesting to investigate the expression of
IL-1ɴ expression in tumour specimens - this is the focus of the following
chapter.
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5.1 Abstract
Background and Aims: The initial metastatic process depends on the ability of
cancer cells to separate from the primary tumour, migrate through the
extracellular matrix protein, adhere and transmigrate between blood or
lymphatic vessels to enter the circulation. Results from previous chapters have
GHPRQVWUDWHG WKDW ,/ȕ VHFUHWHG E\ PDFURSKDJHV PRGXODWHV O\PSKDWLF
endothelial cell adhesion, migration and transmigration. The aim of the current
FKDSWHUZDVWRLQYHVWLJDWHWKHH[SUHVVLRQRI,/ȕLQWXPRXUVSHFLPHQVDQGWHVW
for association with lymphatic vessel invasion. Furthermore, this chapter sought
WRWHVWIRUDVVRFLDWLRQEHWZHHQ,/ȕH[SUHVVLRQDQGFOLQLFRSDWKRORJLFYDULDEOHV
and clinical outcome.
Methods: ,/ȕ expression was investigated using a tissue microarray (TMA)
approach. TMAs were supplied preprepared using 0.6mm cores from 1511
HDUO\VWDJHLQYDVLYHEUHDVWFDQFHUSDWLHQWV$FRPPHUFLDOO\DYDLODEOHDQWL,/ȕ
antibody was used to stain the TMA using a Novolink Novocastra Polymer
detection kit. A histochemical score (H-score) which includes the assessment of
staining intensity and the percentage of positive cells was used to assess the
stained slides after scanning the slides with a Nanozoomer Digital Pathology
Scanner.
Results: 5HVXOWV VKRZ WKDW KLJK ,/ȕ H[SUHVVLRQ LQ WKH WXPRXU FHOOV ZDV
significantly associated with older patients (p=0.001), low tumour stage
(p=0.011), PgR positive tumours (p=0.007), non-basal status (p=<0.001), the
absence of lymphatic vessel invasion (p=0.01 and p=<0.001 respectively) as
ZHOO DV QR GLVWDQW PHWDVWDVLV S  ,Q .DSODQ0HLHU DQDO\VHV ORZ ,/ȕ
expression in the tumour cells was significantly associated with breast cancer
specific survival (p=0.017) and disease free interval (p=0.008) which lost
significance in multivariate Cox regression analysis.
Conclusions: 5HVXOWVIURPWKHFXUUHQWFKDSWHUVKRZWKDWKLJK,/ȕH[SUHVVLRQ
was associated with the absence of lymphatic vessel invasion. However, results
IURP SUHYLRXV LQYLWUR FKDSWHUV VKRZ WKDW ,/ȕ H[HUWV D SRVLWLYH HIIHFW RQ
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tumour cell adhesion, migration and transmigration and that macrophages are
WKH PDLQ SURGXFHU RI ,/ȕ $ PRUH VSHFLILF ,/ȕ VWDLQLQJ RQ PDFURSKDJHV
using a double IHC methodology, is recommended to evaluate the correlation of
this parameter with lymphatic invasion and other clinical criteria.
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5.2 Introduction
Tumour cell migration, adhesion and transmigration across blood or lymphatic
vessels are important in the initial vascular invasion process. In-vitro results
IURPSUHYLRXVFKDSWHUVKDYHGHPRQVWUDWHGWKDW,/ȕFDQLQIOXHQFHWXPRXUFHOO
migration, in addition to tumour cell adhesion and transmigration to/across
lymphatic and blood endothelial cell models, with a preferential increase
REVHUYHGWRDFURVVO\PSKDWLFHQGRWKHOLDOFHOOV7KLV,/ȕLVOLNHO\DVVXJJHVWHG
by results in Chapters 3 and 4, produced by tumour associated macrophages
present in abundance in the tumour microenvironment with, from in vitro
experiments, relatively less produced by tumor cells (from tumour conditioned
media experiments mentioned earlier).
The interaction between cancer cells and tumour associated macrophages
(reviewed in Chapter 1) are pivotal in the metastatic dissemination of cancer.
There exists a complex paracrine signaling loop between tumour associated
macrophages and tumour cells to activate each other. Upon activation by
cancer cells, tumour associated macrophages can release various growth
factors, cytokines, inflammatory mediators and proteolytic enzymes, many of
these factors are key agents in cancer metastasis (Yunping Luo et al., 2006).
Table 5-1 shows various cytokines secreted by macrophages and their role in
WKH LPPXQH UHVSRQVH ,/ȕ UHYLHZHG LQ &KDSWHU  LV RQH RI WKH PDQ\
cytokines secreted by macrophages as a native 31kDa precursor, which is
SURWHRO\WLFDOO\SURFHVVHG WR LWVDFWLYHN'D IRUPE\ ,/ȕFRQYHUWLQJHQ]\PH
,&( RU FDVSDVH  ,/ȕSURGXFWLRQE\ FHOO W\SHV RWKHU WKDQPRQRF\WHV DQG
macrophages has been reported in the literature. These include melanoma,
sarcoma, hepatoblastoma as well as ovarian carcinoma cells (Burger et al.,
'LQDUHOOR ,QDQLPDOPRGHOV ,/ȕSURGXFWLRQE\PHODQRPDFHOOV
correlates with the ability to undergo metastasis to the liver. In many cases, the
SURGXFWLRQRI ,/ȕ E\ WXPRXU FHOOV FDXVHG LQFUHDVHG H[SUHVVLRQRI DGKHVLRQ
molecules and cell surface proteins which in turn contributed to increased
cancer cell dissemination (Pollard, 2008; Wyckoff et al., 2000).
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Table 5-1 Common cytokines secreted by macrophages.Adapted from (Baay et al., 2011;
Pollard, 2008; Qian and Pollard, 2010).
Cytokines Primary functions
71)Į x Increases the expression and cellular responsiveness to growth
factor
x Induces signaling pathway leading to cell proliferation
,/ȕ x Co-stimulatory cytokines with antigen presenting cells and T cells
x Involved in inflammation, fever and the acute phase response
,)1Įȕ x Activates natural killer cells and macrophages
x Induction of Class I MHC on all somatic cells
IL-6 x Involved in the acute phase response of the immune response
x 3URGXFHV\QHUJLVWLFHIIHFWZLWK,/ȕDQG71)ĮLQWKHWLVVXHDQG
tumour microenvironment
IL-10 x Inhibits other cytokine production such as IL-6 and IL-1
x Promotes B cell proliferation and antibody production
IL-12 x 3URPRWHVQDWXUDONLOOHUFHOOVSUROLIHUDWLRQDQG,)1ȖSURGXFWLRQ
IL-13 x Stimulates growth and proliferation of B cells
x Inhibits the production of macrophage inflammatory cytokines
IL-18 x Promotes natural killer cell activity and induces the production of
,)1Ȗ
,QFRQWUDVW,/ȕKDVEHHQUHSRUWHGWRH[HUWDJURZWKLQKLELWRU\HIIHFWRQWXPRXU
cells (melanoma, breast, cervical and ovarian carcinoma cells). In these studies,
,/ȕZDVSURSRVHGWRFDXVHDUUHVWLQFHOOF\FOHUHJXODWRU\SDWKZD\LQFUHDVHG
oxygen radicals release and nitric oxide regeneration (Hanauske et al., 1992;
2OOH HW DO  ,Q IDFW ORZ GRVHV RI ,/ȕ DUH SRVWXODWHG WR LQFUHDVH DQWL
tumour defense mechanisms or could boost the effect of antitumour adjuvants.
,/ȕZDVUHSRUWHGWRSURGXFHDV\QHUJLVWLFHIIHFWLQUHGXFLQJWXPRXUJURZWKLQ
vitro when combined with doxorubicin, cisplatin and other cytokines such as
71)ĮDQG,/2OOHHWDO
Based upon such literature findings, and results generated in Chapters 3 and 4,
LW ZDV RI LQWHUHVW WR VWXG\ ,/ȕ H[SUHVVLRQ LQ WXPRXU WLVVXH 7KH DLP RI WKLV
FKDSWHUZDVWRH[DPLQHH[SUHVVLRQRI,/ȕLQEUHDVWWXPRXUWLVVXHWRWHVWIRU
associations with lymphatic vessel invasion and assess the association of this
expression with clinicopathologic variables and clinical outcome.
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5.3 Materials and Methods
5.3.1 Western blot
7KH VSHFLILFLW\ RI WKH DQWL,/ȕ DQWLERG\ ZDV GHWHUPLQHG SULRU WR
immunohistochemical staining of patients’ specimen using western blot
technique as described in Section 3.3.11 using tumour (MDA-MB-231, MCF7,
MeWo and SKML-30) and PBMC cell lysates.
Numerous antibodies from different suppliers were examined by Western
blotting to determine specificity before deciding on the best ones to be taken
forward for assessment in immunohistochemical staining of patient tissues i.e
DQWL,/ȕDQWLERG\IURP$EFDP8.5	'8.DQG7KHUPR6FLHQWLILF86
 2SWLPLVDWLRQRI,/ȕDQWLERG\
2SWLPLVDWLRQRI ,/ȕDQWLERG\ FRQFHQWUDWLRQ ZDV FDUULHG RXWXVLQJ  GLIIHUHQW
immunohistochemical staining kits; DAKO kit (DAKO, Denmark), Vectastain
Universal Elite ABC kit (Vector Laboratories, San Francisco, USA) and Novolink
1RYRFDVWUDSRO\PHUGHWHFWLRQNLW/HLFD'HQPDUNHDFKXVLQJGLIIHUHQW,/ȕ
antibody concentrations; 1:50, 1:70; 1:100 and 1:150. Liver and breast
composite tissue sections were used in the optimisation experiments. Liver was
XVHGWRRSWLPLVHWKH,/ȕVWDLQLQJDVSHUPDQXIDFWXUHUVUHFRPPHQGDWLRQDVLW
KDVEHHQUHSRUWHGDVEHLQJDKLJK,/ȕSURGXFHU
6WDLQLQJZDVDOVRFDUULHGRXWXVLQJ,/ȕDQWLERG\ZKLFKZDVSUHLQFXEDWHGZLWK
,/ȕUHFRPELQDQWSURWHLQRYHUQLJKW WRHQVXUHWKDW WKH,/ȕVWDLQLQJREVHUYHG
was specific. Such incubation with excess protein, corresponding to the epitope
recognised by the antibody, was carried out to neutralise the antibody thereby
making it unable to bind to the epitope present in the tissue sections. By
comparing the staining from the blocked antibody with the antibody alone, the
staining specificity can be determined.
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5.3.3 Patients and specimens
This study was conducted on 1511 early stage invasive breast cancer patients
treated at Nottingham University Hospitals between 1987 and 1998. Ethical
approval for this study was granted by the Nottingham Research Ethics
committee 2 under the title ‘development of a molecular genetic classification of
breast cancer.’ The median age of patients at time of diagnosis was 54 years
(range: 18 to 72 years). 39.5% (n=752) patients relapsed and 505 patients died
from the disease. Relapse-free survival was calculated from the start of primary
treatment to the first relapse. Breast cancer specific survival was defined as the
time interval between the start of primary surgery to death from breast cancer.
Clinical characteristics of patients are summarised in Table 5-2.
5.3.4 Immunohistochemistry
,/ȕH[SUHVVLRQZDVLQYHVWLJDWHGXVLQJSUHSDUHGE\RWKHUVZLWKLQVXSHUYLVRU\
research groups) tissue microarrays (TMAs) which were constructed using
0.6mm cores from 1511 tissue samples (single cores) as described above. The
WLVVXH VHFWLRQV ZHUH VWDLQHG ZLWK FRPPHUFLDOO\ DYDLODEOH PDUNHU RI ,/ȕ
(Thermo Scientific, UK). This marker was tested and optimised on liver and
breast composite sections before using them in the main cohort. The TMA
slides were placed on a 60ȠC hotplate for 10 minutes and were allowed to cool
before placing them in a Leica autostainer slide rack. The rack was loaded in
the Leica Autostainer XL Staining System ST5010 (Minnesota, USA) for
dewaxing and rehydrating. Briefly, the slides were deparaffinised in two xylene
baths for 5 minutes each then rehydrated in a series of descending industrial
methylated spirit concentrations followed by water for 5 minutes. The slides
were then loaded onto a sequenza slide rack (ThermoFisher Scientific, NY,
USA). A Novolink Novocastra polymer detection kit (Leica, Germany) was used
to stain the tissue sections. 100µl peroxidase block was added onto each slide
for 5 minutes and then washed 2x5 minutes with TBS. 100µl of protein block
was then added for another 5 minutes and washing was carried out as above
EHIRUHWKHDGGLWLRQRI,/ȕDQWLERG\GLOXWLRQLQ/HLFDDQWLERG\GLOXHQWIRU
1 hour at room temperature. The slides were then washed 2x5 minutes.
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Table 5-2 Clinicopathological characteristics of patients
Clinical feature Number (%) Clinical feature Number (%)
Age
<40
>40
129 (8.50)
1382 (91.5)
Size
< 2cm
> 2cm
not determined
904 (59.8)
598 (39.6)
9 (0.60)
Tumour stage
1
2
3
not determined
921 (61.0)
448 (29.6)
135 (8.90)
7 (0.50)
Tumour grade
1
2
3
not determined
253 (16.7)
499 (33.0)
750 (49.6)
9 (0.60)
LVI
negative
positive
1309 (86.6)
202 (13.4)
BVI
negative
positive
1508 (99.8)
3 (0.20)
NPI
<3.4
3.4-5.4
>5.4
Not determined
454 (30.0)
768 (50.8)
279 (18.5)
10 (0.70)
Distant metastasis
No
Yes
Not determined
1025 (67.8)
478 (31.6)
8 (0.50)
Basal status
Non basal
Basal
Not determined
1118 (74.0)
291 (19.3)
102 (6.80)
ER status
negative
positive
Not determined
387 (25.6)
1085 (71.8)
39 (2.60)
PgR status
negative
positive
Not determined
599 (39.6)
827 (54.7)
25 (6.70)
Her2 status
negative
positive
Not determined
1278 (84.6)
201 (13.3)
32 (2.10)
Triple negative status
Non triple negative
Triple negative
Not determined
1207 (79.9)
261 (17.3)
43 (2.80)
100µl of post primary block was added for 30 minutes, washed and 100µl of
Novolink polymer was added for another 30 minutes. DAB solution (1:20 DAB
chromogen in DAB substrate buffer) was applied to the slides for 5 minutes
prior to 2x5 minutes washing. The slides were stained with Novolink
haematoxylin for another 6 minutes. Slides were removed from the sequenza
trays and place in a Leica autostainer for dehydration steps in a series of
ascending industrial methylated spirit concentrations followed by 2x5 minutes in
xylene. Sections were mounted with DPX mounting medium (Leica, Germany)
and were left to dry overnight in a fume cupboard.
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Breast composite sections were used as both positive and negative controls
ZKHQWKH ,/ȕVWDLQLQJZDVFRQGXFWHG7KHSURFHGXUHDVDERYHZDVDSSOLHG
for the positive control. For the negative control, primary antibody was omitted.
5.3.5 TMA scoring
A histochemical score (H-score) was used to assess the stained slides after
scanning the slides with a Nanozoomer Digital Pathology Scanner (Hamamatsu
Photonics). H-score includes the assessment of the staining intensity as well as
the percentage of positive cells. For the intensity assessment, tissue sections
were scored 0 to 3 which correspond to negative, weak, moderate and strong
staining intensity. The percentage of positive cells at each intensity level was
estimated. This score was then calculated as (0 X negatively stained %) + (1 X
weakly stained %) + (2 X moderately stained %) and (3 X strongly stained %).
Therefore, the range of possible score for each slide is between 0 to 300.
Figure 5-1 shows photomicrograph of representative staining intensity from the
breast tissue microarray. 30% of the cores were double assessed by an
independent assessor (Sarah Storr) blinded to clinicopathologic data and
scores. Single measure intraclass correlation coefficients between scores were
0.839 showing excellent concordance between scorers.
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5.3.6 Statistical analysis
&URVVWDEOHDQG3HDUVRQ&KL6TXDUHWHVWRIDVVRFLDWLRQȤ2) (or Fisher’s Exact
test if a cell count was <5) were used to measure the relationship between
categorised protein expression with clinicopathological data. Overall survival
and relapse-free survival analyses were performed using the Kaplan-Meier
method and the statistical significance between groups assessed by the log
rank test. Multivariate survival analysis was performed using Cox regression
analysis. P value of <0.05 was considered statistically significant. Concordance
between results from individual observers was evaluated using intraclass
correlation coefficient (ICC). Statistical analysis was carried out using SPSS
version 17.0. Stratification cut-points were determined using X-Tile software and
were determined prior to statistical analyses (Camp et al., 2004).
Figure 5-1 Photomicrograph showing representative IL-1ȕ staining intensity in breast
tissue microarray used in this study which corresponds to (A) 0 –negatively stained,
(B) 1 –weakly stained, (C) 2 –moderately stained and (D) 3 –strongly stained of the H-
score assessment. 100x magnification. Inset box 200x magnification.
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5.4 Results
 :HVWHUQEORWWLQJIRU,/ȕH[SUHVVLRQ
$V PHQWLRQHG SUHYLRXVO\ WKUHH DQWL,/ȕ DQWLERGLHV IURP WKUHH GLIIHUHQW
suppliers were tested to ensure that the best possible antibody was used in the
LPPXQRKLVWRFKHPLFDOVWDLQLQJRISDWLHQWV¶VSHFLPHQV,/ȕSURWHLQH[SUHVVLRQ
and binding specificity was investigated by Western blot. Antibodies were
GLUHFWHG DJDLQVW PDWXUH KXPDQ ,/ȕ ZLWK WKH H[SHFWHG PROHFXODU ZHLJKW RI
N'D6XFKDQWLERGLHVDOVRUHFRJQLVHQDWLYH,/ȕRIN'D
)LJXUHVKRZV,/ȕH[SUHVVLRQXVLQJWKHDQWL,/ȕDQWLERG\VXSSOLHGIURP
$EFDP8.$VPHQWLRQHGDERYHWKLVDQWLERG\DOVRUHFRJQLVHVQDWLYH,/ȕRI
N'DDVGHWHFWHG LQ/36ȖVWLPXODWHG3%0& O\VDWH+RZHYHU WKHVSHFLILFLW\
RI ,/ȕ DQWLERG\ ZDV TXHVWLRQDEOH DV LW DOVR JDYH QRQVSHFLILF EDQGV LQ WKH
tumour lysates used i.e MDA-MB-231, MCF-7, MeWo and SKMEL-30.
Figure 5-2 IL-1ȕ (Abcam, UK)
expression in MDA-MB-231, MCF7,
MeWo, SKMEL-30, PBMC and
3%0&/36ȖE\:HVWHUQEORWg of
protein were loaded into each well.
1DWLYH ,/ȕexpression was detected
LQ/36ȖVWLPXODWHG3%0&0DWXUH ,/
ȕZDVGHWHFWHG LQ ,/ȕrecombinant
protein sample. However, non-specific
bands were observed in the tumour
lysates and therefore the use of this
antibody in immunohistochemistry
ZDV RPLWWHG Ǻactin bands show
equal protein loading into each well.
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)LJXUH  VKRZV ,/ȕ SURWHLQ H[SUHVVLRQ DVVHVVHG XVLQJ DQ DQWL,/E
antibody supplied by Thermo Scientific, UK. A band of the expected size was
REVHUYHG LQ WKH 3%0& O\VDWH DQG ZDV H[SUHVVHG DW D KLJKHU OHYHO LQ /36Ȗ
stimulated PBMC lysate compared to the unstimulated PBMC control. In the IL-
ȕEHWDUHFRPELQDQWSURWHLQVDPSOHDQ,/ȕEDQGZDVREVHUYHGDWN'D1R
H[SUHVVLRQRI,/ȕFRXOGEHREVHUYHGLQWKHWXPRXUO\VDWHVLH0'$0%
MCF7, MeWo and SKMEL-30 lysates. This Western blot result suggested that
WKHDQWL,/ȕDQWLERG\XVHGZDVVSHFLILFDQGGHWHFWVWKHFRUUHFW ,/ȕSURWHLQ
EDQG± LWZDV WKHUHIRUHXVHGWRDVVHVV ,/ȕH[SUHVVLRQ LQFRQWUROV OLYHUDQG
breast composite blocks) and breast cancer tissue samples via
immunohistochemistry.
5.4.2 Optimisation of IL-1 antibody concentration for IHC
$VPHQWLRQHGDERYHRSWLPLVDWLRQRIDQWL,/ȕDQWLERG\7KHUPR6FLHQWLILF86
in tumour sections was carried out using 3 different immunohistochemical
staining kits i.e DAKO kit (DAKO, Denmark), Vectastain Universal Elite ABC kit
(Vector Laboratories, San Francisco, USA) and Novolink Novocastra polymer
Figure 5-3 : IL-1ȕ (Thermo
Scientific, UK) expression in MDA-
MB-231, MCF7, MeWo, SKMEL-30,
PBMC and PBMC+LPS by western
blot. 25µg of protein were loaded
LQWR HDFK ZHOO 1DWLYH ,/ȕ
expression was detected in PBMC
lysate with stronger expression in
/36ȖVWLPXODWHG3%0&0DWXUH,/
ȕ ZDV GHWHFWHG LQ ,/ȕ
recombinant protein sample. No
,/ȕ EDQG ZDV REVHUYHG LQ
WXPRXU O\VDWHV ǺDFWLQ EDQGV
show equal protein loading into
each well.
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GHWHFWLRQ NLW /HLFD 'HQPDUN HDFK XVLQJ  GLIIHUHQW ,/ȕ DQWLERG\
concentrations; 1:50, 1:70; 1:100 and 1:150. 1:70 dilution of this antibody using
Novolink Novocastra polymer detection kit was determined to give the optimal
staining on the liver and breast tissue sections.
:KHQ EUHDVW FRPSRVLWH VHFWLRQV ZHUH VWDLQHG ZLWK ,/ȕ VWDLQLQJ FRXOG EH
observed in the cytoplasm of the cells. Using the blocking recombinant protein,
there was no staining observed on the cell cytoplasm indicating that the staining
REVHUYHGZLWKWKLVDQWLERG\LVDVSHFLILFIRU,/ȕ)LJXUH
 ,/ȕVWDLQLQJLQWKHEUHDVWWLVVXHPLFURDUUD\
&\WRSODVPLFVWDLQLQJZDVREVHUYHGZLWK WKH ,/ȕDQWLERG\GLVSOD\LQJVWDLQLQJ
KHWHURJHQHLW\EHWZHHQ WXPRXUFHOOV )LJXUH7KLVDQWL,/ȕDQWLERG\DOVR
stained a subset of inflammatory cells. The median H-score for cytoplasmic IL-
ȕH[SUHVVLRQZDVZLWKD UDQJHEHWZHHQDQG;WLOH VRIWZDUHZDV
used to determine the cut off point separating the score into low and high
staining intensity. This cut off point was used to determine correlation with
FOLQLFRSDWKRORJLFYDULDEOHV,QWKLVVWXG\,/ȕKDGDQ+VFRUHFXWRIISRLQWRI
with 259 (17.1%) cases with low score and 1252 (82.9%) cases having high
score. The H-score histogram is shown in Appendix D-Table D2.
Figure 5-4 Representative of IL-1ȕ staining on breast tissue composite sections; No
staining was observed in the negative control section (A). Cytoplasmic staining was
REVHUYHGZLWK,/ȕDQWLERG\%ZKLFKZDVQRWREVHUYHGZKHQUHFRPELQDQWSURWHLQ
was used (C). 200x magnification
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)LJXUH7KHVWDLQLQJSDWWHUQRIDQWL,/ȕDQWLERG\RQEUHDVWWLVVXHPLFURDUUD\7KHUH
was staining heterogeneity observed between tumour cells in the same section - for
example, in this section, low (1) and moderate (2) staining intensity could be observed.
,/ȕDOVRVWDLQHGDVXEVHWRILQIODPPDWRU\FHOOVDVVKRZQE\WKHDUURZ7KHVWDLQLQJRI
,/ȕLVVSHFLILFZLWKQRVWDLQLQJREVHUYHGRQVWURPDODQGIDWFHOOV
 5HODWLRQVKLSEHWZHHQ,/ȕH[SUHVVLRQZLWKFOLQLFRSDWKRORJLFDO
variables
7DEOH  VKRZV WKH DVVRFLDWLRQ RI ,/ȕ H[SUHVVLRQ ZLWK FOLQLFRSDWKRORJLF
YDULDEOHV+LJK,/ȕH[SUHVVLRQZDVVLJQLILFDQWO\DVVRFLDWHGZLWKROGHUSDWLHQWV
Ȥ2 GI S  ORZ WXPRXU VWDJH Ȥ2=9.01; d.f.=2; p=0.011), PgR
SRVLWLYHWXPRXUVȤ2 GI S QRQEDVDOVWDWXVȤ2=51.23; d.f.=1;
S  WKH DEVHQFH RI O\PSKDWLF YHVVHO LQYDVLRQ Ȥ2=7.41; d.f.=1; p=0.01
DQG Ȥ2=21.34; d.f.=1; p=<0.001 respectively) as well as no distant metastasis
Ȥ2=6.45; d.f.=1; p=0.012).
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Table 5-3 7KHDVVRFLDWLRQEHWZHHQ,/ȕH[SUHVVLRQDQGFOLQLFRSDWKRORJLFYDULDEOHV
9DULDEOH ,/ȕ 
Low high P
value
Age <40
>40
9 (3.50)
250 (96.5)
120 (9.60)
1132 (90.4) 0.001
Size < 2cm
> 2cm
156 (61.4)
98 (38.6)
748 (59.9)
500 (40.1) 0.674
Tumour stage 1
2
3
174 (68.2)
56 (22.0)
25 (9.80)
747 (59.8)
392 (31.4)
110 (8.80)
0.011
Tumour grade 1
2
3
59 (23.2)
79 (31.1)
116 (45.7)
194 (15.5)
420 (33.7)
634 (50.8)
0.012
LVI negative
positive
206 (79.5)
53 (20.5)
1103 (88.1)
149 (11.9) <0.001
BVI negative
positive
259 (100)
0 (0.00)
1249 (99.8)
3 (0.20) 1.000
Any vessel invasion negative
positive
206 (79.5)
53 (20.5)
1100 (87.9)
152 (12.1) 0.001
NPI <3.4
3.4-5.4
>5.4
86 (34.0)
130 (51.4)
37 (14.6)
368 (29.5)
638 (51.1)
242 (19.4)
0.136
Distant metastasis No
Yes
158 (61.5)
99 (38.5)
867 (69.6)
379 (30.4) 0.012
Basal status Non basal
Basal
151 (62.4)
91 (37.6)
967 (82.9)
200 (17.1) <0.001
ER status negative
positive
69 (28.2)
176 (71.8)
318 (25.9)
909 (74.1) 0.475
PgR status negative
positive
122 (50.0)
122 (50.0)
477 (40.4)
705 (59.6) 0.007
Her2 status negative
positive
210 (83.3)
42 (16.7)
1068 (87)
159 (13) 0.130
Triple negative status non triple negative
triple negative
206 (84.1)
29 (15.9)
1001 (81.8)
222 (18.2) 0.464
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 5HODWLRQVKLSEHWZHHQ,/ȕH[SUHVVLRQZLWKFOLQLFDORXWFRPH
)URP.DSODQ0HLHUDQDO\VHVORZ,/ȕH[SUHVVLRQZDVVLJQLILFDQWO\DVVRFLDWHG
with breast cancer specific survival (p=0.017) and disease free interval
S )LJXUH+RZHYHULQPXOWLYDULDWH&R[UHJUHVVLRQDQDO\VLV,/ȕ
expression was not an independent indicator of breast cancer specific survival
(HR=1.084; 95% CI=0.846-1.390; p=0.523) and disease free interval
(HR=0.874; 95% CI=0.711-1.075; p=0.202). In these multivariate analyses, the
potential confounding factors included were patient age, tumour stage, PgR
status, intratumoural and peritumoural lymphatic vessel invasion as well as
distant metastasis.
Figure 5-6 Kaplan-Meier analysis of breast cancer specific survival and disease free
LQWHUYDO RI ,/ȕ H[SUHVVLRQ  /RZ ,/ȕ H[SUHVVLRQ ZDV VLJQLILFDQWO\ DVVRFLDWHG ZLWK
breast cancer specific survival (p=0.017) and disease free interval (p=0.008).
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5.5 Discussion
,Q SUHYLRXV FKDSWHUV &KDSWHU  DQG &KDSWHU  LW ZDV IRXQG WKDW ,/ȕPD\
play an important role in regulating the adhesion, migration and transmigration
of cancer cells, especially to/across lymphatic endothelial cells. The main aim of
WKLV FKDSWHU ZDV WR LQYHVWLJDWH WKHH[SUHVVLRQ RI ,/ȕDQG DQ\ DVVRFLDWLRQ LW
may have with lymphatic vessel invasion in tumour specimens. Furthermore we
sought to investigate any apparent associations between this protein expression
and clinicopathologic variables and clinical outcome.
To achieve this, 1511 early stage breast cancer specimens with known
VWDQGDUG FOLQLFDO YDULDEOHV ZHUH XVHG WR GHPRQVWUDWH DVVRFLDWLRQV ZLWK ,/ȕ
H[SUHVVLRQ +LJK ,/ȕ H[SUHVVLRQ ZDV VLJQLILFDQWO\ DVVRFLDWHG ZLWK ROGHU
patients i.e more than 40 years old and this result is in agreement with another
VWXG\ ZKLFK VKRZHG WKDW WKH EDVDO OHYHO RI ,/ȕ DQG RWKHU SURLQIODPPDWRU\
cytokines could be elevated as a result of aging (Barbieri et al., 2003). This
might be due to the fact that in older population, the baseline level of IL-10 was
reduced compared to younger population (Hacham et al., 2004). IL-10 is a
pleiotropic cytokine that can suppress the production of other inflammatory
F\WRNLQHVVXFKDV,/ȕ71)Į,/,/DQG,)1Ȗ
7KHUHDUHVXUSULVLQJO\ IHZVWXGLHVWKDWKDYHH[DPLQHGWKHH[SUHVVLRQRI,/ȕ
LQ EUHDVW FDQFHUV ,/ȕ H[SUHVVLRQ LQ KXPDQ EUHDVW FDQFHU ZDV VKRZQ WR
correlated inversely with estrogen receptor levels (Miller et al., 2000). In one
VWXG\,/ȕH[SUHVVLRQZDVGHWHFWHGLQWKHF\WRSODVPRILQYDVLYHGXFWDOEUHDVW
carcinoma cells and correlated with poor differentiation and decreasing
estrogen receptor expression (Singer et al., 2003). However, no such
DVVRFLDWLRQ EHWZHHQ ,/ȕ H[SUHVVLRQV ZLWK RHVWURJHQ UHFHSWRU VWDWXV ZDV
REVHUYHG LQ WKLV VWXG\ ,Q WKLV FXUUHQW VWXG\ KLJK ,/ȕ H[SUHVVLRQ ZDV
significantly associated with the absence of lymphatic vessel invasion as well as
WKHDEVHQFHRIGLVWDQWPHWDVWDVLV,QVXUYLYDODQDO\VHVORZ,/ȕH[SUHVVLRQLQ
the cytosolic compartment was significantly associated with breast cancer
specific survival and disease free interval; which lost their significance in
PXOWLYDULDWH DQDO\VHV $ GLYHUVH HIIHFW RI ,/ȕ RQ WXPRXU GHYHORSPHQW KDV
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EHHQGHVFULEHG LQ WKH OLWHUDWXUH ,/ȕH[HUWV LWVDQWLWXPRXUHIIHFW WKURXJKWKH
ability to (1) co-stimulate T cell activation, generating a sustained immune
response (2) to induce the secretion of other cytokines such as IL-2,
JUDQXORF\WHPDFURSKDJH FRORQ\VWLPXODWLQJ IDFWRU DQG ,)1Ȗ DQG  WR
potentiate the differentiation of immune surveillance cells. (Song et al., 2003). In
DGGLWLRQ,/ȕKDVEHHQUHSRUWHGWRUHGXFHWXPRXUJURZWKDQGSUROLIHUDWLRQE\
cytocidal or cytotoxic effects (Bhakdi et al., 1990). The expression of several
JHQHV DVVRFLDWHG ZLWK JURZWK DUUHVW VXFK DV JURĮ DQG JURȕ KDV EHHQ
GHVFULEHG ZLWK WKH DGGLWLRQ RI ,/ȕ WR PHODQRPD FHOO OLQH 5DQJQHNDU HW DO
 $GPLQLVWUDWLRQ RI H[RJHQRXV ,/ȕ LQYLYR FRXOG OHDG WR WXPRXU
regression and vascular collapsed especially when this cytokine was
DGPLQLVWHUHGLQDODUJHDPRXQWWRJNJ,QWKLVH[SHULPHQW,/ȕZDV
SURSRVHG WR DFW ZLWK ,)1Ȗ LQ D V\QHUJLVWLF PDQQHU WR LQFUHDVH WXPRXU NLOOLQJ
(Rice and Merchant, 1992).
+RZHYHULQOLJKWRIWKHUHVXOWVGLVFXVVHGLQ&KDSWHUDQG&KDSWHUWKDW,/ȕ
could influence the adhesion, migration and transmigration of tumour cells to
the lymphatic endothelium, immunohistochemistry results in this chapter are
VRPHZKDW XQH[SHFWHG ,/ȕ LV LQLWLDOO\ V\QWKHVLVHG DV DQ LPPDWXUH SUR,/ȕ
precursor molecule which lacks a signal peptide and remains cytosolic until it is
FOHDYHGE\,/ȕFRQYHUWLQJHQ]\PHLQWRDQDFWLYHDQGPDWXUH,/ȕ0DWXUH,/
ȕ LVVHFUHWHG LQWR WKHFHOOXODUFRPSDUWPHQW WKURXJKDPHPEUDQHFKDQQHO ,Q
the in-vitro adhesion, migration and transmigration experiments, the
UHFRPELQDQW ,/ȕXVHG WRVWLPXODWH WKHHQGRWKHOLDODQG WXPRXUFHOOVZDV WKH
SXULILHGN'D,/ȕLQLWVDFWLYHIRUP<HWWKHDQWL,/ȕDQWLERG\XVHGWRVWDLQ
WXPRXU VSHFLPHQV LQ WKLV FKDSWHU GHWHFWV ERWK WKH N'D LPPDWXUH ,/ȕ
SUHFXUVRUSUR,/ȕDQGWKHPDWXUH,/ȕ6XFKGLIIHUHQFHVPLJKWDFFRXQWIRU
the differences in the in-vitro observations and in the patient’s tumours.
In a study by Song and colleagues (2003), the mode of presentation and the
FRPSDUWPHQWDOLVDWLRQRIWKHDFWLYHIRUPRI,/ȕZLWKLQWKHWXPRXUFHOOVDQGLWV
microenvironment determined its effect in the malignant process. Their study
VKRZHG WKDW WKH VHFUHWHG IRUP RI ,/ȕ DQG QRW WKH PDWXUH ,/ȕ LQ WKH
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intracellular compartment, could increase tumour growth, invasion and
metastasis through the up-regulation of growth factors, angiogenesis-promoting
factors, matrix metalloproteinase and the expression of adhesion molecules.
)ROORZLQJ FOHDYDJH RI SUR,/ȕ E\ ,&( PRVW PDWXUH ,/ȕ UHPDLQV F\WRVROLF
EHFDXVHWKHVHFUHWLRQRI,/ȕLVDQLQHIILFLHQWSURFHVVWKDWUHTXLUHVDGGLWLRQDO
signals such as exogenous ATP to promote secretion. Song and colleagues
GHPRQVWUDWHGWKDWDFWLYH,/ȕVHFUHWLRQE\ILEURVDUFRPDFHOOVLQFUHDVHV
their invasive potential and the degree of invasiveness depends on the
FRQFHQWUDWLRQRIVHFUHWHG,/ȕ2WKHUVWXGLHVKDYHDOVRUHSRUWHGVLPLODUUHVXOWV
in which increased invasiveness of lung carcinoma cells was observed when
WKH FHOOV ZHUH WUDQVIHFWHG ZLWK VLJQDO VHTXHQFH ,/ȕ VV,/ȕ FRQVWUXFW WR
DOORZ,/ȕVHFUHWLRQWKURXJKWKH(5*ROJLSDWKZD\6DLMRHWDOD,QWKH
SUHYLRXVLQYLWURFKDSWHUV&KDSWHUDQGWKH,/ȕXVHGLVWKHVHFUHWHGIRUP
RI ,/ȕ LQ WKH PDFURSKDJH VXSHUQDWDQW JHQHUDWHG IURP /36Ȗ DFWLYDWHG
PDFURSKDJHV+RZHYHU LQWKHFXUUHQWFKDSWHU WKH,/ȕGHWHFWHGZDVWKH,/
ȕLQWKHF\WRSODVPRIWKHFHOOVDQGWKLVGLIIHUHQFHPLJKWDFFRXQWIRUWKHUHVXOWV
observed.
Initial results, in Chapter 2 and previous studies (Mohammed et al., 2007; Storr
et al., 2011), examining how lymphatic vessel invasion might be regulated have
identified that lymphatic vessel invasion was particularly evident when
macrophage infiltrates were immediately adjacent to the lymphatic vessels, it
PD\ EH WKDW LQ DGGLWLRQ WR WKH W\SH RI ,/ȕ EHLQJ SURGXFHG LPPDWXUH DQG
PDWXUH ,/ȕ WKDW FRQFHQWUDWLRQ JUDGLHQWV ZLWKLQ WKH WXPRXU PLOLHX H[LVW ,W
ZRXOG EH LQWHUHVWLQJ DV PHQWLRQHG HDUOLHU WR DVVHVV WKH OHYHO RI ,/ȕ
production from macrophage via double immmuno techniques or to assess IL-
ȕ OHYHOV DGMDFHQW WR O\PSKDWLF YHVVHO LQYDVLRQ ,I ,/ȕ DFWLYLW\ FDQQRW EH
directly assessed, it would also be of interest to assess the levels of proteins
involved in the maturation process i.e ICE/caspase and examine their
expression and localisation.
,QVXPPDU\UHVXOWVLQWKHFXUUHQWFKDSWHUVKRZWKDWKLJKH[SUHVVLRQRI,/ȕLQ
tumour cells correlates with the absence of lymphatic vessel invasion, both
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LQWUDWXPRXUDO DQG SHULWXPRXUDO LQYDVLRQ DQG WKDW ORZ ,/ȕ H[SUHVVLRQ
correlates with breast cancer specific survival and disease free interval. Further
work is required to fully elucidate the role that macrophage play in regulating
lymphovascular invasion, with increased attention being focused on the role that
,/ȕSOD\VLQWKLVSURFHVV 
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CHAPTER 6: GENERAL DISCUSSION AND
SUGGESTIONS FOR FUTURE WORK
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As mentioned in previous chapters, tumour progression to invasive metastatic
disease often begins with lymphatic and/or blood vessel invasion. In contrast to
blood vessels, research on lymphatic vessels has lagged behind, primarily due
to the lack of molecular tools capable of specifically distinguishing lymphatic
endothelial cells from blood endothelial cells. It was not until recent years that
the study of the characteristics of lymphatic vessels in tissues and cell culture
were possible, following the discoveries of lymphatic specific markers. The aims
of the current research project were to (1) examine the characteristics of
lymphatic vessels in cutaneous melanoma and their relationship to tumour
clinicopathological characteristics and patient prognosis, (2) to conduct in-vitro
investigations of adhesion, migration and transmigration, conducting
comparisons between lymphatic and blood endothelial cells and (3) to
investigate the influence of macrophage and macrophage associated cytokines
in the initial metastatic processes of lymphovascular invasion.
In the first component of the project (Chapter 2), lymphatic vessels in cutaneous
melanoma samples were examined using the lymphatic marker, D2-40. They
were found to be mostly located in the peritumoural area of the tumour with
fewer vessels in the intratumoural area. Intratumoural lymphatic vessel invasion
was, however, present and was significantly associated with increased stage,
increased Breslow thickness, the presence of ulceration, increased Clark’s
level, high mitotic rate, the presence of microsatellites and nodular histological
subtype. The majority of studies examining lymphatic topography in cutaneous
melanoma have reported the presence of intratumoural lymphatics (Giorgadze
et al., 2004; Niakosari et al., 2005b), some of which were shown to be
correlated with poor disease free and overall survival (Dadras et al., 2003b) and
distant metastasis (Doeden et al., 2009b). Intratumoural lymphatics were also
detected in other human tumours such as breast cancer (Bono et al., 2004;
Mohammed et al., 2011), gastric cancer (Wang et al., 2010), hepatocellular
carcinoma and non small cell lung cancer (Renyi-Vamos et al., 2005). In
contrast, in breast and cervical cancer (Thelen et al., 2009; Williams et al.,
2003), functional intratumoural lymphatics were not reported suggesting that the
distribution of tumoural lymphatics varies between tumour types and also
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anatomical site. In our group’s previous work with breast cancer we found that
peritumoural lymphatics were detected in all 177 specimens whilest
intratumoural lymphatics were detected in 41% of the specimens. Such vessels
are functional in that tumour emboli are observed within them. Such work was
verified in separate expanded cohorts (Mohammed et al., 2011; Rakha et al.,
2011).
In the current cohort of melanoma tumour specimens, although microvessel
density was much higher compared to lymphatic vessel density in the same
tissue section, vascular invasion in melanoma was essentially invasion of
lymphatic vessels (26.9% vs 4.2%). A preference of such lymphatic invasion
over blood vessel invasion was reported previously with varying frequencies of
blood vessel to lymphatic vessel invasion of 3% to 16% (Doeden et al., 2009a),
4.7% to 33% (Xu et al., 2008) and 43% to 47% (Shields et al., 2004)
respectively.
As mentioned above, in the current study, the presence of lymphatic vessel
invasion was associated with increased stage, increased Breslow thickness, the
presence of ulceration, increased Clark’s level, high mitotic rate and the
presence of microsatellites; all of these factors are markers of tumour
aggressiveness. In other studies, lymphatic vessel invasion was also associated
with younger age, the presence of ulceration, sentinel lymph nodes positivity
and distant metastasis (Niakosari et al., 2005b). As a result, lymphatic invasion
has been suggested as a prognostic indicator for the progression and spread of
malignant melanoma and other cancers. In fact, Shields and colleagues have
developed a prognostic index based on their cohort of metastatic melanoma
samples which combined the information on thickness, lymphatic density and
lymphatic invasion, to generate a more efficient predictor of survival (Shields et
al., 2004). However, only 21 samples were used, limiting the clinical value of
this index. Further work is required to assess the robustness of the Shields
index to consider the use of it in clinical settings. It would have been interesting
to have assessed the prognostic value of the Shields index in the current cohort
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– this could be carried out through further work/investigations by others
continuing the study.
It is unclear what factors influence lymphatic vessel invasion in tumours rich in
blood vessels. However, it was observed that lymphatic vessels in tumours,
where lymphatic vessel invasion was noted, were associated with a dense
inflammatory infiltrate. There are a number of reports in the literature, showing
the presence of inflammatory infiltrates in the tumour microenvironment and
suggesting a link between inflammation and cancer (Hagemann et al., 2005;
Johnson et al., 2006). Macrophages were usually detected in abundance
surrounding tumoural vessels. It was therefore off interest in this study to
examine if there was any correlation between macrophage infiltrates and the
presence of lymphatic invasion. The presence of high macrophage count was
associated with the presence of lymphatic vessel invasion which was supported
by other studies investigating the role of macrophages and inflammatory cells in
inducing lymphangiogenesis in tumours and other tissues (Kerjaschki, 2005;
Yano et al., 2006). Such inflammatory cells have been shown to produce
lymphangiogenic growth factors and cytokines thereby contributing to
lymphangiogenesis (Kerjaschki, 2005).
The conclusion of this part of the project was that, as previously found with
breast cancer, lymphatics play an important role in melanoma cell progression
by being important routes for tumour cell dissemination and that this process
might be driven by macrophages and their secreted factors.
In-vitro investigation of tumour cell adhesion, migration and
transmigration
In the initial metastatic process, tumour cells must first be able to detach from
the primary tumour mass, migrate through the extracellular matrix, and adhere
to the blood or lymphatic endothelial cells before transmigrating across the
endothelial cells to enter the circulation or lymph. Many phenotypical and
biochemical changes occur to/in the tumour cells during these processes which
involve alterations of growth factor signalling, cell-cell adhesion, gene
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expression, motility and cell shape (Leber and Efferth, 2009). Furthermore,
stromal cells in the tumour microenvironment may also affect the
aforementioned changes via secretion of various cytokines. Our histopathology
studies suggest that inflammatory cells might play an important role in
regulating at least some of these processes. Based on our findings that
macrophage might influence lymphatic vessel invasion in tumour specimens,
the second part of the study dealt with in-vitro investigations of adhesion,
migration and transmigration between lymphatic and blood endothelial cells in
control conditions and the influence of macrophage and macrophage
associated cytokines in these processes.
Tumour cell adhesion to blood (HUVEC and hMEC-1) and lymphatic endothelial
cells (hTERT-LEC and hMVEC-dLy Neo) was compared. The side-side
comparison between tumour cell adhesion to lymphatic and blood endothelial
cells was novel and has not been examined in previous studies. Previous in
vitro studies of tumour cell adhesion usually included only one endothelial cell
model, mostly HUVEC or microvascular endothelial cells. Tumour cell adhesion
to lymphatic endothelium has, however, been studied before using fresh frozen
lymph node whole sections (Irjala et al., 2003) and non small cell lung
carcinoma cell adhesion to lymphatic endothelial cells (Irigoyen et al., 2007),
however with no direct comparison with a vascular comparator. In the current
study, MDA-MB-231, MCF7, MeWo and SKMEL-30 cell lines were used to
demonstrate the adhesion pattern of these cells towards large vein and
microvessel endothelial cells, HUVEC and hMEC-1 respectively as well as
primary and immortalised lymphatic endothelial cells, hMVEC-dLy Neo and
hTERT-LEC respectively. Under unstimulated conditions, these cell lines
showed preferential adhesion to blood endothelial cells as opposed to the
lymphatic endothelial cells. The preferential adhesion of tumour to blood and
lymphatic endothelial cells was unexpected, considering the findings in patients
specimens showing that vascular invasion in these tumour types is principally
lymphatic vessels. Such conflicting findings raised important questions about
the physiological mechanisms of lymphatic vascular invasion; are there
molecular mechanisms that could initiate and control the tumour-endothelial
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interaction which eventually drive the tumour cells to lymphatic endothelial cells
or was the preferential lymphatic vessel invasion simply a reflection of
differences in vessel structure (i.e. lymphatic vessels being ‘easier’ to
transmigrate)?
The correlation between high macrophage count and the presence of lymphatic
vessel invasion as observed in patients’ samples could indicate that
macrophages, inflammatory cells present in abundance in the tumour
PLFURHQYLURQPHQWPLJKWLQIOXHQFHO\PSKDWLFYHVVHOLQYDVLRQ7KHUHIRUH71)Į
DQG ,/ȕ ERWK RI ZKLFK DUH PDFURSKDJH VHFUHWHG F\WRNLQHV ZHUH XVHG WR
stimulate the endothelial cells (HUVEC, hMEC-1, hTERT-LEC and hMVEC-dLy
Neo) and tumour cells (MDA-MB-231, MCF7, MeWo and SKMEL-30) to
determine whether these factors alter the adhesion, migration and
transmigration patterns of these tumour cells.
7XPRXUFHOODGKHVLRQWR71)ĮVWLPXODWHG+89(&K0(&K7(57/(&DQG
HMVEC-dLy Neo did not vary significantly when compared to the unstimulated
endothelium. However, a significant increased was observed when both the
WXPRXU DQG WKH HQGRWKHOLDO FHOOV ZHUH VLPXOWDQHRXVO\ VWLPXODWHG ZLWK 71)Į
VXJJHVWLQJ WKDW GXDO DFWLYDWLRQ ZLWK 71)Į PLJKW EH QHFHVVDU\ WR SURPRWH
WXPRXUHQGRWKHOLDO FHOO DGKHVLRQ  8SRQ ,/ȕ VWLPXODWLRQ D VLJQLILFDQW
increased of tumour cell adhesion was observed which was notably higher to
WKHO\PSKDWLFHQGRWKHOLDOFHOOVVXJJHVWLQJDQRYHODQGLPSRUWDQWUROHIRU,/ȕ
in cancer cell adhesion to lymphatic vessels. This was supported by the fact
WKDW LQ PLFH PRGHOV ODFNLQJ WKH ,/ȕ JHQH WKH DEVHQFH RI PHWDVWDVLV ZDV
observed (Moore et al., 1999). Pre-incubation of human microvascular
HQGRWKHOLDOFHOOVZLWK,/ȕZHUHDOVRVKRZQWRLQFUHDVHWKHDGKHVLRQRIKXPDQ
pancreatic cancer cell lines.
Questions then arise as to whether the increased tumour cell binding is
dependent upon the up-regulation of adhesion molecules on the endothelial
cells and if so, which adhesion molecules are responsible? Therefore, in
addition to the in-vitro adhesion assays, the role of adhesion molecules
expressed on the endothelial cell models in regulating lymphatic vessel invasion
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was also examined. CLEVER-1, common lymphatic endothelial and vascular
endothelial receptor 1, is differentially expressed in lymphatic, but not vascular
endothelial cells (Salmi et al., 2004). In this study, CLEVER-1 expression
between blood and lymphatic endothelial cells, and between primary and
immortalised cell lines was compared. Results showed that although all
endothelial cell models expressed CLEVER-1 intracellularly, only the
immortalised lymphatics, hTERT-LEC, showed significant surface expression of
&/(9(5 8SRQ VWLPXODWLRQ ZLWK 71)Į RQO\ WKH SULPDU\ O\PSKDWLF FHOOV
model, hMVEC-dLy Neo showed significant increase of CLEVER-1 expression
on both surface and intracellular staining suggesting that hTERT-LEC may be a
model of activated lymphendothelium.However, stimulation of HUVEC, hMEC-
 K7(57/(& DQG +09(&G/\ 1HR ZLWK ,/ȕ GLG QRW VKRZ DQ\ VLJQLILFDQW
altered CLEVER-1 expression. Such results, in light of the adhesion assay
results, suggest that although CLEVER-1 may be an important lymphatic
specific adhesion molecule, it may not be a principal regulator of lymphatic
vessel invasion mediated via IL-1E. The expression of ICAM-1 and VCAM-1
were also studied. Results showed that both hMEC-1 and hTERT-LEC
expressed ICAM-1 and VCAM-1 on their surface with higher expression
REVHUYHG RQ K0(& FHOOV 8SRQ VWLPXODWLRQ ZLWK ,/ȕ ERWK ,&$0 DQG
VCAM-1 expression increased significantly on hMEC-1 and hTERT-LEC
suggesting that these adhesion molecules might be responsible, at least in part,
for the regulation of lymphatic vessel invasion. ICAM-1 and VCAM-1 knockdown
in lymphatic and blood vascular endothelial cells would be required to further
examine the role that these molecules play in regulating tumour cell trafficking
via lymphatic vessels. It would also be of interest to examine expression of
other adhesion molecules associated with lymphatic endothelium (mentioned in
Section 1.5 –Chapter 1) and determine if their expression is altered by exposure
to IL-1E or macrophage conditioned media.
,QWKHVFUDWFKZRXQGPLJUDWLRQDVVD\71)ĮDQG,/ȕVWLPXODWLRQZDVVKRZQ
to increase the migratory ability of all tumour cell lines used in this study (MDA-
MB-231, MCF7, MeWo and SKMEL-30), which was observed at numerous time
points and these observations are in agreement with other studies (Hidalgo et
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al., 2005; Katerinaki et al., 2003). In the in-vivo settings, tumour cells that
detach from the tumour mass migrate through the extracellular matrix
components present in the tumour microenvironment such as collagen,
fibronection, laminin and others. Therefore, it would be potentially interesting to
examine tumour cell migration by coating the tissue culture wells with
H[WUDFHOOXODU PDWUL[ VXEVWUDWHV ILUVW EHIRUH SODWLQJ WKH FRQWURO DQG ,/ȕ
stimulated cells. By doing this, the effect of extracellular matrix on control and
cytokine stimulated cells could be studied in detail, using conditions which
better mimick the in-vivo migration process.
Tumour transendothelial migration follows migration and adhesion steps and
therefore was also off interest to this study. Experiments comparing
transendothelial migration of tumour cell lines; MDA-MB-231 and MeWo across
blood and lymphatic endothelial cells in a single experiment have not been
previously reported. As with adhesion assays, most transendothelial migration
assays have used large vein endothelial cells (HUVEC). In the current study,
MDA-MB-231 cells and MeWo show similar transmigratory abilities across both
blood and lymphatic endothelial cells. However, MDA-MB-231, being the more
aggressive cell type, transmigrated in higher number compared to MeWo cells.
8SRQVWLPXODWLRQZLWK,/ȕWKHUHZDVDVLJQLILFDQWLQFUHDVHGLQWKHQXPEHURI
MDA-MB-231 cells that transmigrated across both hMEC-1 and hTERT-LEC
with similar affinity to both endothelial cell types; blood and lymphatic
HQGRWKHOLXP6LPLODUO\XSRQVWLPXODWLRQZLWK ,/ȕ WKHUHZDVDQ LQFUHDVHG LQ
the transmigratory ability of MeWo cells across hMEC-1 and hTERT-LEC which
was notably observed across hMEC-1 cells.
The adhesion, migration and transmigration assays in this study were also
carried out using tumour conditioned media and macrophage conditioned media
LQDQDWWHPSWWRGHWHUPLQHWKHSRWHQWLDOVRXUFHRI,/ȕWKDWPLJKWLQIOXHQFHWKH
LQLWLDO PHWDVWDWLF SURFHVVHV 5HVXOWV IURP ,/ȕ (/,6$¶V VKRZHG WKDW QR
VLJQLILFDQW ,/ȕ H[SUHVVLRQ ZDV GHWHFWDEOH LQ WKH WXPRXU FRQGLWLRQHG PHGLD
When adhesion assays were conducted using such tumour conditioned media,
no significant changes were observed in the adhesive patterns of tumour cells
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to the endothelium of either blood or lymphatics compared to the unstimulated
controls. Similarly, tumour cells stimulated with their own respective tumour
conditioned media showed no significant changes in their migratory ability
compared to their unstimulated counterparts. However, the use of macrophage
FRQGLWLRQHGPHGLDJHQHUDWHG IURP/36ȖVWLPXODWHGPDFURSKDJHV LQFUHDVHG
the number of adhered MDA-MB-231 cells compared to the unstimulated
controls. In the transwell migration assay, there was an increased in the
transmigratory ability of MDA-MB-231 cells when the endothelial cells were
stimulated with such macrophage supernatant. In both adhesion and
transmigration assays, the increased adhesion and transmigration ability were
both higher across hTERT-LEC compared to hMEC-1 cells and was statistically
significant in one donor in particular i.e. donor 2. When both hMEC-1 and
hTERT-LEC cells were exposed to macrophage conditioned media generated
IURP /36Ȗ,&( LQKLELWRUV VWLPXODWHG PDFURSKDJHV WKH QXPEHU RI FHOOV
adhered and transmigrated to/across both endothelial cell types significantly
GHFUHDVHG ,/ȕ (/,6$ UHVXOWV VKRZHG KLJK ,/ȕ H[SUHVVLRQ LQ /36Ȗ
stimulated macrophages which was reduced when ICE inhibitor was used. ICE
is a cysteine protease responsible for proteolytic activation of the biologically
LQDFWLYH ,/ȕ SUHFXUVRU WR WKH SURLQIODPPDWRU\ DFWLYH F\WRNLQH /LYLQJVWRQ
 7KHUHIRUH FXUUHQW UHVXOWV VXJJHVW WKDW ,/ȕ PLJKW EH LQYROYHG LQ WKH
regulation of tumour cell adhesion and transmigration across the endothelial
cells. The fact that it was detected in macrophage conditioned media and not
the tumour conditioned media suggested that macrophage may be the main
VRXUFHRIWKH,/ȕWKDWLVFDSDEOHRIUHJXODWLQJWKHLQLWLDOPHWDVWDWLFSURFHVVHV
7RIXUWKHUHYDOXDWHZKHWKHU,/ȕDUHJXODWRURILQYDVLRQVSHFLILFEORFNLQJRI,/
ȕ UHFHSWRUV FRXOG EH FDUULHG RXW E\ XVLQJ WKH ,/ȕ UHFHSWRU DQWDJRQLVW ,/
5D ,/5D LV D QDWXUDOO\ RFFXUULQJ LQKLELWRU RI ,/ȕ WKDW ELQGV WR ,/ȕ
UHFHSWRUV ZLWK WKH VDPH DIILQLW\ DV ,/ȕ EXW ZLWKRXW WULJJHULQJ D ELRFKHPLFDO
UHVSRQVH LQ FHOOV 9LGDO9DQDFORFKD HW DO  7KH UROH RI ,/ȕ FRXOG EH
VWXGLHGE\FXOWXULQJWKHHQGRWKHOLDOFHOOVLQWKHSUHVHQFHDQGDEVHQFHRI,/ȕ
receptor blockade. Furthermore, co-culture experiments of endothelial cells and
macrophages could also be carried out to assess the influence of macrophage
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LQ,/ȕSURGXFWLRQWKXVLQIOXHQFLQJDGKHVLRQDQGWUDQVPLJUDWLRQRIWXPRXUFHOOV
in metastasis.
7KHODFNRI,/ȕLQWKHWXPRXUGHULYHGO\VDWHLVLQWHUHVWLQJDVWXPRXUFHOOVFDQ
DOVR SURGXFH ,/ȕ 6WXGLHV XVLQJ PHODQRPD QRQ VPDOO FHOO FDUFLQRPD DQG
colon cancer cell lines have shown that these cell lines exhibited significantly
LQFUHDVHG FRS\ QXPEHU RI ,/ȕ (ODUDM HW DO  /HZLV HW DO 
However, macrophages and monocytes also produce IL-10, an anti-
LQIODPPDWRU\ F\WRNLQH ZKLFK KDV EHHQ VKRZQ WR LQKLELW /36LQGXFHG ,/ȕ
mRNA and protein production in human monocytes and neutrophils (Jenkins et
al., 1994). IL-10 has also been shown to enhance the level of IL1Ra mRNA in
/36LQGXFHG PRQRF\WHV UHVXOWLQJ LQ DQ LQFUHDVHG UDWLR RI ,/5D WR ,/ȕ
%RJGDQHWDO,QDGGLWLRQ,/PLJKWDOVRLQKLELWWKHSURGXFWLRQRI,/ȕ
through the activation of IL-10 and IL1Ra. Therefore, based on the results of
this study, IL-6 and IL-10 ELISA’s could be carried out on the macrophage
supernatant and tumour conditioned media to confirm the expression of these
F\WRNLQHVDQGGHWHUPLQHKRZ,/ȕLVUHJXODWHGLQWKHVHFHOOV
The conclusion for this part of the project was that macrophage associated
F\WRNLQHV 71)Į DQG PRUH LPSRUWDQWO\ ,/ȕ FRXOG UHJXODWH PHODQRPD DQG
breast cancer cell adhesion, migration and transmigration in-vitro.
,/ȕH[SUHVVLRQLQEUHDVWWLVVXH
Based on the in-vitro results generated, the third part of the current study dealt
ZLWKLPPXQRKLVWRFKHPLFDOLQYHVWLJDWLRQRI,/ȕH[SUHVVLRQLQHDUO\VWDJH
EUHDVW FDQFHU VSHFLPHQV ,Q WHUP RI O\PSKDWLF YHVVHO LQYDVLRQ KLJK ,/ȕ
expression in the cytoplasm of tumour cells was significantly associated with the
absence of lymphatic vessel invasion - this observation differs to the in-vitro
DGKHVLRQ PLJUDWLRQ DQG WUDQVPLJUDWLRQ UHVXOWV REVHUYHG ,/ȕ LV LQLWLDOO\
V\QWKHVLVHG DV DQ LPPDWXUH N'D SUR,/ȕ SUHFXUVRU ZKLFK UHPDLQV LQ WKH
F\WRSODVPXQWLOLWLVFOHDYHGLQWRDPDWXUHN'D,/ȕWKDWLVVHFUHWHGLQWRWKH
cellular compartment through a membrane channel. In the in-vitro assays, it
ZDV WKHPDWXUH ,/ȕ WKDWZDVXVHG WRVWLPXODWHHQGRWKHOLDODQG WXPRXUFHOOV
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EXW\HWWKHDQWL,/ȕDQWLERG\XVHGWRVWDLQEUHDVWWXPRXUVSHFLPHQVGHWHFWV
ERWK LPPDWXUHDQGPDWXUH IRUPVRI ,/ȕ6XFKGLIIHUHQFHVPLJKWDFFRXQW IRU
the differences observed between the in-vitro observations and the tumour
specimens.
7KH PRGH RI SUHVHQWDWLRQ RI WKH DFWLYH ,/ȕ ZLWKLQ WKH WXPRXU FHOOV DQG WKH
microenvironment can also determine its effect in the malignant process (Song
et al., 2003). It was shown from the studies of Song and colleagues that the
VHFUHWHG IRUP RI PDWXUH ,/ȕ LQ WKH H[WUDFHOOXODU FRPSDUWPHQW EXW QRW WKH
PDWXUHF\WRVROLF,/ȕFRXOGLQFUHDVHWXPRXUJURZWKLQYDVLRQDQGPHWDVWDVLV
The degree of invasiveness of fibrosarcoma cells (Song et al., 2003) and lung
carcinoma cells (Saijo et al., 2002a) may depends on the concentration of
VHFUHWHG ,/ȕ +RZHYHU UHVXOWV IURP WKH FXUUHQW EUHDVW WXPRXU VSHFLPHQV
ZHUHEDVHGRQF\WRSODVPLF,/ȕDQGWKLVPLJKWDOVRDFFRXQWIRUWKHGLIIHUHQFHV
observed in the in-vitro assays.
As with the suggestions for further in vitro work, mentioned above, it would also
be of interest to assess expression of IL-6 and IL-10 in the breast tumour
sections. Interleukin 10 which is also known as cytokine synthesis inhibitory
factor (CSIF) is an anti-inflammatory cytokines capable of inhibiting the
SURGXFWLRQRIRWKHUF\WRNLQHVVXFKDV,)1Ȗ,/Į,/ȕ,/,/DQG71)Į
,W ZDV VKRZQ WKDW ,/ FRXOG UHGXFH WKH V\QWKHVLV RI ,/ȕ E\ XS WR 
following the optimal activation of monocytes by LPS (de Waal Malefyt et al.,
1991). Therefore, it would be interesting to stain patients tissue samples to
VWXG\DQ\FRUUHODWLRQ WKDW ,/ȕKDVZLWK ,/DQGZKHWKHU ,/EHLQJDQWL
LQIODPPDWRU\ F\WRNLQHV DQG QHJDWLYH UHJXODWRU RI ,/ȕ FRXOG UHGXFH WXPRXU
cells invasion especially to the lymphatic vessels.
Furthermore, results from the in vitro component of the project concluded that
PDFURSKDJHVDUHDPDLQSURGXFHURI ,/ȕ WKDWPD\KDYHDSRVLWLYHHIIHFW LQ
WXPRXU FHOO LQYDVLRQ HVSHFLDOO\ WR WKH O\PSKDWLF FLUFXODWLRQ 7KHUHIRUH ,/ȕ
staining on macrophages (using a double immunohistochemical staining
technique) should be evaluated to study the correlation of this parameter with
lymphatic vessel invasion and other clinicopathological criteria. A further area
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of future interest, in terms of potential histopathology based studies, might be to
look at macrophage subtyping i.e. to determine whether it was M1 or M2
associated macrophage that were associated with lymphatic vessel invasion.
Each of these macrophage subtypes produce a different spectrum of cytokines
and so such information may narrow the spectrum of factors to be examined.
In summary:
In conclusion, this study showed that (1) lymphatic vessel invasion occurred
predominantly in melanoma although lymphatic vessel density was detected in
lower number compared to microvessel density in the same tissue samples, (2)
the use of immunohistochemical marker, D2-40 increased the accuracy of
lymphatic vessel invasion detection compared to the use of conventional
staining and (3) the presence of high macrophage count was associated with
the presence of lymphatic vessel invasion which might indicate the role of
macrophage in the regulation of this process.
,QWKH LQYLWURVHWWLQJV WKLVVWXG\KDVVKRZQWKDW ,/ȕSUHVHQW LQPDFURSKDJH
conditioned media can regulate the adhesion, migration and transmigration
processes as shown in the static adhesion assays, haplotaxis scratch wound
migration assay and the Boyden chamber transmigration assays respectively.
)XUWKHU VWXGLHV DUH QHHGHG WR YDOLGDWH WKH UROH RI ,/ȕ LQ WKH UHJXODWLRQ RI
O\PSKDWLFYHVVHOLQYDVLRQE\XVLQJ,/ȕUHFHSWRUDQWDJRQLVWRUFDUU\LQJRXWFR
culture experiments with tumour associated macrophages as discussed above.
%DVHG RQ WKHVH UHVXOWV TXHVWLRQV DULVH RQ KRZ ,/ȕ UHJXODWHV WKH LQLWLDO
metastatic processes? In this study, it was shown that the surface expression of
ICAM-1 and VCAM-1 increased significantly in both blood and lymphatic
endothelial cell models used indicating that these adhesion molecules might be
the regulator of lymphatic vessel invasion. To address this, ICAM-1 and VCAM-
1 knockdown would be required to further examine the role that this molecule
plays in mediating tumour cell trafficking via lymphatic vessels. Although current
results suggest that CLEVER-1 may not be involved it would also be of interest
to examine expression of other ‘lymphatic specific’ adhesion molecules such as
junctional adhesion molecules, sphingosine 1 phosphate receptor and mannose
191
receptor (as reviewed in Section 1.6). All the results mentioned in this study
were based on static assays. It would be interesting to study the effect of flow
on adhesion, migration and transmigration of tumour cells. Using a flow based
assay is important as it better represents the in vivo process.
The current study has yielded important results, shedding some light on our
understanding of the lymphatic vasculature and the modulation of lymphatic
vessel invasion. Understanding these processes is crucial to enable translation
of research into research for patient benefit and identification of therapeutic
targets.
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APPENDIX A: SUPPLEMENTARY INFORMATION FOR CHAPTER 1
Table A1: TNM staging categories for cutaneous melanoma. Reproduced and adapted
from (Balch et al., 2009). Copyright© 2009 by American Society of Clinical Oncology with
permission conveyed through Copyright Clearance Center Inc.
Tumour (T) Breslow thickness (mm) Ulceration status/mitoses
T0 NA NA
T1 < 1.00 a. without ulceration and mitosis <1/mm2
b. with ulceration or mitoses >1/mm2
T2 1.01-2.00 a. without ulceration
b. with ulceration
T3 2.01-4.00 a. without ulceration
b. with ulceration
T4 >4.00 a. without ulceration
b. with ulceration
Nodes (N) No of metastatic nodes Nodal metastatic burden
N0 0 NA
N1 1 a. micrometastasis* b. macrometastasis+
N2 2-3 a. micrometastasis* b. macrometastasis+
c. in transit metastases/satellites without
metastatic nodes
N3 4+ metastatic or matted nodes, or in transit
metastases/ satellites with metastatic
nodes
Metastases (M) Site Serum lactate dehydrogenase
M0 no distant metastases NA
M1a distant/subcutaneous/nodal normal
M1b lung metastases normal
M1c all other visceral metastases
any distant metastasis
Normal
Elevated
Abbreviations: NA-not applicable
*micrometastases are diagnosed after sentinel lymph node biopsy
+macrometastases are defined as clinically detectable nodal metastases confirmed
pathologically
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Table A2: Anatomic stage groupings (clinical and pathologic stage) in cutaneous
melanoma. Reproduced and adapted from (Balch et al., 2009). Copyright© 2009 by
American Society of Clinical Oncology with permission conveyed through Copyright
Clearance Center Inc.
Clinical staging* Pathological staging+ 5 years
survival
(%)
Stage T N M Stage T N M
0 Tis N0 M0 0 Tis N0 M0 99.9
IA T1a N0 M0 IA T1a N0 M0 >90
IB T1b
T2a
N0
N0
M0
M0
IB T1b
T2a
N0
N0
M0
M0
IIA T2b
T3a
N0
N0
M0
M0
IIA T2b
T3a
N0
N0
M0
M0
40-85
IIB T3b
T4a
N0
N0
M0
M0
IIB T3b
T4a
N0
N0
M0
M0
IIC T4b N0 M0 IIC T4b N0 M0
III Any
T
N>N0 M0 IIIA T1-4a
T1-4a
N1a
N2a
M0
M0
25-60
IIIB T1-4b
T1-4b
T1-4a
T1-4a
T1-4a
N1a
N2a
N1b
N2b
N2c
M0
M0
M0
M0
M0
IIIC T1-4b
T1-4b
T1-4b
Any T
N1b
N2b
N2c
N3
M0
M0
M0
M0
IV Any
T
Any N M1 IV Any T Any N M1 9-18
*Clinical staging includes microstaging of primary melanoma and clinical evaluation of
metastases. It is used after complete excision of the primary melanoma.
+Pathological staging includes microstaging of primary melanoma and pathologic information
about the regional lymph nodes after lymphadenectomy.
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APPENDIX B: SUPPLEMENTARY INFORMATION FOR CHAPTER 2
Table B1: TNM staging categories for breast cancer. Reproduced and adapted from
(Singletary et al., 2002). Copyright© 2002 byAmerican Society of Clinical Oncology with
permission conveyed through Copyright Clearance Center Inc,
Tumour (T)
TX primary tumour cannot be assessed
T0 no evidence of primary tumour
Tis Carcinoma in situ: ductal carcinoma in situ, lobular carcinoma in situ
Paget disease of the nipple with no tumour
T1
T1mic
T1a
T1b
T1c
Tumour <2cm in greatest dimension
<0.1cm
>0.1cm but <0.5cm
>0.5cm but <1.0cm
>1.0cm but <2.0cm
T2 >2.0cm but <5.0cm
T3 >5cm
T4
T4a
T4b
T4c
T4d
Tumour of any size extend to the (a) chest wall or (b) skin
Extend to chest wall not including the pectoralis muscle
Edema/ulceration of the breast
T4a + T4b
Inflammatory carcinoma
Regional lymph nodes (N)
NX Cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in movable ipsilateral axillary lymph node
N2
N2a
N2b
Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted)
or to other structures
Metastasis only in clinically apparent* ipsilateral internal mammary nodes
and in the absence of clinically evident axillary lymph node metastasis
N3
N3a
N3b
N3c
Metastasis in ipsilateral infraclavicular lymph node and axillary lymph node
Metastasis in ipsilateral internal mammary lymph node and axillary lymph
node
Metastasis in ipsilateral supraclavicular lymph node
Distant Metastasis (M)
MX cannot be assessed
M0 no distant metastases
M1 distant metastasis
M1c all other visceral metastases
any distant metastasis
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Table B2: Stage grouping for breast cancer. Reproduced and adapted from (Singletary et
al., 2002). Copyright© 2002 by American Society of Clinical Oncology with permission
conveyed through Copyright Clearance Center Inc,
Stage
T N M
0 Tis N0 M0
I T1 N0 M0
IIA T0
TI
T2
N1
N1
N0
M0
M0
M0
IIB T2
T3
N1
N0
M0
M0
IIIA T0
TI
T2
T3
T3
N2
N2
N2
N1
N2
M0
M0
M0
M0
M0
IIIB T4
T4
T4
N0
N1
N2
M0
M0
M0
IIIC Any T N3 M0
IV Any T Any N M1
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APPENDIX C: SUPPLEMENTARY INFORMATION FOR CHAPTER 3
Figure C1: Proliferation assay comparing cells growth cultured with normal cell culture
media and tumour conditioned media generated as in Chapter 3 -Section 3.3.5 used in
adhesion and migration assay. there was no difference in cell count between both media
across MDA-MB-231 (A), MCF7 (B), MeWo (C) and SKMEL-30 (D), showing that the
tumour conditioned media used is still bioreactive. Experiments were carried out twice,
each in duplicate (n=4).
Figure C2: Optimisation of ICE inhibitor concentration used to stimulate macrophages to
generate macrophage conditioned media (A). 250µm of ICE inhibitor was used in
subsequent assay as at this concentration, 86% inhibition was observed which would not
effect macrophages viability (B).
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APPENDIX D: SUPPLEMENTARY INFORMATION FOR CHAPTER 5
Figure D1: Descriptive statistic of cytoplasmic IL-
ȕ+VFRUHGRIEUHDVWWLVVXHPLFURDUUD\
)LJXUH'+LVWRJUDPVKRZLQJ WKHGLVWULEXWLRQRIF\WRSODVPLF ,/ȕ+VFRUHGRIEUHDVW
WLVVXHPLFURDUUD\IURPSDWLHQWV$,/ȕKDGD+VFRUHFXWRIISRLQWRIZLWK
(17.1%) cases with low score and 1252 (82.9%) cases having high score (B).
IL1Beta
N Valid 1511
Missing 0
Mean 111.48
Std. Error of Mean 1.500
Median 125.00
Std. Deviation 58.290
Range 230
Minimum 0
Maximum 230
